(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁷: A61K 48/00, C12Q 1/70

(21) International Application Number: PCT/US00/34724

(22) International Filing Date:
21 December 2000 (21.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/171,542   22 December 1999 (22.12.1999)   US

(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): SHIVER, John, W. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). PERRY, Helen, C. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). CASIMIRO, Danilo, R. [PH/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). FU, Tong-Ming [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL

(57) Abstract: Pharmaceutical compositions which comprise HIV Pol DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The pol-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and preferably express inactivated versions of the HIV Pol protein devoid of protease, reverse transcriptase activity, RNase H activity and integrase activity, inducing a cellular immune response which specifically recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open reading frame of these DNA vaccines are synthetic DNA molecules encoding codon optimized HIV-1 Pol and codon optimized inactive derivatives of optimized HIV-1 Pol, including DNA molecules which encode inactive Pol proteins which comprise an amino terminal leader peptide.

TITLE OF THE INVENTION
POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1
5   POL AND MODIFIED HIV-1 POL

CROSS-REFERENCE TO RELATED APPLICATIONS
        This application claims the benefit, under 35 U.S.C. §119(e), of U.S.
provisional application 60/171,542, filed December 22, 1999.
10

STATEMENT REGARDING FEDERALLY-SPONSORED R&D
        Not Applicable

15   REFERENCE TO MICROFICHE APPENDIX
        Not Applicable

FIELD OF THE INVENTION
        The present invention relates to HIV Pol polynucleotide pharmaceutical
20   products, as well as the production and use thereof which, when directly introduced
     into living vertebrate tissue, preferably a mammalian host such as a human or a
     non-human mammal of commercial or domestic veterinary importance, express the
     HIV Pol protein or biologically relevant portions thereof within the animal, inducing a
     cellular immune response which specifically recognizes human immunodeficiency
25   virus-1 (HIV-1). The polynucleotides of the present invention are synthetic DNA
     molecules encoding codon optimized HIV-1 Pol and derivatives of optimized HIV-1
     Pol, including constructs wherein protease, reverse transcriptase, RNAse H and
     integrase activity of HIV-1 Pol is inactivated. The polynucleotide vaccines of the
     present invention should offer a prophylactic advantage to previously uninfected
30   individuals and/or provide a therapeutic effect by reducing viral load levels within an
     infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

BACKGROUND OF THE INVENTION

Human Immunodeficiency Virus-1 (HIV-1) is the etiological agent of acquired human immune deficiency syndrome (AIDS) and related disorders. HIV-1 is an RNA virus of the Retroviridae family and exhibits the 5'LTR-*gag-pol-env-*

5   LTR 3' organization of all retroviruses. The integrated form of HIV-1, known as the provirus, is approximately 9.8 Kb in length. Each end of the viral genome contains flanking sequences known as long terminal repeats (LTRs). The HIV genes encode at least nine proteins and are divided into three classes; the major structural proteins (Gag, Pol, and Env), the regulatory proteins (Tat and Rev); and the accessory proteins

10   (Vpu, Vpr, Vif and Nef).

The *gag* gene encodes a 55-kilodalton (kDa) precursor protein (p55) which is expressed from the unspliced viral mRNA and is proteolytically processed by the HIV protease, a product of the *pol* gene. The mature p55 protein products are p17 (matrix), p24 (capsid), p9 (nucleocapsid) and p6.

15   The *pol* gene encodes proteins necessary for virus replication; a reverse transcriptase, a protease, integrase and RNAse H. These viral proteins are expressed as a Gag-Pol fusion protein, a 160 kDa precursor protein which is generated via a ribosomal frame shifting. The viral encoded protease proteolytically cleaves the Pol polypeptide away from the Gag-Pol fusion and further cleaves the Pol polypeptide to

20   the mature proteins which provide protease (Pro, P10), reverse transcriptase (RT, P50), integrase (IN, p31) and RNAse H (RNAse, p15) activities.

The *nef* gene encodes an early accessory HIV protein (Nef) which has been shown to possess several activities such as down regulating CD4 expression, disturbing T-cell activation and stimulating HIV infectivity.

25   The *env* gene encodes the viral envelope glycoprotein that is translated as a 160-kilodalton (kDa) precursor (gp160) and then cleaved by a cellular protease to yield the external 120-kDa envelope glycoprotein (gp120) and the transmembrane 41-kDa envelope glycoprotein (gp41). Gp120 and gp41 remain associated and are displayed on the viral particles and the surface of HIV-infected cells.

30   The *tat* gene encodes a long form and a short form of the Tat protein, a RNA binding protein which is a transcriptional transactivator essential for HIV-1 replication.

The *rev* gene encodes the 13 kDa Rev protein, a RNA binding protein. The Rev protein binds to a region of the viral RNA termed the Rev response element

(RRE). The Rev protein is promotes transfer of unspliced viral RNA from the nucleus to the cytoplasm. The Rev protein is required for HIV late gene expression and in turn, HIV replication.

Gp120 binds to the CD4/chemokine receptor present on the surface of helper

5   T-lymphocytes, macrophages and other target cells in addition to other co-receptor molecules. X4 (macrophage tropic) virus show tropism for CD4/CXCR4 complexes while a R5 (T-cell line tropic) virus interacts with a CD4/CCR5 receptor complex. After gp120 binds to CD4, gp41 mediates the fusion event responsible for virus entry. The virus fuses with and enters the target cell, followed by reverse transcription of its

10 single stranded RNA genome into the double-stranded DNA via a RNA dependent DNA polymerase. The viral DNA, known as provirus, enters the cell nucleus, where the viral DNA directs the production of new viral RNA within the nucleus, expression of early and late HIV viral proteins, and subsequently the production and cellular release of new virus particles. Recent advances in the ability to detect viral load

15 within the host shows that the primary infection results in an extremely high generation and tissue distribution of the virus, followed by a steady state level of virus (albeit through a continual viral production and turnover during this phase), leading ultimately to another burst of virus load which leads to the onset of clinical AIDS. Productively infected cells have a half life of several days, whereas chronically or

20 latently infected cells have a 3-week half life, followed by non-productively infected cells which have a long half life (over 100 days) but do not significantly contribute to day to day viral loads seen throughout the course of disease.

Destruction of CD4 helper T lymphocytes, which are critical to immune defense, is a major cause of the progressive immune dysfunction that is the hallmark

25 of HIV infection. The loss of CD4 T-cells seriously impairs the body's ability to fight most invaders, but it has a particularly severe impact on the defenses against viruses, fungi, parasites and certain bacteria, including mycobacteria.

Effective treatment regimens for HIV-1 infected individuals have become available recently. However, these drugs will not have a significant impact on the

30 disease in many parts of the world and they will have a minimal impact in halting the spread of infection within the human population. As is true of many other infectious diseases, a significant epidemiologic impact on the spread of HIV-1 infection will only occur subsequent to the development and introduction of an effective vaccine. There are a number of factors that have contributed to the lack of successful vaccine

development to date. As noted above, it is now apparent that in a chronically infected person there exists constant virus production in spite of the presence of anti-HIV-1 humoral and cellular immune responses and destruction of virally infected cells. As in the case of other infectious diseases, the outcome of disease is the result of a

5 balance between the kinetics and the magnitude of the immune response and the pathogen replicative rate and accessibility to the immune response. Pre-existing immunity may be more successful with an acute infection than an evolving immune response can be with an established infection. A second factor is the considerable genetic variability of the virus. Although anti-HIV-1 antibodies exist that can

10 neutralize HIV-1 infectivity in cell culture, these antibodies are generally virus isolate-specific in their activity. It has proven impossible to define serological groupings of HIV-1 using traditional methods. Rather, the virus seems to define a serological "continuum" so that individual neutralizing antibody responses, at best, are effective against only a handful of viral variants. Given this latter observation, it

15 would be useful to identify immunogens and related delivery technologies that are likely to elicit anti-HIV-1 cellular immune responses. It is known that in order to generate CTL responses antigen must be synthesized within or introduced into cells, subsequently processed into small peptides by the proteasome complex, and translocated into the endoplasmic reticulum/Golgi complex secretory pathway for

20 eventual association with major histocompatibility complex (MHC) class I proteins. CD8$^+$ T lymphocytes recognize antigen in association with class I MHC via the T cell receptor (TCR) and the CD8 cell surface protein. Activation of naive CD8$^+$ T cells into activated effector or memory cells generally requires both TCR engagement of antigen as described above as well as engagement of costimulatory proteins. Optimal

25 induction of CTL responses usually requires "help" in the form of cytokines from CD4$^+$ T lymphocytes which recognize antigen associated with MHC class II molecules via TCR and CD4 engagement.

Larder, et al., (1987, *Nature* 327: 716-717) and Larder, et al., (1989, *Proc. Natl. Acad. Sci.* 86: 4803-4807) disclose site specific mutagenesis of HIV-1 RT and

30 the effect such changes have on *in vitro* activity and infectivity related to interaction with known inhibitors of RT.

Davies, et al. (1991, *Science* 252:, 88-95) disclose the crystal structure of the RNase H domain of HIV-1 Pol.

Schatz, et al. (1989, *FEBS Lett.* 257: 311-314) disclose that mutations
Glu478Gln and His539Phe in a complete HIV-1 RT/RNase H DNA fragment results
in defective RNase activity without effecting RT activity.

Mizrahi, et al. (1990, *Nucl. Acids. Res.* 18: pp. 5359-5353) disclose additional

5   mutations Asp443Asn and Asp498Asn in the RNase region of the *pol* gene which also
results in defective RNase activity. The authors note that the Asp498Asn mutant was
difficult to characterize due to instability of this mutant protein.

Leavitt, et al. (1993, *J. Biol. Chem.* 268: 2113-2119) disclose several
mutations, including a Asp64Val mutation, which show differing effect on HIV-1

10   integrase (IN) activity.

Wiskerchen, et al. (1995, *J. Virol.* 69: 376-386) disclose singe and double
mutants, including mutation of aspartic acid residues which effect HIV-1 IN and viral
replication functions.

It would be of great import in the battle against AIDS to produce a

15   prophylactic- and/or therapeutic-based HIV vaccine which generates a strong cellular
immune response against an HIV infection. The present invention addresses and
meets this needs by disclosing a class of DNA vaccines based on host delivery and
expression of modified versions of the HIV-1 gene, *pol*.

20   SUMMARY OF THE INVENTION

The present invention relates to synthetic DNA molecules (also referred to
herein as "polynucleotides") and associated DNA vaccines (also referred to herein as
"polynucleotide vaccines") which elicit cellular immune and humoral responses upon
administration to the host, including primates and especially humans, and also

25   including a non-human mammal of commercial or domestic veterinary importance.
An effect of the cellular immune-directed vaccines of the present invention should be
the lower transmission rate to previously uninfected individuals and/or reduction in
the levels of the viral loads within an infected individual, so as to prolong the
asymptomatic phase of HIV-1 infection. In particular, the present invention relates to

30   DNA vaccines which encode various forms of HIV-1 Pol, wherein administration,
intracellular delivery and expression of the HIV-1 Pol gene of interest elicits a host
CTL and Th response. The preferred synthetic DNA molecules of the present
invention encode codon optimized versions of wild type HIV-1 Pol, codon optimized
versions of HIV-1 Pol fusion proteins, and codon optimized versions of HIV-1 Pol

proteins and fusion protein, including but not limited to *pol* modifications involving
residues within the catalytic regions responsible for RT, RNase and IN activity within
the host cell.

A particular embodiment of the present invention relates to codon optimized

5   wt-pol DNA constructs wherein DNA sequences encoding the protease.(PR) activity
are deleted, leaving codon optimized "wild type" sequences which encode RT
(reverse transcriptase and RNase H activity) and IN integrase activity. The nucleotide
sequence of a DNA molecule which encodes this protein is disclosed herein as SEQ
ID NO:1 and the corresponding amino acid sequence of the expressed protein is

10   disclosed herein as SEQ ID NO:2.

The present invention preferably relates to a HIV-1 DNA pol construct which
is devoid of DNA sequences encoding any PR activity, as well as containing a
mutation(s) which at least partially, and preferably substantially, abolishes RT, RNase
and/or IN activity. One type of HIV-1 pol mutant may include but is not limited to a

15   mutated DNA molecule comprising at least one nucleotide substitution which results
in a point mutation which effectively alters an active site within the RT, RNase and/or
IN regions of the expressed protein, resulting in at least substantially decreased
enzymatic activity for the RT, RNase H and/or IN functions of HIV-1 Pol. In a
preferred embodiment of this portion of the invention, a HIV-1 DNA pol construct

20   contains a mutation or mutations within the Pol coding region which effectively
abolishes RT, RNase H and IN activity. An especially preferable HIV-1 DNA pol
construct in a DNA molecule which contains at least one point mutation which alters
the active site of the RT, RNase H and IN domains of Pol, such that each activity is at
least substantially abolished. Such a HIV-1 Pol mutant will most likely comprise at

25   least one point mutation in or around each catalytic domain responsible for RT,
RNase H and IN activity, respectfully. To this end, an especially preferred HIV-1
DNA pol construct is exemplified herein and contains nine codon substitution
mutations which results in an inactivated Pol protein (IA Pol: SEQ ID NO:4, Figure
2A-C) which has no PR, RT, RNase or IN activity, wherein three such point

30   mutations reside within each of the RT, RNase and IN catalytic domains. Any
combination of the mutations disclosed herein may suitable and therefore may be
utilized as an IA-Pol-based vaccine of the present invention. While addition and
deletion mutations are contemplated and within the scope of the invention, the

preferred mutation is a point mutation resulting in a substitution of the wild type amino acid with an alternative amino acid residue.

Another aspect of the present invention is to generate HIV-1 Pol-based vaccine constructions which comprise a eukaryotic trafficking signal peptide such as
5   the leader peptide from human tPA. To this end, the present invention relates to a DNA molecule which encodes a codon optimized wt-pol DNA construct wherein the protease (PR) activity is deleted and a human tPA leader sequence is fused to the 5' end of the coding region. A DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:5, the open reading frame disclosed herein as SEQ ID NO:6.
10   The present invention especially relates to a HIV-1 Pol mutant such as IA-Pol (SEQ ID NO:4) which comprises a leader peptide, such as the human tPA leader, at the amino terminal portion of the protein, which may effect cellular trafficking and hence, immunogenicity of the expressed protein within the host cell. Any such HIV-1 DNA pol mutant disclosed in the above paragraphs is suitable for fusion downstream of a leader
15   peptide, including but by no means limited to the human tPA leader sequence. Therefore, any such leader peptide-based HIV-1 pol mutant construct may include but is not limited to a mutated DNA molecule which effectively alters the catalytic activity of the RT, RNase and/or IN region of the expressed protein, resulting in at least substantially decreased enzymatic activity one or more of the RT, RNase H and/or IN functions of
20   HIV-1 Pol. In a preferred embodiment of this portion of the invention, a leader peptide/HIV-1 DNA pol construct contains a mutation or mutations within the Pol coding region which effectively abolishes RT, RNase H and IN activity. An especially preferable HIV-1 DNA pol construct is a DNA molecule which contains at least one point mutation which alters the active site and catalytic activity within the RT, RNase H and IN
25   domains of Pol, such that each activity is at least substantially abolished, and preferably totally abolished. Such a HIV-1 Pol mutant will most likely comprise at least one point mutation in or around each catalytic domain responsible for RT, RNase H and IN activity, respectfully. An especially preferred embodiment of this portion of the invention relates to a human tPA leader fused to the IA-Pol protein comprising the nine mutations shown
30   in Table 1. The DNA molecule is disclosed herein as SEQ ID NO:7 and the expressed tPA-IA Pol protein comprises a fusion junction as shown in Figure 3. The complete amino acid sequence of the expressed protein is set forth in SEQ ID NO:8.

The present invention also relates to a substantially purified protein expressed from the DNA polynucleotide vaccines of the present invention, especially the purified

proteins set forth below as SEQ ID NOs: 2, 4, 6, and 8. These purified proteins may be useful as protein-based HIV vaccines.

The present invention also relates to non-codon optimized versions of DNA molecules and associated polynucleotides and associated DNA vaccines which
5 encode the various wild type and modified forms of the HIV Pol protein disclosed herein. Partial or fully codon optimized DNA vaccine expression vector constructs are preferred, but it is within the scope of the present invention to utilize "non-codon optimized" versions of the constructs disclosed herein, especially modified versions of HIV Pol which are shown to promote a substantial cellular immune and humoral
10 immune responses subsequent to host administration.

The DNA backbone of the DNA vaccines of the present invention are preferably DNA plasmid expression vectors. DNA plasmid expression vectors utilized in the present invention include but are not limited to constructs which comprise the cytomegalovirus promoter with the intron A sequence (CMV-intA) and
15 a bovine growth hormone transcription termination sequence. In addition, DNA plasmid vectors of the present invention preferably comprise an antibiotic resistance marker, including but not limited to an ampicillin resistance gene, a neomycin resistance gene or any other pharmaceutically acceptable antibiotic resistance marker. In addition, an appropriate polylinker cloning site and a prokaryotic origin of
20 replication sequence are also preferred. Specific DNA vectors exemplified herein include V1, V1J (SEQ ID NO:13), V1Jneo (SEQ ID NO:14), V1Jns (Figure 1A, SEQ ID NO:15), V1R (SEQ ID NO:26), and any of the aforementioned vectors wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to
25 V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:28.

The present invention especially relates to a DNA vaccine and a pharmaceutically active vaccine composition which contains this DNA vaccine, and the use as prophylactic and/or therapeutic vaccine for host immunization, preferably human host immunization, against an HIV infection or to combat an existing HIV
30 condition. These DNA vaccines are represented by codon optimized DNA molecules encoding codon optimized HIV-1 Pol (e.g. SEQ ID NO:2), codon optimized HIV-1 Pol fused to an amino terminal localized leader sequence (e.g. SEQ ID NO:6), and especially preferable, and the essence of the present invention, biologically inactive Pol proteins (IA Pol; e.g., SEQ ID NO:4) devoid of significant PR, RT, RNase or IN

-8-

activity associated with wild type Pol and a concomitant construct which contains a
leader peptide at the amino terminal region of the IA Pol protein. These constructs
are ligated within an appropriate DNA plasmid vector, with or without a nucleotide
sequence encoding a functional leader peptide. Preferred DNA vaccines of the

5   present invention comprise codon optimized DNA molecules encoding codon
optimized HIV-1 Pol and inactivated version of Pol, ligated in DNA vectors disclosed
herein, or any of the aforementioned vectors wherein a nucleotide sequence encoding
a leader peptide, preferably the human tPA leader, is fused directly downstream of the
CMV-intA promoter, including but not limited to V1Jns-tpa, as shown in Figure 1B

10   and SEQ ID NO:28.

Therefore, the present invention relates to DNA vaccines which include, but
are in no way limited to V1Jns-WTPol (comprising the DNA molecule encoding WT
Pol, as set forth in SEQ ID NO:2), V1Jns-tPA-WTPol, (comprising the DNA
molecule encoding tPA Pol, as set forth in SEQ ID NO:6), V1Jns-IAPol (comprising

15   the DNA molecule encoding IA Pol, as set forth in SEQ ID NO:4), and V1Jns-tPA-
IAPol, (comprising the DNA molecule encoding tPA-IA Pol, as set forth in SEQ ID
NO:8). Especially preferred are V1Jns-IAPol and V1Jns-tPA-IAPol, as exemplified
in Example Section 2.

The present invention also relates to HIV Pol polynucleotide

20   pharmaceutical products, as well as the production and use thereof, wherein the
DNA vaccines are formulated with an adjuvant or adjuvants which may increase
immunogenicity of the DNA polynucleotide vaccines of the present invention,
namely by promoting an enhanced cellular and/or humoral response subsequent to
inoculation. A preferred adjuvant is an aluminum phosphate-based adjuvant or a

25   calcium phosphate based adjuvant, with an aluminum phosphate adjuvant being
especially preferred. Another preferred adjuvant is a non-ionic block copolymer,
preferably comprising the blocks of polyoxyethylene (POE) and
polyoxypropylene (POP) such as a POE-POP-POE block copolymer. These
adjuvanted forms comprising the DNA vaccines disclosed herein are useful in

30   increasing cellular responses to DNA vaccination.

As used herein, a DNA vaccine or DNA polynucleotide vaccine is a DNA
molecule (i.e., "nucleic acid", "polynucleotide") which contains essential regulatory
elements such that upon introduction into a living, vertebrate cell, it is able to direct
the cellular machinery to produce translation products encoded by the respective pol

genes of the present invention.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1A-B shows schematic representation of DNA vaccine expression
vectors V1Jns (A) and V1Jns-tPA (B) utilized for HIV-1 pol and HIV-1 modified pol
constructs.

Figure 2A-C shows the nucleotide (SEQ ID NO:3) and amino acid sequence
(SEQ ID NO:4) of IA-Pol. Underlined codons and amino acids denote mutations, as
listed in Table 1.

Figure 3 shows the codon optimized nucleotide and amino acid sequences
through the fusion junction of tPA-IA-Pol (contained within SEQ ID NOs: 7 and 8,
respectively). The underlined portion represents the NH_2-terminal region of IA-Pol.

Figure 4 shows generation of a humoral response (measured as the geometric
means of anti-RT endpoint titers) from mice immunized with one or two doses of
codon optimized V1Jns-IApol and V1Jns-tpa-IApol. A portion of mice that received
30 ug of each plasmid was boosted at T=8 wks; sera from all mice were collected at 4
wk post dose 2.

Figure 5 shows the number of IFN-gamma secreting cells per 10e6 cells
following stimulation with pools of either $CD4^+$ (aa641-660, aa731-750) or $CD8^+$
(aa201-220, aa311-330, aa571-590, aa781-800) specific peptides of splenocytes (pool
of 5 spleens/cohort) from control mice and those vaccinated with increasing single
dose of codon optimized V1Jns-IApol or 30 ug of codon optimized V1Jns-tpa-IApol
(13 wks post dose 1). Mice (n=5) vaccinated with a second dose of 30 ug of either
plasmid were analyzed in an Elispot assay at 6 wks post dose 2. Reported are the
sums of the number of spots stimulated by each individual $CD8^+$ peptides because the
spots in the wells to which the pool was added are too dense to acquire accurate
counts. The $CD4^+$ cell counts are taken from the responses to the peptide pool. Error
bars represent standard deviations for counts from triplicate wells per sample per
antigen.

Figure 6A-C shows ELIspot analysis of peripheral blood cells collected from
rhesus macaques immunized three times (T=0, 4, 8 wks) with 5 mgs of codon
optimized HIV-1 Pol expressing plasmids. Antigen-specific IFN-gamma secretion
was stimulated by adding one of two pools consisting of 20-mer peptides derived
from vaccine sequence (mpol-1, aa1-420; mpol-2, aa411-850). (A) Frequencies of

spot-forming cells (SFC) as a function of time for 3 monkeys (Tag No. 94R008, 94R013, 94R033) vaccinated with V1Jns-IApol. The reported values are corrected for background responses without peptide restimulation. (B) Frequencies of spot-forming cells (SFC) as a function of time for 3 monkeys (Tag No. 920078, 920073,

5   94R028) vaccinated with 5mgs of V1Jns-tpa-IApol. (C) ELIspot responses were also measured from a monkey (920072) that did not receive any immunization.

        Figure 7A-B show bulk CTL killing from rhesus macaques immunized with codon optimized V1Jns-IApol (A)or codon optimized V1Jns-tpa-IApol (B) at 8 weeks following the third vaccination. Restimulation was performed using recombinant

10   vaccinia virus expressing pol and target cells were prepared by pulsing with the peptide pools, mpol-1 and mpol-2.

        Figure 8 shows detection of *in vitro* pol expression from cell lysates of 293 cells transfected with 10 ug of various pol constructs. Bands were detected using anti-serum from an HIV-1 seropositive human subject. Equal amounts of total protein

15   were loaded for each lane. The lanes contain the lysates from cells transfected with the following: 1: mock; 2: V1Jns-wt-pol; 3: V1Jns-IApol (codon optimized); 4: V1Jns-tpa-IApol (codon optimized); 5: V1Jns-tpa-pol (codon optimized); 6: V1R-wt-pol (codon optimized); 7: blank; and 8: 80 ng RT.

        Figure 9 shows the geometric mean anti-RT titers (GMT) plus the standard

20   errors of the geometric means for cohorts of 5 mice that received one (open circles) or two doses (solid circles) of 1, 10, 100 μg of V1R-wt-pol (codon optimized) or V1Jns-wt-pol. Sera from all animals were collected at 2 weeks post dose 2 (or 7 wks post dose 1) and assayed simultaneously. Statistical analyses were performed to compare cohorts that received the same amount and number of immunization of either

25   plasmids; p values (two-tail) less than 5% are above the bars the connect the correlated cohorts to reflect statistically significant differences.

        Figure 10 shows cellular immune responses in BALB/c mice vaccinated i.m. with 1 (pd1) or 2 (pd2) doses of varying amounts of either wt-pol (virus derived) or wt-pol (codon optimized) plasmids. At 3 wks post dose 2, frequencies of IFN-γ-

30   secreting splenocytes are determined from pools of 5 spleens per cohort against mixtures of either CD4$^+$ peptides (aa21-40, aa411-430, aa531-550, aa641-660, aa731-750, aa771-790) or CD8$^+$ peptides (aa201-220, aa311-330) at 4 μg/mL final concentration per peptide.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to synthetic DNA molecules and associated
DNA vaccines which elicit CTL and Th cellular immune responses upon
administration to the host, including primates and especially humans. An effect of the
5   cellular immune-directed vaccines of the present invention should be a lower
transmission rate to previously uninfected individuals and/or reduction in the levels of
the viral loads within an infected individual, so as to prolong the asymptomatic phase
of HIV-1 infection. In particular, the present invention relates to DNA vaccines
which encode various forms of HIV-1 Pol, wherein administration, intracellular
10   delivery and expression of the HIV-1 Pol gene of interest elicits a host CTL and Th
response. The preferred synthetic DNA molecules of the present invention encode
codon optimized wild type Pol (without Pro activity) and various codon optimized
inactivated HIV-1 Pol proteins. The HIV-1 *pol* constructs disclosed herein are
especially preferred for pharmaceutical uses, especially for human administration as a
15   DNA vaccine. The HIV-1 genome employs predominantly uncommon codons
compared to highly expressed human genes. Therefore, the pol open reading frame
has been synthetically manipulated using optimal codons for human expression. As
noted above, a preferred embodiment of the present invention relates to DNA
molecules which comprise a HIV-1 pol open reading frame, whether encoding full
20   length pol or a modification or fusion as described herein, wherein the codon usage
has been optimized for expression in a mammal, especially a human.

The synthetic *pol* gene disclosed herein comprises the coding sequences for
the reverse transcriptase (or RT which consists of a polymerase and RNase H activity)
and integrase (IN). The protein sequence is based on that of Hxb2r, a clonal isolate of
25   IIIB; this sequence has been shown to be closest to the consensus clade B sequence
with only 16 nonidentical residues out of 848 (Korber, et al., 1998, Human
retroviruses and AIDS, Los Alamos National Laboratory, Los Alamos, New Mexico).
The skilled artisan will understand after review of this specification that any available
HIV-1 or HIV-2 strain provides a potential template for the generation of HIV pol
30   DNA vaccine constructs disclosed herein. It is further noted that the protease gene is
excluded from the DNA vaccine constructs of the present invention to insure safety
from any residual protease activity in spite of mutational inactivation. The design of
the gene sequences for both wild-type (wt-pol) and inactivated pol (IA-pol)
incorporates the use of human preferred ("humanized") codons for each amino acid

-12-

residue in the sequence in order to maximize *in vivo* mammalian expression (Lathe, 1985, J. Mol. Biol. 183:1-12). As can be discerned by inspecting the codon usage in SEQ ID NOs: 1, 3, 5 and 7, the following codon usage for mammalian optimization is preferred: Met (ATG), Gly (GGC), Lys (AAG), Trp (TGG), Ser (TCC), Arg (AGG),

5   Val (GTG), Pro (CCC), Thr (ACC), Glu (GAG); Leu (CTG), His (CAC), Ile (ATC), Asn (AAC), Cys (TGC), Ala (GCC), Gln (CAG), Phe (TTC) and Tyr (TAC). For an additional discussion relating to mammalian (human) codon optimization, see WO 97/31115 (PCT/US97/02294), which is hereby incorporated by reference. It is intended that the skilled artisan may use alternative versions of codon optimization or

10   may omit this step when generating HIV pol vaccine constructs within the scope of the present invention. Therefore, the present invention also relates to non-codon optimized versions of DNA molecules and associated DNA vaccines which encode the various wild type and modified forms of the HIV Pol protein disclosed herein. However, codon optimization of these constructs is a preferred embodiment of this

15   invention.

A particular embodiment of the present invention relates to codon optimized wt-pol DNA constructs (herein, "wt-pol" or "wt-pol (codon optimized))" wherein DNA sequences encoding the protease (PR) activity are deleted, leaving codon optimized "wild type" sequences which encode RT (reverse transcriptase and RNase

20   H activity) and IN integrase activity. A DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:1, the open reading frame being contained from an initiating Met residue at nucleotides 10-12 to a termination codon from nucleotides 2560-2562. SEQ ID NO:1 is as follows:

```
     AGATCTACCA TGGCCCCCAT CTCCCCCATT GAGACTGTGC CTGTGAAGCT GAAGCCTGGC
25   ATGGATGGCC CCAAGGTGAA GCAGTGGCCC CTGACTGAGG AGAAGATCAA GGCCCTGGTG
     GAAATCTGCA CTGAGATGGA GAAGGAGGGC AAAATCTCCA AGATTGGCCC CGAGAACCCC
     TACAACACCC CTGTGTTTGC CATCAAGAAG AAGGACTCCA CCAAGTGGAG GAAGCTGGTG
     GACTTCAGGG AGCTGAACAA GAGGACCCAG GACTTCTGGG AGGTGCAGCT GGGCATCCCC
     CACCCCGCTG GCCTGAAGAA GAAGAAGTCT GTGACTGTGC TGGATGTGGG GGATGCCTAC
30   TTCTCTGTGC CCCTGGATGA GGACTTCAGG AAGTACACTG CCTTCACCAT CCCCTCCATC
     AACAATGAGA CCCCTGGCAT CAGGTACCAG TACAATGTGC TGCCCCAGGG CTGGAAGGGC
     TCCCCTGCCA TCTTCCAGTC CTCCATGACC AAGATCCTGG AGCCCTTCAG GAAGCAGAAC
     CCTGACATTG TGATCTACCA GTACATGGAT GACCTGTATG TGGGCTCTGA CCTGGAGATT
     GGGCAGCACA GGACCAAGAT TGAGGAGCTG AGGCAGCACC TGCTGAGGTG GGGCCTGACC
```

```
ACCCCTGACA AGAAGCACCA GAAGGAGCCC CCCTTCCTGT GGATGGGCTA TGAGCTGCAC
CCCGACAAGT GGACTGTGCA GCCCATTGTG CTGCCTGAGA AGGACTCCTG GACTGTGAAT
GACATCCAGA AGCTGGTGGG CAAGCTGAAC TGGGCCTCCC AAATCTACCC TGGCATCAAG
GTGAGGCAGC TGTGCAAGCT GCTGAGGGGC ACCAAGGCCC TGACTGAGGT GATCCCCCTG
ACTGAGGAGG CTGAGCTGGA GCTGGCTGAG AACAGGGAGA TCCTGAAGGA GCCTGTGCAT
GGGGTGTACT ATGACCCCTC CAAGGACCTG ATTGCTGAGA TCCAGAAGCA GGGCCAGGGC
CAGTGGACCT ACCAAATCTA CCAGGAGCCC TTCAAGAACC TGAAGACTGG CAAGTATGCC
AGGATGAGGG GGGCCCACAC CAATGATGTG AAGCAGCTGA CTGAGGCTGT GCAGAAGATC
ACCACTGAGT CCATTGTGAT CTGGGGCAAG ACCCCCAAGT TCAAGCTGCC CATCCAGAAG
GAGACCTGGG AGACCTGGTG GACTGAGTAC TGGCAGGCCA CCTGGATCCC TGAGTGGGAG
TTTGTGAACA CCCCCCCCCT GGTGAAGCTG TGGTACCAGC TGGAGAAGGA GCCCATTGTG
GGGGCTGAGA CCTTCTATGT GGATGGGGCT GCCAACAGGG AGACCAAGCT GGGCAAGGCT
GGCTATGTGA CCAACAGGGG CAGGCAGAAG GTGGTGACCC TGACTGACAC CACCAACCAG
AAGACTGAGC TCCAGGCCAT CTACCTGGCC CTCCAGGACT CTGGCCTGGA GGTGAACATT
GTGACTGACT CCCAGTATGC CCTGGGCATC ATCCAGGCCC AGCCTGATCA GTCTGAGTCT
GAGCTGGTGA ACCAGATCAT TGAGCAGCTG ATCAAGAAGG AGAAGGTGTA CCTGGCCTGG
GTGCCTGCCC ACAAGGGCAT TGGGGGCAAT GAGCAGGTGG ACAAGCTGGT GTCTGCTGGC
ATCAGGAAGG TGCTGTTCCT GGATGGCATT GACAAGGCCC AGGATGAGCA TGAGAAGTAC
CACTCCAACT GGAGGGCTAT GGCCTCTGAC TTCAACCTGC CCCCTGTGGT GGCTAAGGAG
ATTGTGGCCT CCTGTGACAA GTGCCAGCTG AAGGGGGAGG CCATGCATGG GCAGGTGGAC
TGCTCCCCTG GCATCTGGCA GCTGGACTGC ACCCACCTGG AGGGCAAGGT GATCCTGGTG
GCTGTGCATG TGGCCTCCGG CTACATTGAG GCTGAGGTGA TCCCTGCTGA GACAGGCCAG
GAGACTGCCT ACTTCCTGCT GAAGCTGGCT GGCAGGTGGC CTGTGAAGAC CATCCACACT
GACAATGGCT CCAACTTCAC TGGGGCCACA GTGAGGGCTG CCTGCTGGTG GGCTGGCATC
AAGCAGGAGT TTGGCATCCC CTACAACCCC CAGTCCCAGG GGGTGGTGGA GTCCATGAAC
AAGGAGCTGA AGAAGATCAT TGGGCAGGTG AGGGACCAGG CTGAGCACCT GAAGACAGCT
GTGCAGATGG CTGTGTTCAT CCACAACTTC AAGAGGAAGG GGGGCATCGG GGGCTACTCC
GCTGGGGAGA GGATTGTGGA CATCATTGCC ACAGACATCC AGACCAAGGA GCTCCAGAAG
CAGATCACCA AGATCCAGAA CTTCAGGGTG TACTACAGGG ACTCCAGGAA CCCCCTGTGG
AAGGGCCCTG CCAAGCTGCT GTGGAAGGGG GAGGGGGCTG TGGTGATCCA GGACAACTCT
GACATCAAGG TGGTGCCCAG GAGGAAGGCC AAGATCATCA GGGACTATGG CAAGCAGATG
GCTGGGGATG ACTGTGTGGC CTCCAGGCAG GATGAGGACT AAAGCCCGGG CAGATCT (SEQ
ID NO:1).
```

The open reading frame of the wild type pol construct disclosed as SEQ ID
NO:1 contains 850 amino acids, disclosed herein as SEQ ID NO:2, as follows:

```
      Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro
      Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys
 5    Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys
      Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala
      Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg
      Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile
      Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp
 10   Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys
      Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile
      Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala
      Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln
      Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Gly
 15   Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg
      Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln
      Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys
      Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val
      Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile
 20   Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr
      Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu
      Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr
      Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln
      Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys
 25   Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys
      Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile
      Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp
      Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp
      Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu
 30   Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala
      Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly
      Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Glu
      Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn
      Ile Val Thr Asp Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro
```

Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile

Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile

Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys

Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys

5   Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro

Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys

Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln

Leu Asp Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His

Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly

10   Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val

Lys Thr Ile His Thr Asp Asn Gly Ser Asn Phe Thr Gly Ala Thr Val

Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro

Tyr Asn Pro Gln Ser Gln Gly Val Val Glu Ser Met Asn Lys Glu Leu

Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr

15   Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly

Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr

Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn

Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro

Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn

20   Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp

Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp

Glu Asp (SEQ ID NO:2).

The present invention especially relates to a codon optimized HIV-1 DNA pol construct wherein, in addition to deletion of the portion of the wild type sequence

25   encoding the protease activity, a combination of active site residue mutations are introduced which are deleterious to HIV-1 pol (RT-RH-IN) activity of the expressed protein. Therefore, the present invention preferably relates to a HIV-1 DNA pol construct which is devoid of DNA sequences encoding any PR activity, as well as containing a mutation(s) which at least partially, and preferably substantially,

30   abolishes RT, RNase and/or IN activity. One type of HIV-1 pol mutant may include but is not limited to a mutated DNA molecule comprising at least one nucleotide substitution which results in a point mutation which effectively alters an active site within the RT, RNase and/or IN regions of the expressed protein, resulting in at least substantially decreased enzymatic activity for the RT, RNase H and/or IN functions of

HIV-1 Pol. In a preferred embodiment of this portion of the invention, a HIV-1 DNA
pol construct contains a mutation or mutations within the Pol coding region which
effectively abolishes RT, RNase H and IN activity. An especially preferable HIV-1
DNA pol construct in a DNA molecule which contains at least one point mutation
5   which alters the active site of the RT, RNase H and IN domains of Pol, such that each
activity is at least substantially abolished. Such a HIV-1 Pol mutant will most likely
comprise at least one point mutation in or around each catalytic domain responsible
for RT, RNase H and IN activity, respectfully. To this end, an especially preferred
HIV-1 DNA pol construct is exemplified herein and contains nine codon substitution
10   mutations which results in an inactivated Pol protein (IA Pol: SEQ ID NO:4, Figure
2A-C) which has no PR, RT, RNase or IN activity, wherein three such point
mutations reside within each of the RT, RNase and IN catalytic domains. Therefore,
an especially preferred exemplification is a DNA molecule which encodes IA-pol,
which contains all nine mutations as shown below in Table 1. An additional preferred
15   amino acid residue for substitution is Asp551, localized within the RNase domain of
Pol. Any combination of the mutations disclosed herein may suitable and therefore
may be utilized as an IA-Pol-based vaccine of the present invention. While addition
and deletion mutations are contemplated and within the scope of the invention, the
preferred mutation is a point mutation resulting in a substitution of the wild type
20   amino acid with an alternative amino acid residue.

Table 1

wt aa	aa residue	mutant aa	enzyme function
Asp	112	Ala	RT
Asp	187	Ala	RT
Asp	188	Ala	RT
Asp	445	Ala	RNase H
Glu	480	Ala	RNase H
Asp	500	Ala	RNase H
Asp	626	Ala	IN
Asp	678	Ala	IN
Glu	714	Ala	IN

It is preferred that point mutations be incorporated into the IApol mutant vaccines of the present invention so as to lessen the possibility of altering epitopes in and around the active site(s) of HIV-1 Pol.

To this end, SEQ ID NO:3 discloses the nucleotide sequence which codes for
5   a codon optimized pol in addition to the nine mutations shown in Table 1, disclosed as follows, and referred to herein as "IApol":

```
     AGATCTACCA TGGCCCCCAT CTCCCCCATT GAGACTGTGC CTGTGAAGCT GAAGCCTGGC
     ATGGATGGCC CCAAGGTGAA GCAGTGGCCC CTGACTGAGG AGAAGATCAA GGCCCTGGTG
     GAAATCTGCA CTGAGATGGA GAAGGAGGGC AAAATCTCCA AGATTGGCCC CGAGAACCCC
10   TACAACACCC CTGTGTTTGC CATCAAGAAG AAGGACTCCA CCAAGTGGAG GAAGCTGGTG
     GACTTCAGGG AGCTGAACAA GAGGACCCAG GACTTCTGGG AGGTGCAGCT GGGCATCCCC
     CACCCCGCTG GCCTGAAGAA GAAGAAGTCT GTGACTGTGC TGGCTGTGGG GGATGCCTAC
     TTCTCTGTGC CCCTGGATGA GGACTTCAGG AAGTACACTG CCTTCACCAT CCCCTCCATC
     AACAATGAGA CCCCTGGCAT CAGGTACCAG TACAATGTGC TGCCCCAGGG CTGGAAGGGC
15   TCCCCTGCCA TCTTCCAGTC CTCCATGACC AAGATCCTGG AGCCCTTCAG GAAGCAGAAC
     CCTGACATTG TGATCTACCA GTACATGGCT GCCCTGTATG TGGGCTCTGA CCTGGAGATT
     GGGCAGCACA GGACCAAGAT TGAGGAGCTG AGGCAGCACC TGCTGAGGTG GGGCCTGACC
     ACCCCTGACA AGAAGCACCA GAAGGAGCCC CCCTTCCTGT GGATGGGCTA TGAGCTGCAC
     CCCGACAAGT GGACTGTGCA GCCCATTGTG CTGCCTGAGA AGGACTCCTG GACTGTGAAT
20   GACATCCAGA AGCTGGTGGG CAAGCTGAAC TGGGCCTCCC AAATCTACCC TGGCATCAAG
     GTGAGGCAGC TGTGCAAGCT GCTGAGGGGC ACCAAGGCCC TGACTGAGGT GATCCCCCTG
     ACTGAGGAGG CTGAGCTGGA GCTGGCTGAG AACAGGGAGA TCCTGAAGGA GCCTGTGCAT
     GGGGTGTACT ATGACCCCTC CAAGGACCTG ATTGCTGAGA TCCAGAAGCA GGGCCAGGGC
     CAGTGGACCT ACCAAATCTA CCAGGAGCCC TTCAAGAACC TGAAGACTGG CAAGTATGCC
25   AGGATGAGGG GGGCCCACAC CAATGATGTG AAGCAGCTGA CTGAGGCTGT GCAGAAGATC
     ACCACTGAGT CCATTGTGAT CTGGGGCAAG ACCCCCAAGT TCAAGCTGCC CATCCAGAAG
     GAGACCTGGG AGACCTGGTG GACTGAGTAC TGGCAGGCCA CCTGGATCCC TGAGTGGGAG
     TTTGTGAACA CCCCCCCCCT GGTGAAGCTG TGGTACCAGC TGGAGAAGGA GCCCATTGTG
     GGGGCTGAGA CCTTCTATGT GGCTGGGGCT GCCAACAGGG AGACCAAGCT GGGCAAGGCT
30   GGCTATGTGA CCAACAGGGG CAGGCAGAAG GTGGTGACCC TGACTGACAC CACCAACCAG
     AAGACTGCCC TCCAGGCCAT CTACCTGGCC CTCCAGGACT CTGGCCTGGA GGTGAACATT
     GTGACTGCCT CCCAGTATGC CCTGGGCATC ATCCAGGCCC AGCCTGATCA GTCTGAGTCT
     GAGCTGGTGA ACCAGATCAT TGAGCAGCTG ATCAAGAAGG AGAAGGTGTA CCTGGCCTGG
     GTGCCTGCCC ACAAGGGCAT TGGGGGCAAT GAGCAGGTGG ACAAGCTGGT GTCTGCTGGC
```

```
     ATCAGGAAGG TGCTGTTCCT GGATGGCATT GACAAGGCCC AGGATGAGCA TGAGAAGTAC
     CACTCCAACT GGAGGGCTAT GGCCTCTGAC TTCAACCTGC CCCCTGTGGT GGCTAAGGAG
     ATTGTGGCCT CCTGTGACAA GTGCCAGCTG AAGGGGGAGG CCATGCATGG GCAGGTGGAC
     TGCTCCCCTG GCATCTGGCA GCTGGCCTGC ACCCACCTGG AGGGCAAGGT GATCCTGGTG
  5  GCTGTGCATG TGGCCTCCGG CTACATTGAG GCTGAGGTGA TCCCTGCTGA GACAGGCCAG
     GAGACTGCCT ACTTCCTGCT GAAGCTGGCT GGCAGGTGGC CTGTGAAGAC CATCCACACT
     GCCAATGGCT CCAACTTCAC TGGGGCCACA GTGAGGGCTG CCTGCTGGTG GGCTGGCATC
     AAGCAGGAGT TTGGCATCCC CTACAACCCC CAGTCCCAGG GGGTGGTGGC CTCCATGAAC
     AAGGAGCTGA AGAAGATCAT TGGGCAGGTG AGGGACCAGG CTGAGCACCT GAAGACAGCT
 10  GTGCAGATGG CTGTGTTCAT CCACAACTTC AAGAGGAAGG GGGGCATCGG GGGCTACTCC
     GCTGGGGAGA GGATTGTGGA CATCATTGCC ACAGACATCC AGACCAAGGA GCTCCAGAAG
     CAGATCACCA AGATCCAGAA CTTCAGGGTG TACTACAGGG ACTCCAGGAA CCCCCTGTGG
     AAGGGCCCTG CCAAGCTGCT GTGGAAGGGG GAGGGGGCTG TGGTGATCCA GGACAACTCT
     GACATCAAGG TGGTGCCCAG GAGGAAGGCC AAGATCATCA GGGACTATGG CAAGCAGATG
 15  GCTGGGGATG ACTGTGTGGC CTCCAGGCAG GATGAGGACT AAAGCCCGGG CAGATCT (SEQ ID
     NO:3).
```

In order to produce the IA-pol DNA vaccine construction, inactivation of the enzymatic functions was achieved by replacing a total of nine active-site residues from the enzyme subunits with alanine side-chains. As shown in Table 1, all residues

20   that comprise the catalytic triad of the polymerase, namely Asp112, Asp187, and Asp188, were substituted with alanine (Ala) residues (Larder, et al., *Nature* 1987, 327: 716-717; Larder, et al., 1989, *Proc. Natl. Acad. Sci.* 1989, 86: 4803-4807). Three additional mutations were introduced at Asp445, Glu480 and Asp500 to abolish RNase H activity (Asp551 was left unchanged in this IA Pol construct), with each

25   residue being substituted for an Ala residue, respectively (Davies, et al., 1991, Science 252:, 88-95; Schatz, et al., 1989, *FEBS Lett.* 257: 311-314; Mizrahi, et al., 1990, Nucl. Acids. Res. 18: pp. 5359-5353). HIV pol integrase function was abolished through three mutations at Asp626, Asp678 and Glu714. Again, each of these residues has been substituted with an Ala residue (Wiskerchen, et al., 1995, J.

30   Virol. 69: 376-386; Leavitt, et al., 1993, J. Biol. Chem. 268: 2113-2119). Amino acid residue Pro3 of SEQ ID NO:4 marks the start of the RT gene. The complete amino acid sequence of IA-Pol is disclosed herein as SEQ ID NO:4, as follows:

```
     Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro
     Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys
```

```
        Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys
        Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala
        Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg
        Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile
 5      Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Ala
        Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys
        Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile
        Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala
        Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln
 10     Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly
        Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg
        Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln
        Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys
        Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val
 15     Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile
        Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr
        Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu
        Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr
        Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln
 20     Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys
        Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys
        Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile
        Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp
        Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp
 25     Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu
        Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Ala Gly Ala Ala
        Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly
        Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Ala
        Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn
 30     Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro
        Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile
        Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile
        Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys
        Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys
```

Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro
Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys
Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln
Leu Ala Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His
5   Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly
Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val
Lys Thr Ile His Thr Ala Asn Gly Ser Asn Phe Thr Gly Ala Thr Val
Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro
Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Met Asn Lys Glu Leu
10   Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr
Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly
Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr
Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn
Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro
15   Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn
Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp
Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp
Glu Asp (SEQ ID NO:4).

As noted above, it will be understood that any combination of the mutations
20   disclosed above may be suitable and therefore be utilized as an IA-pol-based vaccine
of the present invention. For example, it may be possible to mutate only 2 of the 3
residues within the respective reverse transcriptase, RNase H, and integrase coding
regions while still abolishing these enzymatic activities. However, the IA-pol
construct described above and disclosed as SEQ ID NO:3, as well as the expressed
25   protein (SEQ ID NO:4) is preferred. It is also preferred that at least one mutation be
present in each of the three catalytic domains.

Another aspect of the present invention is to generate codon optimized HIV-1
Pol-based vaccine constructions which comprise a eukaryotic trafficking signal
peptide such as from tPA (tissue-type plasminogen activator) or by a leader peptide
30   such as is found in highly expressed mammalian proteins such as immunoglobulin
leader peptides. Any functional leader peptide may be tested for efficacy. However,
a preferred embodiment of the present invention is to provide for HIV-1 Pol mutant
vaccine constructions as disclosed herein which also comprise a leader peptide,
preferably a leader peptide from human tPA. In other words, a codon optimized

-21-

HIV-1 Pol mutant such as IA-Pol (SEQ ID NO:4) may also comprise a leader peptide
at the amino terminal portion of the protein, which may effect cellular trafficking and
hence, immunogenicity of the expressed protein within the host cell. As shown in
Figure 1A-B for the DNA vector V1Jns, a DNA vector which may be utilized to

5   practice the present invention may be modified by known recombinant DNA
methodology to contain a leader signal peptide of interest, such that downstream
cloning of the modified HIV-1 protein of interest results in a nucleotide sequence
which encodes a modified HIV-1 tPA/Pol protein. In the alternative, as noted above,
insertion of a nucleotide sequence which encodes a leader peptide may be inserted

10   into a DNA vector housing the open reading frame for the Pol protein of interest.
Regardless of the cloning strategy, the end result is a polynucleotide vaccine which
comprises vector components for effective gene expression in conjunction with
nucleotide sequences which encode a modified HIV-1 Pol protein of interest,
including but not limited to a HIV-1 Pol protein which contains a leader peptide. The

15   amino acid sequence of the human tPA leader utilized herein is as follows:
MDAMKRGLCCVLLLCGAVFVSPSEISS (SEQ ID NO:28). Therefore, another
aspect of the present invention is to generate HIV-1 Pol-based vaccine constructions
which comprise a eukaryotic trafficking signal peptide such as from tPA. To this end,
the present invention relates to a DNA molecule which encodes a codon optimized

20   wt-pol DNA construct wherein the protease (PR) activity is deleted and a human tPA
leader sequence is fused to the 5' end of the coding region. A DNA molecule which
encodes this protein is disclosed herein as SEQ ID NO:5, the open reading frame
disclosed herein as SEQ ID NO:6.

       To this end, the present invention relates to a DNA molecule which encodes a

25   codon optimized wt-pol DNA construct wherein the protease (PR) activity is deleted
and a human tPA leader sequence is fused to the 5' end of the coding region (herein,
"tPA-wt-pol"). A DNA molecule which encodes this protein is disclosed herein as
SEQ ID NO:5, the open reading frame being contained from an initiating Met residue
at nucleotides 8-10 to a termination codon from nucleotides 2633-2635. SEQ ID

30   NO:5 is as follows:

```
GATCACCATG GATGCAATGA AGAGAGGGCT CTGCTGTGTG CTGCTGCTGT GTGGAGCAGT
CTTCGTTTCG CCCAGCGAGA TCTCCGCCCC CATCTCCCCC ATTGAGACTG TGCCTGTGAA
GCTGAAGCCT GGCATGGATG GCCCCAAGGT GAAGCAGTGG CCCCTGACTG AGGAGAAGAT
CAAGGCCCTG GTGGAAATCT GCACTGAGAT GGAGAAGGAG GGCAAAATCT CCAAGATTGG
```

CCCCGAGAAC CCCTACAACA CCCCTGTGTT TGCCATCAAG AAGAAGGACT CCACCAAGTG

GAGGAAGCTG GTGGACTTCA GGGAGCTGAA CAAGAGGACC CAGGACTTCT GGGAGGTGCA

GCTGGGCATC CCCCACCCCG CTGGCCTGAA GAAGAAGAAG TCTGTGACTG TGCTGGATGT

GGGGGATGCC TACTTCTCTG TGCCCCTGGA TGAGGACTTC AGGAAGTACA CTGCCTTCAC

5 CATCCCCTCC ATCAACAATG AGACCCCTGG CATCAGGTAC CAGTACAATG TGCTGCCCCA

GGGCTGGAAG GGCTCCCCTG CCATCTTCCA GTCCTCCATG ACCAAGATCC TGGAGCCCTT

CAGGAAGCAG AACCCTGACA TTGTGATCTA CCAGTACATG GATGACCTGT ATGTGGGCTC

TGACCTGGAG ATTGGGCAGC ACAGGACCAA GATTGAGGAG CTGAGGCAGC ACCTGCTGAG

GTGGGGCCTG ACCACCCCTG ACAAGAAGCA CCAGAAGGAG CCCCCCTTCC TGTGGATGGG

10 CTATGAGCTG CACCCCGACA AGTGGACTGT GCAGCCCATT GTGCTGCCTG AGAAGGACTC

CTGGACTGTG AATGACATCC AGAAGCTGGT GGGCAAGCTG AACTGGGCCT CCCAAATCTA

CCCTGGCATC AAGGTGAGGC AGCTGTGCAA GCTGCTGAGG GGCACCAAGG CCCTGACTGA

GGTGATCCCC CTGACTGAGG AGGCTGAGCT GGAGCTGGCT GAGAACAGGG AGATCCTGAA

GGAGCCTGTG CATGGGGTGT ACTATGACCC CTCCAAGGAC CTGATTGCTG AGATCCAGAA

15 GCAGGGCCAG GGCCAGTGGA CCTACCAAAT CTACCAGGAG CCCTTCAAGA ACCTGAAGAC

TGGCAAGTAT GCCAGGATGA GGGGGGCCCA CACCAATGAT GTGAAGCAGC TGACTGAGGC

TGTGCAGAAG ATCACCACTG AGTCCATTGT GATCTGGGGC AAGACCCCCA AGTTCAAGCT

GCCCATCCAG AAGGAGACCT GGGAGACCTG GTGGACTGAG TACTGGCAGG CCACCTGGAT

CCCTGAGTGG GAGTTTGTGA ACACCCCCCC CCTGGTGAAG CTGTGGTACC AGCTGGAGAA

20 GGAGCCCATT GTGGGGGCTG AGACCTTCTA TGTGGATGGG CTGCCAACA GGGAGACCAA

GCTGGGCAAG GCTGGCTATG TGACCAACAG GGGGCAGGCA AAGGTGGTGA CCCTGACTGA

CACCACCAAC CAGAAGACTG AGCTCCAGGC CATCTACCTG GCCCTCCAGG ACTCTGGCCT

GGAGGTGAAC ATTGTGACTG ACTCCCAGTA TGCCCTGGGC ATCATCCAGG CCCAGCCTGA

TCAGTCTGAG TCTGAGCTGG TGAACCAGAT CATTGAGCAG CTGATCAAGA AGGAGAAGGT

25 GTACCTGGCC TGGGTGCCTG CCCACAAGGG CATTGGGGGC AATGAGCAGG TGGACAAGCT

GGTGTCTGCT GGCATCAGGA AGGTGCTGTT CCTGGATGGC ATTGACAAGG CCCAGGATGA

GCATGAGAAG TACCACTCCA ACTGGAGGGC TATGGCCTCT GACTTCAACC TGCCCCCTGT

GGTGGCTAAG GAGATTGTGG CCTCCTGTGA CAAGTGCCAG CTGAAGGGGG AGGCCATGCA

TGGGCAGGTG GACTGCTCCC CTGGCATCTG GCAGCTGGAC TGCACCCACC TGGAGGGCAA

30 GGTGATCCTG GTGGCTGTGC ATGTGGCCTC CGGCTACATT GAGGCTGAGG TGATCCCTGC

TGAGACAGGC CAGGAGACTG CCTACTTCCT GCTGAAGCTG GCTGGCAGGT GGCCTGTGAA

GACCATCCAC ACTGACAATG GCTCCAACTT CACTGGGGCC ACAGTGAGGG CTGCCTGCTG

GTGGGCTGGC ATCAAGCAGG AGTTTGGCAT CCCCTACAAC CCCCAGTCCC AGGGGGTGGT

GGAGTCCATG AACAAGGAGC TGAAGAAGAT CATTGGGCAG GTGAGGGACC AGGCTGAGCA

CCTGAAGACA GCTGTGCAGA TGGCTGTGTT CATCCACAAC TTCAAGAGGA AGGGGGGCAT

CGGGGGCTAC TCCGCTGGGG AGAGGATTGT GGACATCATT GCCACAGACA TCCAGACCAA

GGAGCTCCAG AAGCAGATCA CCAAGATCCA GAACTTCAGG GTGTACTACA GGGACTCCAG

GAACCCCCTG TGGAAGGGCC CTGCCAAGCT GCTGTGGAAG GGGGAGGGGG CTGTGGTGAT

5   CCAGGACAAC TCTGACATCA AGGTGGTGCC CAGGAGGAAG GCCAAGATCA TCAGGGACTA

TGGCAAGCAG ATGGCTGGGG ATGACTGTGT GGCCTCCAGG CAGGATGAGG ACTAAAGCCC

GGGCAGATCT (SEQ ID NO:5).

The open reading frame of the wild type tPA-pol construct disclosed as SEQ
ID NO:5 contains 875 amino acids, disclosed herein as SEQ ID NO:6, as follows:

10   Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly

Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile

Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val

Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile

Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu

15   Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr

Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln

Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys

Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr Phe Ser

Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro

20   Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu

Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr

Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr

Gln Tyr Met Asp Asp Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln

His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly

25   Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp

Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val

Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val

Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg

Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile

30   Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile

Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu

Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile

Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met

Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln

Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe

Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr

Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro

Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala

5   Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Glu Thr Lys. Leu Gly

Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu

Thr Asp Thr Thr Asn Gln Lys Thr Glu Leu Gln Ala Ile Tyr Leu Ala

Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Asp Ser Gln Tyr

Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu

10 Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu

Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp

Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile

Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala

Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val

15 Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln

Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Asp Cys Thr His Leu Glu

Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu

Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu

Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Asp Asn

20 Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala

Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly

Val Val Glu Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val

Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe

Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly

25 Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu

Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp

Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly

Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro

Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly

30 Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp (SEQ ID NO:6).

The present invention also relates to a codon optimized HIV-1 Pol mutant such
as IA-Pol (SEQ ID NO:4) which comprises a leader peptide at the amino terminal
portion of the protein, which may effect cellular trafficking and hence,
immunogenicity of the expressed protein within the host cell. Any such HIV-1 DNA

pol mutant disclosed in the above paragraphs is suitable for fusion downstream of a leader peptide, such as a leader peptide including but not limited to the human tPA leader sequence. Therefore, any such leader peptide-based HIV-1 pol mutant construct may include but is not limited to a mutated DNA molecule which effectively

5   alters the catalytic activity of the RT, RNase and/or IN region of the expressed protein, resulting in at least substantially decreased enzymatic activity one or more of the RT, RNase H and/or IN functions of HIV-1 Pol. In a preferred embodiment of this portion of the invention, a leader peptide/HIV-1 DNA pol construct contains a mutation or mutations within the Pol coding region which effectively abolishes RT, RNase H and

10   IN activity. An especially preferable HIV-1 DNA pol construct is a DNA molecule which contains at least one point mutation which alters the active site and catalytic activity within the RT, RNase H and IN domains of Pol, such that each activity is at least substantially abolished, and preferably totally abolished. Such a HIV-1 Pol mutant will most likely comprise at least one point mutation in or around each

15 ·   catalytic domain responsible for RT, RNase H and IN activity, respectfully. An · especially preferred embodiment of this portion of the invention relates to a human tPA leader fused to the IA-Pol protein comprising the nine mutations shown in Table 1. The DNA molecule is disclosed herein as SEQ ID NO:7 and the expressed tPA-IA Pol protein comprises a fusion junction as shown in Figure 3. The complete amino

20   acid sequence of the expressed protein is set forth in SEQ ID NO:8. To this end, SEQ ID NO:7 discloses the nucleotide sequence which codes for a human tPA leader fused to the IA Pol protein comprising the nine mutations shown in Table 1 (herein, "tPA-opt-IApol"). The open reading frame begins with the initiating Met (nucleotides 8-10) and terminates with a "TAA" codon at nucleotides 2633-2635. The nucleotide

25   sequence encoding tPA-IAPol is also disclosed as follows:

```
GATCACCATG GATGCAATGA AGAGAGGGCT CTGCTGTGTG CTGCTGCTGT GTGGAGCAGT
CTTCGTTTCG CCCAGCGAGA TCTCCGCCCC CATCTCCCCC ATTGAGACTG TGCCTGTGAA
GCTGAAGCCT GGCATGGATG GCCCCAAGGT GAAGCAGTGG CCCCTGACTG AGGAGAAGAT
CAAGGCCCTG GTGGAAATCT GCACTGAGAT GGAGAAGGAG GGCAAAATCT CCAAGATTGG
```
30
```
CCCCGAGAAC CCCTACAACA CCCCTGTGTT TGCCATCAAG AAGAAGGACT CCACCAAGTG
GAGGAAGCTG GTGGACTTCA GGGAGCTGAA CAAGAGGACC CAGGACTTCT GGGAGGTGCA
GCTGGGCATC CCCCACCCCG CTGGCCTGAA GAAGAAGAAG TCTGTGACTG TGCTGGCTGT
GGGGGATGCC TACTTCTCTG TGCCCCTGGA TGAGGACTTC AGGAAGTACA CTGCCTTCAC
CATCCCCTCC ATCAACAATG AGACCCCTGG CATCAGGTAC CAGTACAATG TGCTGCCCCA
```

GGGCTGGAAG GGCTCCCCTG CCATCTTCCA GTCCTCCATG ACCAAGATCC TGGAGCCCTT

CAGGAAGCAG AACCCTGACA TTGTGATCTA CCAGTACATG GCTGCCCTGT ATGTGGGCTC

TGACCTGGAG ATTGGGCAGC ACAGGACCAA GATTGAGGAG CTGAGGCAGC ACCTGCTGAG

GTGGGGCCTG ACCACCCCTG ACAAGAAGCA CCAGAAGGAG CCCCCCTTCC TGTGGATGGG

5   CTATGAGCTG CACCCCGACA AGTGGACTGT GCAGCCCATT GTGCTGCCTG AGAAGGACTC

CTGGACTGTG AATGACATCC AGAAGCTGGT GGGCAAGCTG AACTGGGCCT CCCAAATCTA

CCCTGGCATC AAGGTGAGGC AGCTGTGCAA GCTGCTGAGG GGCACCAAGG CCCTGACTGA

GGTGATCCCC CTGACTGAGG AGGCTGAGCT GGAGCTGGCT GAGAACAGGG AGATCCTGAA

GGAGCCTGTG CATGGGGTGT ACTATGACCC CTCCAAGGAC CTGATTGCTG AGATCCAGAA

10   GCAGGGCCAG GGCCAGTGGA CCTACCAAAT CTACCAGGAG CCCTTCAAGA ACCTGAAGAC

TGGCAAGTAT GCCAGGATGA GGGGGGCCCA CACCAATGAT GTGAAGCAGC TGACTGAGGC

TGTGCAGAAG ATCACCACTG AGTCCATTGT GATCTGGGGC AAGACCCCCA AGTTCAAGCT

GCCCATCCAG AAGGAGACCT GGGAGACCTG GTGGACTGAG TACTGGCAGG CCACCTGGAT

CCCTGAGTGG GAGTTTGTGA ACACCCCCCC CCTGGTGAAG CTGTGGTACC AGCTGGAGAA .

15   GGAGCCCATT GTGGGGGCTG AGACCTTCTA TGTGGCTGGG GCTGCCAACA GGGAGACCAA

GCTGGGCAAG GCTGGCTATG TGACCAACAG GGGCAGGCAG AAGGTGGTGA CCCTGACTGA

CACCACCAAC CAGAAGACTG CCCTCCAGGC CATCTACCTG GCCCTCCAGG ACTCTGGCCT

GGAGGTGAAC ATTGTGACTG CCTCCCAGTA TGCCCTGGGC ATCATCCAGG CCCAGCCTGA

TCAGTCTGAG TCTGAGCTGG TGAACCAGAT CATTGAGCAG CTGATCAAGA AGGAGAAGGT

20   GTACCTGGCC TGGGTGCCTG CCCACAAGGG CATTGGGGGC AATGAGCAGG TGGACAAGCT

GGTGTCTGCT GGCATCAGGA AGGTGCTGTT CCTGGATGGC ATTGACAAGG CCCAGGATGA

GCATGAGAAG TACCACTCCA ACTGGAGGGC TATGGCCTCT GACTTCAACC TGCCCCCTGT

GGTGGCTAAG GAGATTGTGG CCTCCTGTGA CAAGTGCCAG CTGAAGGGGG AGGCCATGCA

TGGGCAGGTG GACTGCTCCC CTGGCATCTG GCAGCTGGCC TGCACCCACC TGGAGGGCAA

25   GGTGATCCTG GTGGCTGTGC ATGTGGCCTC CGGCTACATT GAGGCTGAGG TGATCCCTGC

TGAGACAGGC CAGGAGACTG CCTACTTCCT GCTGAAGCTG GCTGGCAGGT GGCCTGTGAA

GACCATCCAC ACTGCCAATG GCTCCAACTT CACTGGGGCC ACAGTGAGGG CTGCCTGCTG

GTGGGCTGGC ATCAAGCAGG AGTTTGGCAT CCCCTACAAC CCCCAGTCCC AGGGGGTGGT

GGCCTCCATG AACAAGGAGC TGAAGAAGAT CATTGGGCAG GTGAGGGACC AGGCTGAGCA

30   CCTGAAGACA GCTGTGCAGA TGGCTGTGTT CATCCACAAC TTCAAGAGGA AGGGGGGCAT

CGGGGGCTAC TCCGCTGGGG AGAGGATTGT GGACATCATT GCCACAGACA TCCAGACCAA

GGAGCTCCAG AAGCAGATCA CCAAGATCCA GAACTTCAGG GTGTACTACA GGGACTCCAG

GAACCCCCTG TGGAAGGGCC CTGCCAAGCT GCTGTGGAAG GGGGAGGGGG CTGTGGTGAT

CCAGGACAAC TCTGACATCA AGGTGGTGCC CAGGAGGAAG GCCAAGATCA TCAGGGACTA

TGGCAAGCAG ATGGCTGGGG ATGACTGTGT GGCCTCCAGG CAGGATGAGG ACTAAAGCCC
GGGCAGATCT (SEQ ID NO:7).

The open reading frame of the tPA-IA-pol construct disclosed as SEQ ID
NO:7 contains 875 amino acids, disclosed herein as tPA-IA-Pol and SEQ ID NO:8, as
5   follows:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly

Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile

Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val

Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile

10   Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu

Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr

Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln

Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys

Lys Lys Lys Ser Val Thr Val Leu Ala Val Gly Asp Ala Tyr Phe Ser

15   Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro

Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu

Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr

Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr

Gln Tyr Met Ala Ala Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln

20   His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly

Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp

Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val

Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val

Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg

25   Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile

Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile

Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu

Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile

Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met

30   Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln

Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe

Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr

Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro

Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala

```
      Glu Thr Phe Tyr Val Ala Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly
      Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu
      Thr Asp Thr Thr Asn Gln Lys Thr Ala Leu Gln Ala Ile Tyr Leu Ala
      Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Ala Ser Gln Tyr
   5  Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu
      Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu
      Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp
      Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile
      Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala
  10  Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val
      Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln
      Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Ala Cys Thr His Leu Glu
      Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu
      Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu
  15  Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Ala Asn
      Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala
      Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly
      Val Val Ala Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val
      Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe
  20  Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly
      Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu
      Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp
      Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly
      Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro
  25  Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly
      Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp (SEQ ID NO:8).
```

The present invention also relates to a substantially purified protein expressed from the DNA polynucleotide vaccines of the present invention, especially the purified proteins set forth below as SEQ ID NOs: 2, 4, 6, and 8. These purified proteins may be useful as protein-based HIV vaccines.

The DNA backbone of the DNA vaccines of the present invention are preferably DNA plasmid expression vectors. DNA plasmid expression vectors are well known in the art and the present DNA vector vaccines may be comprised of any such expression backbone which contains at least a promoter for RNA polymerase

transcription, and a transcriptional terminator 3' to the HIV pol coding sequence. In one preferred embodiment, the promoter is the Rous sarcoma virus (RSV) long terminal repeat (LTR) which is a strong transcriptional promoter. A more preferred promoter is the cytomegalovirus promoter with the intron A sequence (CMV-intA).

5   A preferred transcriptional terminator is the bovine growth hormone terminator. In addition, to assist in large scale preparation of an HIV pol DNA vector vaccine, an antibiotic resistance marker is also preferably included in the expression vector. Ampicillin resistance genes, neomycin resistance genes or any other pharmaceutically acceptable antibiotic resistance marker may be used. In a preferred embodiment of

10   this invention, the antibiotic resistance gene encodes a gene product for neomycin resistance. Further, to aid in the high level production of the pharmaceutical by fermentation in prokaryotic organisms, it is advantageous for the vector to contain an origin of replication and be of high copy number. Any of a number of commercially available prokaryotic cloning vectors provide these benefits. In a preferred

15   embodiment of this invention, these functionalities are provided by the commercially available vectors known as pUC. It is desirable to remove non-essential DNA sequences. Thus, the lacZ and lacI coding sequences of pUC are removed in one embodiment of the invention.

       DNA expression vectors which exemplify but in no way limit the present

20   invention are disclosed in PCT International Application No. PCT/US94/02751, International Publication No. WO 94/21797, hereby incorporated by reference. A first DNA expression vector is the expression vector pnRSV, wherein the rous sarcoma virus (RSV) long terminal repeat (LTR) is used as the promoter. A second embodiment relates to plasmid V1, a mutated pBR322 vector into which the CMV

25   promoter and the BGH transcriptional terminator is cloned. Another embodiment regarding DNA vector backbones relates to plasmid V1J. Plasmid V1J is derived from plasmid V1 and removes promoter and transcription termination elements in order to place them within a more defined context, create a more compact vector, and to improve plasmid purification yields. Therefore, V1J also contains the CMVintA

30   promoter and (BGH) transcription termination elements which control the expression of the HIV pol-based genes disclosed herein. The backbone of V1J is provided by pUC18. It is known to produce high yields of plasmid, is well-characterized by sequence and function, and is of minimum size. The entire *lac* operon was removed and the remaining plasmid was purified from an agarose electrophoresis gel,

blunt-ended with the T4 DNA polymerase, treated with calf intestinal alkaline phosphatase, and ligated to the CMVintA/BGH element. In a preferred DNA expression vector, the ampicillin resistance gene is removed from V1J and replaced with a neomycin resistance gene, to generate V1Jneo. An especially preferred DNA

5 expression vector is V1Jns, which is the same as V1J except that a unique Sfi1 restriction site has been engineered into the single Kpn1 site at position 2114 of V1J-neo. The incidence of Sfi1 sites in human genomic DNA is very low (approximately 1 site per 100,000 bases). Thus, this vector allows careful monitoring for expression vector integration into host DNA, simply by Sfi1 digestion of extracted genomic

10 DNA. Yet another preferred DNA expression vector used as the backbone to the HIV-1 pol-based DNA vaccines of the present invention is V1R. In this vector, as much non-essential DNA as possible is "trimmed" from the vector to produce a highly compact vector. This vector is a derivative of V1Jns. This vector allows larger inserts to be used, with less concern that undesirable sequences are encoded and

15 optimizes uptake by cells when the construct encoding specific influenza virus genes is introduced into surrounding tissue. The specific DNA vectors of the present invention include but are not limited to V1, V1J (SEQ ID NO:13), V1Jneo (SEQ ID NO:14), V1Jns (Figure 1A, SEQ ID NO:15), V1R (SEQ ID NO:26), and any of the aforementioned vectors wherein a nucleotide sequence encoding a leader peptide,

20 preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:28.

The present invention especially relates to a DNA vaccine and a pharmaceutically active vaccine composition which contains this DNA vaccine, and

25 the use as prophylactic and/or therapeutic vaccine for host immunization, preferably human host immunization, against an HIV infection or to combat an existing HIV condition. These DNA vaccines are represented by codon optimized DNA molecules encoding HIV-1 Pol or biologically active Pol modifications or Pol-containing fusion proteins which are ligated within an appropriate DNA plasmid vector, with or without

30 a nucleotide sequence encoding a functional leader peptide. DNA vaccines of the present invention may comprise codon optimized DNA molecules encoding HIV-1 Pol or biologically active Pol modifications or Pol-containing fusion proteins ligated in DNA vectors V1, V1J (SEQ ID NO:14), V1Jneo (SEQ ID NO:15), V1Jns (Figure 1A, SEQ ID NO:16), V1R (SEQ ID NO:26), or any of the aforementioned vectors

wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:28. To this end, polynucleotide vaccine constructions include , V1Jns-wtpol and V1R-wtpol

5   (comprising the DNA molecule encoding WT Pol, as set forth in SEQ ID NO:2), V1Jns-tPA-WTPol, (comprising the DNA molecule encoding tPA Pol, as set forth in SEQ ID NO:6), V1Jns-IAPol (comprising the DNA molecule encoding IA Pol, as set forth in SEQ ID NO:4), and V1Jns-tPA-IAPol, (comprising the DNA molecule encoding tPA-IA Pol, as set forth in SEQ ID NO:8). Polynucleotide vaccine

10   constructions V1R-wtpol, V1Jns-IAPol, and V1Jns-tPA-IAPol, are exemplified in Example Sections 3-5.

It will be evident upon review of the teaching within this specification that numerous vector/Pol antigen constructs may be generated. While the exemplified constructs are preferred, any number of vector/Pol antigen combinations are within

15   the scope of the present invention, especially wild type or modified/inactivated Pol proteins which comprise at least one, preferably 5 or more and especially all nine mutations as shown in Table 1, with or without the inclusion of a leader sequence such as human tPA.

The DNA vector vaccines of the present invention may be formulated in any

20   pharmaceutically effective formulation for host administration. Any such formulation may be, for example, a saline solution such as phosphate buffered saline (PBS). It will be useful to utilize pharmaceutically acceptable formulations which also provide long-term stability of the DNA vector vaccines of the present invention. During storage as a pharmaceutical entity, DNA plasmid vaccines undergo a

25   physiochemical change in which the supercoiled plasmid converts to the open circular and linear form. A variety of storage conditions (low pH, high temperature, low ionic strength) can accelerate this process. Therefore, the removal and/or chelation of trace metal ions (with succinic or malic acid, or with chelators containing multiple phosphate ligands) from the DNA plasmid solution, from the formulation buffers or

30   from the vials and closures, stabilizes the DNA plasmid from this degradation pathway during storage. In addition, inclusion of non-reducing free radical scavengers, such as ethanol or glycerol, are useful to prevent damage of the DNA plasmid from free radical production that may still occur, even in apparently demetalated solutions. Furthermore, the buffer type, pH, salt concentration, light

exposure, as well as the type of sterilization process used to prepare the vials, may be controlled in the formulation to optimize the stability of the DNA vaccine. Therefore, formulations that will provide the highest stability of the DNA vaccine will be one that includes a demetalated solution containing a buffer (phosphate or bicarbonate)

5   with a pH in the range of 7-8, a salt (NaCl, KCl or LiCl) in the range of 100-200 mM, a metal ion chelator (e.g., EDTA, diethylenetriaminepenta-acetic acid (DTPA), malate, inositol hexaphosphate, tripolyphosphate or polyphosphoric acid), a non-reducing free radical scavenger (e.g. ethanol, glycerol, methionine or dimethyl sulfoxide) and the highest appropriate DNA concentration in a sterile glass vial,

10   packaged to protect the highly purified, nuclease free DNA from light. A particularly preferred formulation which will enhance long term stability of the DNA vector vaccines of the present invention would comprise a Tris-HCl buffer at a pH from about 8.0 to about 9.0; ethanol or glycerol at about 3% w/v; EDTA or DTPA in a concentration range up to about 5 mM; and NaCl at a concentration from about 50

15   mM to about 500 mM. The use of such stabilized DNA vector vaccines and various alternatives to this preferred formulation range is described in detail in PCT International Application No. PCT/US97/06655 and PCT International Publication No. WO 97/40839, both of which are hereby incorporated by reference.

The DNA vector vaccines of the present invention may also be formulated

20   with an adjuvant or adjuvants which may increase immunogenicity of the DNA polynucleotide vaccines of the present invention. A number of these adjuvants are known in the art and are available for use in a DNA vaccine, including but not limited to particle bombardment using DNA-coated gold beads, co-administration of DNA vaccines with plasmid DNA expressing cytokines, chemokines, or

25   costimulatory molecules, formulation of DNA with cationic lipids or with experimental adjuvants such as saponin, monophosphoryl lipid A or other compounds which increase immunogenicity of the DNA vaccine. Another adjuvant for use in the DNA vector vaccines of the present invention are one or more forms of an aluminum phosphate-based adjuvant wherein the aluminum

30   phosphate-based adjuvant possesses a molar PO_4/Al ratio of approximately 0.9. An additional mineral-based adjuvant may be generated from one or more forms of a calcium phosphate. These mineral-based adjuvants are useful in increasing cellular and humoral responses to DNA vaccination. These mineral-based compounds for use as DNA vaccines adjuvants are disclosed in PCT International

Application No. PCT/US98/02414, PCT International Publication No.
WO 98/35562, which is hereby incorporated by reference. Another preferred
adjuvant is a non-ionic block copolymer which shows adjuvant activity with DNA
vaccines. The basic structure comprises blocks of polyoxyethylene (POE) and

5 polyoxypropylene (POP) such as a POE-POP-POE block copolymer. Newman et
al. (1998, *Critical Reviews in Therapeutic Drug Carrier Systems* 15(2): 89-142)
review a class of non-ionic block copolymers which show adjuvant activity. The
basic structure comprises blocks of polyoxyethylene (POE) and polyoxypropylene
(POP) such as a POE-POP-POE block copolymer. Newman et al. *id.*, disclose

10 that certain POE-POP-POE block copolymers may. be useful as adjuvants to an
influenza protein-based vaccine, namely higher molecular weight POE-POP-POE·
block copolymers containing a central POP block having a molecular weight of
over about 9000 daltons to about 20,000 daltons and flanking POE blocks which
comprise up to about 20% of the total molecular weight of the copolymer (see also

15 U.S. Reissue Patent No. 36,665, U.S. Patent No. 5,567,859, U.S. Patent No.
5,691,387, U.S. Patent No. 5,696,298 and U.S. Patent No. 5,990,241, all issued to
Emanuele, et al., regarding these POE-POP-POE block copolymers).
WO 96/04932 further discloses higher molecular weight POE/POP block
copolymers which have surfactant characteristics and show biological efficacy as

20 vaccine adjuvants. The above cited references within this paragraph are hereby
incorporated by reference in their entirety. It is therefore within the purview of
the skilled artisan to utilize available adjuvants which may increase the immune
response of the polynucleotide vaccines of the present invention in comparison to
administration of a non-adjuvanted polynucleotide vaccine.

25   The DNA vector vaccines of the present invention are administered to the host
by any means known in the art, such as enteral and parenteral routes. These routes of
delivery include but are not limited to intramusclar injection, intraperitoneal injection,
intravenous injection, inhalation or intranasal delivery, oral delivery, sublingual
administration, subcutaneous administration, transdermal administration,

30 transcutaneous administration, percutaneous administration or any form of particle
bombardment, such as a biolostic device such as a "gene gun" or by any available
needle-free injection device. The preferred methods of delivery of the HIV-1 Pol-
based DNA vaccines disclosed herein are intramuscular injection, subcutaneous
administration and needle-free injection. An especially preferred method is

intramuscular delivery.

The amount of expressible DNA to be introduced to a vaccine recipient will depend on the strength of the transcriptional and translational promoters used in the DNA construct, and on the immunogenicity of the expressed gene product. In
5   general, an immunologically or prophylactically effective dose of about 1 μg to greater than about 20 mg, and preferably in doses from about 1 mg to about 5 mg is administered directly into muscle tissue. As noted above, subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, inhalation and oral delivery are
10 also contemplated. It is also contemplated that booster vaccinations are to be provided in a fashion which optimizes the overall immune response to the Pol-based DNA vector vaccines of the present invention.

The aforementioned polynucleotides, when directly introduced into a vertebrate *in vivo*, express the respective HIV-1 Pol protein within the animal and in
15 turn induce a cellular immune response within the host to the expressed Pol antigen. To this end, the present invention also relates to methods of using the HIV-1 Pol-based polynucleotide vaccines of the present invention to provide effective immunoprophylaxis, to prevent establishment of an HIV-1 infection following exposure to this virus, or as a post-HIV infection therapeutic vaccine to mitigate the
20 acute HIV-1 infection so as to result in the establishment of a lower virus load with beneficial long term consequences. As noted above, the present invention contemplates a method of administration or use of the DNA pol-based vaccines of the present invention using an any of the known routes of introducing polynucleotides into living tissue to induce expression of proteins.
25   Therefore, the present invention provides for methods of using a DNA pol-based vaccine utilizing the various parameters disclosed herein as well as any additional parameters known in the art, which, upon introduction into mammalian tissue induces intracellular expression of these DNA pol-based vaccines. This intracellular expression of the Pol-based immunogen induces a cellular immune
30 response which provides a substantial level of protection against an existing HIV-1 infection or provides a substantial level of protection against a future infection in a presently uninfected host.

The following examples are provided to illustrate the present invention without, however, limiting the same hereto.

EXAMPLE 1

Vaccine Vectors

V1 – Vaccine vector V1 was constructed from pCMVIE-AKI-DHFR (Whang
5   et al., 1987, *J. Virol.* 61: 1796). The AKI and DHFR genes were removed by cutting
the vector with EcoRI and self-ligating. This vector does not contain intron A in the
CMV promoter, so it was added as a PCR fragment that had a deleted internal SacI
site [at 1855 as numbered in Chapman, et al., 1991, *Nuc. Acids Res.* 19: 3979). The
template used for the PCR reactions was pCMVintA-Lux, made by ligating the
10   HindIII and NheI fragment from pCMV6a120 (see Chapman et al., *ibid.*), which
includes hCMV-IE1 enhancer/promoter and intron A, into the HindIII and XbaI sites
of pBL3 to generate pCMVIntBL. The 1881 base pair luciferase gene fragment
(HindIII-SmaI Klenow filled-in) from RSV-Lux (de Wet et al., 1987, *Mol. Cell Biol.*
7: 725) was ligated into the SalI site of pCMVIntBL, which was Klenow filled-in and
15   phosphatase treated. The primers that spanned intron A are: 5' primer: 5'-CTATAT
AAGCAGAGCTCGTTTAG-3' (SEQ ID NO:10); 3' primer: 5'-GTAGCAAA
GATCTAAGGACGGTGACTGCAG-3' (SEQ ID NO:11). The primers used to
remove the SacI site are: sense primer, 5'-GTATGTGTCTGAAAATGAGCG
TGGAGATTGGGCTCGCAC-3' (SEQ ID NO:12) and the antisense primer,
20   5'-GTGCGAGCCCAATCTCCACGCTCATTTTCAGAC ACATAC-3' (SEQ ID
NO:13). The PCR fragment was cut with Sac I and Bgl II and inserted into the vector
which had been cut with the same enzymes.

V1J – Vaccine vector V1J was generated to remove the promoter and
transcription termination elements from vector V1 in order to place them within a
25   more defined context, create a more compact vector, and to improve plasmid
purification yields. V1J is derived from vectors V1 and pUC18, a commercially
available plasmid. V1 was digested with SspI and EcoRI restriction enzymes
producing two fragments of DNA. The smaller of these fragments, containing the
CMVintA promoter and Bovine Growth Hormone (BGH) transcription termination
30   elements which control the expression of heterologous genes, was purified from an
agarose electrophoresis gel. The ends of this DNA fragment were then "blunted"
using the T4 DNA polymerase enzyme in order to facilitate its ligation to another
"blunt-ended" DNA fragment. pUC18 was chosen to provide the "backbone" of the
expression vector. It is known to produce high yields of plasmid, is well-

characterized by sequence and function, and is of small size. The entire *lac* operon was removed from this vector by partial digestion with the HaeII restriction enzyme. The remaining plasmid was purified from an agarose electrophoresis gel, blunt-ended with the T4 DNA polymerase treated with calf intestinal alkaline phosphatase, and

5   ligated to the CMVintA/BGH element described above. Plasmids exhibiting either of two possible orientations of the promoter elements within the pUC backbone were obtained. One of these plasmids gave much higher yields of DNA in *E. coli* and was designated V1J. This vector's structure was verified by sequence analysis of the junction regions and was subsequently demonstrated to give comparable or higher

10   expression of heterologous genes compared with V1. The nucleotide sequence of V1J is as follows:

```
      TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
      CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
      TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
15 ·   ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
      CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
      TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
      GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
      CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
20   CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
      TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
      TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
      TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
      CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
25   CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
      CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
      AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
      TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
      TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCCTTGGC
30   TTCTTATGCA TGCTATACTG TTTTTGGCTT GGGGTCTATA CACCCCCGCT TCCTCATGTT
      ATAGGTGATG GTATAGCTTA GCCTATAGGT GTGGGTTATT GACCATTATT GACCACTCCC
      CTATTGGTGA CGATACTTTC CATTACTAAT CCATAACATG GCTCTTTGCC ACAACTCTCT
      TTATTGGCTA TATGCCAATA CACTGTCCTT CAGAGACTGA CACGGACTCT GTATTTTTAC
      AGGATGGGGT CTCATTTATT ATTTACAAAT TCACATATAC AACACCACCG TCCCCAGTGC
```

```
        CCGCAGTTTT TATTAAACAT AACGTGGGAT CTCCACGCGA ATCTCGGGTA CGTGTTCCGG
        ACATGGGCTC TTCTCCGGTA GCGGCGGAGC TTCTACATCC GAGCCCTGCT CCCATGCCTC
        CAGCGACTCA TGGTCGCTCG GCAGCTCCTT GCTCCTAACA GTGGAGGCCA GACTTAGGCA
        CAGCACGATG CCCACCACCA CCAGTGTGCC GCACAAGGCC GTGGCGGTAG GGTATGTGTC
  5     TGAAAATGAG CTCGGGGAGC GGGCTTGCAC CGCTGACGCA TTTGGAAGAC TTAAGGCAGC
        GGCAGAAGAA GATGCAGGCA GCTGAGTTGT TGTGTTCTGA TAAGAGTCAG AGGTAACTCC
        CGTTGCGGTG CTGTTAACGG TGGAGGGCAG TGTAGTCTGA GCAGTACTCG TTGCTGCCGC
        GCGCGCCACC AGACATAATA GCTGACAGAC TAACAGACTG TTCCTTTCCA TGGGTCTTTT
        CTGCAGTCAC CGTCCTTAGA TCTGCTGTGC CTTCTAGTTG CCAGCCATCT GTTGTTTGCC
 10     CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCCTT TCCTAATAAA
        ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATTC TATTCTGGGG GGTGGGGTGG
        GGCAGCACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG
        GCTCTATGGG TACCCAGGTG CTGAAGAATT GACCCGGTTC CTCCTGGGCC AGAAAGAAGC
        AGGCACATCC CCTTCTCTGT GACACACCCT GTCCACGCCC CTGGTTCTTA GTTCCAGCCC
 15     CACTCATAGG ACACTCATAG CTCAGGAGGG CTCCGCCTTC AATCCCACCC GCTAAAGTAC
        TTGGAGCGGT CTCTCCCTCC CTCATCAGCC CACCAAACCA AACCTAGCCT CCAAGAGTGG
        GAAGAAATTA AAGCAAGATA GGCTATTAAG TGCAGAGGGA GAGAAAATGC CTCCAACATG
        TGAGGAAGTA ATGAGAGAAA TCATAGAATT TCTTCCGCTT CCTCGCTCAC TGACTCGCTG
        CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA
 20     TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAAGGCC
        AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCCATA GGCTCCGCCC CCCTGACGAG
        CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC
        CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT GCCGCTTACC
        GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG CTCACGCTGT
 25     AGGTATCTCA GTTCGGTGTA GGTCGTTCGC TCCAAGCTGG GCTGTGTGCA CGAACCCCCC
        GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA
        CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA
        GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA
        TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA
 30     TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG
        CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG
        TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC
        TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA TGAGTAAACT
        TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT
```

```
      CGTTCATCCA TAGTTGCCTG ACTCCCCGTC GTGTAGATAA CTACGATACG GGAGGGCTTA
      CCATCTGGCC CCAGTGCTGC AATGATACCG CGAGACCCAC GCTCACCGGC TCCAGATTTA
      TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA GTGGTCCTGC AACTTTATCC
      GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC GCCAGTTAAT
5     AGTTTGCGCA ACGTTGTTGC CATTGCTACA GGCATCGTGG TGTCACGCTC GTCGTTTGGT
      ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG TTACATGATC CCCCATGTTG
      TGCAAAAAAG CGGTTAGCTC CTTCGGTCCT CCGATCGTTG TCAGAAGTAA GTTGGCCGCA
      GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC TTACTGTCAT GCCATCCGTA
      AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA GTGTATGCGG
10    CGACCGAGTT GCTCTTGCCC GGCGTCAATA CGGGATAATA CCGCGCCACA TAGCAGAACT
      TTAAAAGTGC TCATCATTGG AAAACGTTCT TCGGGGCGAA AACTCTCAAG GATCTTACCG
      CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGCACCCA ACTGATCTTC AGCATCTTTT
      ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC AAAATGCCGC AAAAAAGGGA
      ATAAGGGCGA CACGGAAATG TTGAATACTC ATACTCTTCC TTTTTCAATA TTATTGAAGC
15    ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG AATGTATTTA GAAAAATAAA
      CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC CTGACGTCTA AGAAACCATT
      ATTATCATGA CATTAACCTA TAAAAATAGG CGTATCACGA GGCCCTTTCG TC (SEQ ID
      NO:14).
```

V1Jneo – Construction of vaccine vector V1Jneo expression vector involved

20   removal of the amp^r gene and insertion of the kan^r gene (neomycin
     phosphotransferase). The amp^r gene from the pUC backbone of V1J was removed by
     digestion with SspI and Eam1105I restriction enzymes. The remaining plasmid was
     purified by agarose gel electrophoresis, blunt-ended with T4 DNA polymerase, and
     then treated with calf intestinal alkaline phosphatase. The commercially available

25   kan^r gene, derived from transposon 903 and contained within the pUC4K plasmid,
     was excised using the PstI restriction enzyme, purified by agarose gel electrophoresis,
     and blunt-ended with T4 DNA polymerase. This fragment was ligated with the V1J
     backbone and plasmids with the kan^r gene in either orientation were derived which
     were designated as V1Jneo #'s 1 and 3. Each of these plasmids was confirmed by

30   restriction enzyme digestion analysis, DNA sequencing of the junction regions, and
     was shown to produce similar quantities of plasmid as V1J. Expression of
     heterologous gene products was also comparable to V1J for these V1Jneo vectors.
     V1Jneo#3, referred to as V1Jneo hereafter, was selected which contains the kan^r gene
     in the same orientation as the amp^r gene in V1J as the expression construct and

provides resistance to neomycin, kanamycin and G418. The nucleotide sequence of
V1Jneo is as follows:

```
       TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
       CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
  5    TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
       ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
       CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
       TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
       GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
 10    CCCGCCTGGC TGACCGCCCA ACGACCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
       CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
       TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
       TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
       TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
 15    CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
       CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
       CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
       AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
       TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
 20    TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCCTTGGC
       TTCTTATGCA TGCTATACTG TTTTTGGCTT GGGGTCTATA CACCCCCGCT TCCTCATGTT
       ATAGGTGATG GTATAGCTTA GCCTATAGGT GTGGGTTATT GACCATTATT GACCACTCCC
       CTATTGGTGA CGATACTTTC CATTACTAAT CCATAACATG GCTCTTTGCC ACAACTCTCT
       TTATTGGCTA TATGCCAATA CACTGTCCTT CAGAGACTGA CACGGACTCT GTATTTTTAC
 25    AGGATGGGGT CTCATTTATT ATTTACAAAT TCACATATAC AACACCACCG TCCCCAGTGC
       CCGCAGTTTT TATTAAACAT AACGTGGGAT CTCCACGCGA ATCTCGGGTA CGTGTTCCGG
       ACATGGGCTC TTCTCCGGTA GCGGCGGAGC TTCTACATCC GAGCCCTGCT CCCATGCCTC
       CAGCGACTCA TGGTCGCTCG GCAGCTCCTT GCTCCTAACA GTGGAGGCCA GACTTAGGCA
       CAGCACGATG CCCACCACCA CCAGTGTGCC GCACAAGGCC GTGGCGGTAG GGTATGTGTC
 30    TGAAAATGAG CTCGGGGAGC GGGCTTGCAC CGCTGACGCA TTTGGAAGAC TTAAGGCAGC
       GGCAGAAGAA GATGCAGGCA GCTGAGTTGT TGTGTTCTGA TAAGAGTCAG AGGTAACTCC
       CGTTGCGGTG CTGTTAACGG TGGAGGGCAG TGTAGTCTGA GCAGTACTCG TTGCTGCCGC
       GCGCGCCACC AGACATAATA GCTGACAGAC TAACAGACTG TTCCTTTCCA TGGGTCTTTT
       CTGCAGTCAC CGTCCTTAGA TCTGCTGTGC CTTCTAGTTG CCAGCCATCT GTTGTTTGCC
```

```
     CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCCTT TCCTAATAAA
     ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATTC TATTCTGGGG GGTGGGGTGG
     GGCAGCACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG
     GCTCTATGGG TACCCAGGTG CTGAAGAATT GACCCGGTTC CTCCTGGGCC AGAAAGAAGC
  5  AGGCACATCC CCTTCTCTGT GACACACCCT GTCCACGCCC CTGGTTCTTA GTTCCAGCCC
     CACTCATAGG ACACTCATAG CTCAGGAGGG CTCCGCCTTC AATCCCACCC GCTAAAGTAC
     TTGGAGCGGT CTCTCCCTCC CTCATCAGCC CACCAAACCA AACCTAGCCT CCAAGAGTGG
     GAAGAAATTA AAGCAAGATA GGCTATTAAG TGCAGAGGGA GAGAAAATGC CTCCAACATG
     TGAGGAAGTA ATGAGAGAAA TCATAGAATT TCTTCCGCTT CCTCGCTCAC TGACTCGCTG
 10  CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA
     TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAAGGCC
     AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCCATA GGCTCCGCCC CCCTGACGAG
     CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC
     CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT GCCGCTTACC
 15  GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG CTCACGCTGT
     AGGTATCTCA GTTCGGTGTA GGTCGTTCGC TCCAAGCTGG GCTGTGTGCA CGAACCCCCC
     GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA
     CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA
     GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA
 20  TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA
     TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG
     CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG
     TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC
     TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA TGAGTAAACT
 25  TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT
     CGTTCATCCA TAGTTGCCTG ACTCCGGGGG GGGGGGGCGC TGAGGTCTGC CTCGTGAAGA
     AGGTGTTGCT GACTCATACC AGGCCTGAAT CGCCCCATCA TCCAGCCAGA AAGTGAGGGA
     GCCACGGTTG ATGAGAGCTT TGTTGTAGGT GGACCAGTTG GTGATTTGA ACTTTTGCTT
     TGCCACGGAA CGGTCTGCGT TGTCGGGAAG ATGCGTGATC TGATCCTTCA ACTCAGCAAA
 30  AGTTCGATTT ATTCAACAAA GCCGCCGTCC CGTCAAGTCA GCGTAATGCT CTGCCAGTGT
     TACAACCAAT TAACCAATTC TGATTAGAAA AACTCATCGA GCATCAAATG AAACTGCAAT
     TTATTCATAT CAGGATTATC AATACCATAT TTTTGAAAAA GCCGTTTCTG TAATGAAGGA
     GAAAACTCAC CGAGGCAGTT CCATAGGATG GCAAGATCCT GGTATCGGTC TGCGATTCCG
     ACTCGTCCAA CATCAATACA ACCTATTAAT TTCCCCTCGT CAAAAATAAG GTTATCAAGT
```

```
        GAGAAATCAC CATGAGTGAC GACTGAATCC GGTGAGAATG GCAAAAGCTT ATGCATTTCT
        TTCCAGACTT GTTCAACAGG CCAGCCATTA CGCTCGTCAT CAAAATCACT CGCATCAACC
        .AAACCGTTAT TCATTCGTGA TTGCGCCTGA GCGAGACGAA ATACGCGATC GCTGTTAAAA
        GGACAATTAC AAACAGGAAT CGAATGCAAC CGGCGCAGGA ACACTGCCAG CGCATCAACA
5       ATATTTTCAC CTGAATCAGG ATATTCTTCT AATACCTGGA ATGCTGTTTT CCCGGGGATC
        GCAGTGGTGA GTAACCATGC ATCATCAGGA GTACGGATAA AATGCTTGAT GGTCGGAAGA
        GGCATAAATT CCGTCAGCCA GTTTAGTCTG ACCATCTCAT CTGTAACATC ATTGGCAACG
        CTACCTTTGC CATGTTTCAG AAACAACTCT GGCGCATCGG GCTTCCCATA CAATCGATAG
        ATTGTCGCAC CTGATTGCCC GACATTATCG CGAGCCCATT TATACCCATA TAAATCAGCA
10      TCCATGTTGG AATTTAATCG CGGCCTCGAG CAAGACGTTT CCCGTTGAAT ATGGCTCATA
        ACACCCCTTG TATTACTGTT TATGTAAGCA GACAGTTTTA TTGTTCATGA TGATATATTT
        TTATCTTGTG CAATGTAACA TCAGAGATTT TGAGACACAA CGTGGCTTTC CCCCCCCCCC
        CATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT
        TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC
15      TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GGCGTATCAC GAGGCCCTTT
        CGTC (SEQ ID NO:15).
```

V1Jns - The expression vector VIJns was generated by adding an SfiI site to
V1Jneo to facilitate integration studies. A commercially available 13 base pair SfiI
linker (New England BioLabs) was added at the KpnI site within the BGH sequence
20 of the vector. V1Jneo was linearized with KpnI, gel purified, blunted by T4 DNA
polymerase, and ligated to the blunt SfiI linker. Clonal isolates were chosen by
restriction mapping and verified by sequencing through the linker. The new vector
was designated V1Jns. Expression of heterologous genes in V1Jns (with SfiI) was
comparable to expression of the same genes in V1Jneo (with KpnI).

25   The nucleotide sequence of V1Jns is as follows:
```
        TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
        CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
        TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
        ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
30      CTATTGGCCA TTGCATACGT·TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
        TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
        GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
        CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
        CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
```

```
       TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
       TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
       TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
       CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
  5    CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
       CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
       AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
       TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
       TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGACTC TATAGGCACA CCCCTTTGGC
  10   TCTTATGCAT GCTATACTGT TTTTGGCTTG GGGCCTATAC ACCCCGCTT CCTTATGCTA
       TAGGTGATGG TATAGCTTAG CCTATAGGTG TGGGTTATTG ACCATTATTG ACCACTCCCC
       TATTGGTGAC GATACTTTCC ATTACTAATC CATAACATGG CTCTTTGCCA CAACTATCTC
       TATTGGCTAT ATGCCAATAC TCTGTCCTTC AGAGACTGAC ACGGACTCTG TATTTTTACA
       GGATGGGGTC CCATTTATTA TTTACAAATT CACATATACA ACAACGCCGT CCCCCGTGCC
  15   CGCAGTTTTT ATTAAACATA GCGTGGGATC TCCACGCGAA TCTCGGGTAC GTGTTCCGGA
       CATGGGCTCT TCTCCGGTAG CGGCGGAGCT TCCACATCCG AGCCCTGGTC CCATGCCTCC
       AGCGGCTCAT GGTCGCTCGG CAGCTCCTTG CTCCTAACAG TGGAGGCCAG ACTTAGGCAC
       AGCACAATGC CCACCACCAC CAGTGTGCCG CACAAGGCCG TGGCGGTAGG GTATGTGTCT
       GAAAATGAGC GTGGAGATTG GGCTCGCACG GCTGACGCAG ATGGAAGACT TAAGGCAGCG
  20   GCAGAAGAAG ATGCAGGCAG CTGAGTTGTT GTATTCTGAT AAGAGTCAGA GGTAACTCCC
       GTTGCGGTGC TGTTAACGGT GGAGGGCAGT GTAGTCTGAG CAGTACTCGT TGCTGCCGCG
       CGCGCCACCA GACATAATAG CTGACAGACT AACAGACTGT TCCTTTCCAT GGGTCTTTTC
       TGCAGTCACC GTCCTTAGAT CTGCTGTGCC TTCTAGTTGC CAGCCATCTG TTGTTTGCCC
       CTCCCCCGTG CCTTCCTTGA CCCTGGAAGG TGCCACTCCC ACTGTCCTTT CCTAATAAAA
  25.   TGAGGAAATT GCATCGCATT GTCTGAGTAG GTGTCATTCT ATTCTGGGGG GTGGGGTGGG
       GCAGGACAGC AAGGGGGAGG ATTGGGAAGA CAATAGCAGG CATGCTGGGG ATGCGGTGGG
       CTCTATGGCC GCTGCGGCCA GGTGCTGAAG AATTGACCCG GTTCCTCCTG GCCAGAAAG
       AAGCAGGCAC ATCCCCTTCT CTGTGACACA CCCTGTCCAC GCCCCTGGTT CTTAGTTCCA
       GCCCCACTCA TAGGACACTC ATAGCTCAGG AGGGCTCCGC CTTCAATCCC ACCCGCTAAA
  30   GTACTTGGAG CGGTCTCTCC CTCCCTCATC AGCCCACCAA ACCAAACCTA GCCTCCAAGA
       GTGGGAAGAA ATTAAAGCAA GATAGGCTAT TAAGTGCAGA GGGAGAGAAA ATGCCTCCAA
       CATGTGAGGA AGTAATGAGA GAAATCATAG AATTTCTTCC GCTTCCTCGC TCACTGACTC
       GCTGCGCTCG GTCGTTCGGC TGCGGCGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG
       GTTATCCACA GAATCAGGGG ATAACGCAGG AAAGAACATG TGAGCAAAAG GCCAGCAAAA
```

```
          GGCCAGGAAC CGTAAAAAGG CCGCGTTGCT GGCGTTTTTC CATAGGCTCC GCCCCCCTGA

          CGAGCATCAC AAAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG

          ATACCAGGCG TTTCCCCCTG GAAGCTCCCT CGTGCGCTCT CCTGTTCCGA CCCTGCCGCT

          TACCGGATAC CTGTCCGCCT TTCTCCCTTC GGGAAGCGTG GCGCTTTCTC ATAGCTCACG

     5    CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGCTGTG TGCACGAACC

          CCCCGTTCAG CCCGACCGCT GCGCCTTATC CGGTAACTAT CGTCTTGAGT CCAACCCGGT

          AAGACACGAC TTATCGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA GAGCGAGGTA

          TGTAGGCGGT GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGAAC

          AGTATTTGGT ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG TTGGTAGCTC

     10   TTGATCCGGC AAACAAACCA CCGCTGGTAG CGGTGGTTTT TTTGTTTGCA AGCAGCAGAT

          TACGCGCAGA AAAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC

          TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGATTATCAA AAAGGATCTT

          CACCTAGATC CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA

          AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG CGATCTGTCT

     15   ATTTCGTTCA TCCATAGTTG CCTGACTCGG GGGGGGGGGG CGCTGAGGTC TGCCTCGTGA

          AGAAGGTGTT GCTGACTCAT ACCAGGCCTG AATCGCCCCA TCATCCAGCC AGAAAGTGAG

          GGAGCCACGG TTGATGAGAG CTTTGTTGTA GGTGGACCAG TTGGTGATTT TGAACTTTTG

          CTTTGCCACG GAACGGTCTG CGTTGTCGGG AAGATGCGTG ATCTGATCCT TCAACTCAGC

          AAAAGTTCGA TTTATTCAAC AAAGCCGCCG TCCCGTCAAG TCAGCGTAAT GCTCTGCCAG

     20   TGTTACAACC AATTAACCAA TTCTGATTAG AAAAACTCAT CGAGCATCAA ATGAAACTGC

          AATTTATTCA TATCAGGATT ATCAATACCA TATTTTTGAA AAAGCCGTTT CTGTAATGAA

          GGAGAAAACT CACCGAGGCA GTTCCATAGG ATGGCAAGAT CCTGGTATCG GTCTGCGATT

          CCGACTCGTC AACATCAAT ACAACCTATT AATTTCCCCT CGTCAAAAAT AAGGTTATCA

          AGTGAGAAAT CACCATGAGT GACGACTGAA TCCGGTGAGA ATGGCAAAAG CTTATGCATT

     25   TCTTTCCAGA CTTGTTCAAC AGGCCAGCCA TTACGCTCGT CATCAAAATC ACTCGCATCA

          ACCAAACCGT TATTCATTCG TGATTGCGCC TGAGCGAGAC GAAATACGCG ATCGCTGTTA

          AAAGGACAAT TACAAACAGG AATCGAATGC AACCGGCGCA GGAACACTGC CAGCGCATCA

          ACAATATTTT CACCTGAATC AGGATATTCT TCTAATACCT GGAATGCTGT TTTCCCGGGG

          ATCGCAGTGG TGAGTAACCA TGCATCATCA GGAGTACGGA TAAAATGCTT GATGGTCGGA

     30   AGAGGCATAA ATTCCGTCAG CCAGTTTAGT CTGACCATCT CATCTGTAAC ATCATTGGCA

          ACGCTACCTT TGCCATGTTT CAGAAACAAC TCTGGCGCAT CGGGCTTCCC ATACAATCGA

          TAGATTGTCG CACCTGATTG CCCGACATTA TCGCGAGCCC ATTTATACCC ATATAAATCA

          GCATCCATGT TGGAATTTAA TCGCGGCCTC GAGCAAGACG TTTCCCGTTG AATATGGCTC

          ATAACACCCC TTGTATTACT GTTTATGTAA GCAGACAGTT TTATTGTTCA TGATGATATA
```

```
TTTTTATCTT GTGCAATGTA ACATCAGAGA TTTTGAGACA CAACGTGGCT TTCCCCCCCC
CCCCATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT
ATTTAGAAAA ATAAACAAAT AGGGGTTCCG CGCACATTTC CCCGAAAAGT GCCACCTGAC
GTCTAAGAAA CCATTATTAT CATGACATTA ACCTATAAAA ATAGGCGTAT CACGAGGCCC
```
5   TTTCGTC(SEQ ID NO:16).

The underlined nucleotides of SEQ ID NO:16 represent the Sfi1 site introduced into the Kpn 1 site of V1Jneo.

V1Jns-tPA – The vaccine vector V1Jns-tPA was constructed in order to fuse an heterologous leader peptide sequence to the pol DNA constructs of the present
10   invention. More specifically, the vaccine vector V1Jns was modified to include the human tissue-specific plasminogen activator (tPA) leader. As an exemplification, but by no means a limitation of generating a pol DNA construct comprising an amino-terminal leader sequence, plasmid V1Jneo was modified to include the human tissue-specific plasminogen activator (tPA) leader. Two synthetic complementary oligomers
15   were annealed and then ligated into V1Jneo which had been BglII digested. The sense and antisense oligomers were 5'-GATCACCATGGATGCAATGAAGAG AGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTTTCGCCCAG CGA-3' (SEQ ID NO:17); and, 5'-GATCTCGCTGGGCGAAACGAAGACTGCTCC ACACAGCAGCAGCACACAGCAGAGCCCTCTCTTCATTGCATCCATGGT-3'
20   (SEQ ID NO:18). The Kozak sequence is underlined in the sense oligomer. These oligomers have overhanging bases compatible for ligation to BglII-cleaved sequences. After ligation the upstream BglII site is destroyed while the downstream BglII is retained for subsequent ligations. Both the junction sites as well as the entire tPA leader sequence were verified by DNA sequencing. Additionally, in order to conform
25   with V1Jns (=V1Jneo with an SfiI site), an SfiI restriction site was placed at the KpnI site within the BGH terminator region of V1Jneo-tPA by blunting the KpnI site with T4 DNA polymerase followed by ligation with an SfiI linker (catalogue #1138, New England Biolabs), resulting in V1Jns-tPA. This modification was verified by restriction digestion and agarose gel electrophoresis.
30   The V1Jns-tpa vector nucleotide sequence is as follows:
```
TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
```

```
      CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
      TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
      GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
      CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
  5   CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
      TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
      TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
      TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
      CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
  10  CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
      CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
      AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
      TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
      TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGACTC TATAGGCACA CCCCTTTGGC
  15  TCTTATGCAT GCTATACTGT TTTTGGCTTG GGGCCTATAC ACCCCCGCTT CCTTATGCTA
      TAGGTGATGG TATAGCTTAG CCTATAGGTG TGGGTTATTG ACCATTATTG ACCACTCCCC
      TATTGGTGAC GATACTTTCC ATTACTAATC CATAACATGG CTCTTTGCCA CAACTATCTC
      TATTGGCTAT ATGCCAATAC TCTGTCCTTC AGAGACTGAC ACGGACTCTG TATTTTTACA
      GGATGGGGTC CCATTTATTA TTTACAAATT CACATATACA ACAACGCCGT CCCCCGTGCC
  20  CGCAGTTTTT ATTAAACATA GCGTGGGATC TCCACGCGAA TCTCGGGTAC GTGTTCCGGA
      CATGGGCTCT TCTCCGGTAG CGGCGGAGCT TCCACATCCG AGCCCTGGTC CCATGCCTCC
      AGCGGCTCAT GGTCGCTCGG CAGCTCCTTG CTCCTAACAG TGGAGGCCAG ACTTAGGCAC
      AGCACAATGC CCACCACCAC CAGTGTGCCG CACAAGGCCG TGGCGGTAGG GTATGTGTCT
      GAAAATGAGC GTGGAGATTG GGCTCGCACG GCTGACGCAG ATGGAAGACT TAAGGCAGCG
  25  GCAGAAGAAG ATGCAGGCAG CTGAGTTGTT GTATTCTGAT AAGAGTCAGA GGTAACTCCC
      GTTGCGGTGC TGTTAACGGT GGAGGGCAGT GTAGTCTGAG CAGTACTCGT TGCTGCCGCG
      CGCGCCACCA GACATAATAG CTGACAGACT AACAGACTGT TCCTTTCCAT GGGTCTTTTC
      TGCAGTCACC GTCCTT*AGAT CACCATGGAT GCAATGAAGA GAGGGCTCTG CTGTGTGCTG*
      *CTGCTGTGTG GAGCAGTCTT CGTTTCGCCC AGCGAGATCT* GCTGTGCCTT CTAGTTGCCA
  30  GCCATCTGTT GTTTGCCCCT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCCAC
      TGTCCTTTCC TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT
      TCTGGGGGGT GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA
      TGCTGGGGAT GCGGTGGGCT CTATGGCCGC TGCGGCCAGG TGCTGAAGAA TTGACCCGGT
      TCCTCCTGGG CCAGAAAGAA GCAGGCACAT CCCCTTCTCT GTGACACACC CTGTCCACGC
```

```
        CCCTGGTTCT TAGTTCCAGC CCCACTCATA GGACACTCAT AGCTCAGGAG GGCTCCGCCT
        TCAATCCCAC CCGCTAAAGT ACTTGGAGCG GTCTCTCCCT CCCTCATCAG CCCACCAAAC
        CAAACCTAGC CTCCAAGAGT GGGAAGAAAT TAAAGCAAGA TAGGCTATTA AGTGCAGAGG
        GAGAGAAAAT GCCTCCAACA TGTGAGGAAG TAATGAGAGA AATCATAGAA TTTCTTCCGC
   5    TTCCTCGCTC ACTGACTCGC TGCGCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA
        CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG
        AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA
        TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA
        CCCGACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TGCGCTCTCC
  10    TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC
        GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTC GCTCCAAGCT
        GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACTATCG
        TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG
        GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA
  15    CGGCTACACT AGAAGAACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG
        AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT
        TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT
        TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACTCACGT TAAGGGATTT TGGTCATGAG
        ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT
  20    CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC
        TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC TGACTCGGGG GGGGGGGGCG
        CTGAGGTCTG CCTCGTGAAG AAGGTGTTGC TGACTCATAC CAGGCCTGAA TCGCCCCATC
        ATCCAGCCAG AAAGTGAGGG AGCCACGGTT GATGAGAGCT TTGTTGTAGG TGGACCAGTT
        GGTGATTTTG AACTTTTGCT TTGCCACGGA ACGGTCTGCG TTGTCGGGAA GATGCGTGAT
  25    CTGATCCTTC AACTCAGCAA AAGTTCGATT TATTCAACAA AGCCGCCGTC CCGTCAAGTC
        AGCGTAATGC TCTGCCAGTG TTACAACCAA TTAACCAATT CTGATTAGAA AAACTCATCG
        AGCATCAAAT GAAACTGCAA TTTATTCATA TCAGGATTAT CAATACCATA TTTTTGAAAA
        AGCCGTTTCT GTAATGAAGG AGAAAACTCA CCGAGGCAGT TCCATAGGAT GGCAAGATCC
        TGGTATCGGT CTGCGATTCC GACTCGTCCA ACATCAATAC AACCTATTAA TTTCCCCTCG
  30    TCAAAAATAA GGTTATCAAG TGAGAAATCA CCATGAGTGA CGACTGAATC CGGTGAGAAT
        GGCAAAAGCT TATGCATTTC TTTCCAGACT TGTTCAACAG GCCAGCCATT ACGCTCGTCA
        TCAAAATCAC TCGCATCAAC CAAACCGTTA TTCATTCGTG ATTGCGCCTG AGCGAGACGA
        AATACGCGAT CGCTGTTAAA GGACAATTA CAAACAGGAA TCGAATGCAA CCGGCGCAGG
        AACACTGCCA GCGCATCAAC AATATTTTCA CCTGAATCAG GATATTCTTC TAATACCTGG
```

```
    AATGCTGTTT  TCCCGGGGAT  CGCAGTGGTG  AGTAACCATG  CATCATCAGG  AGTACGGATA

    AAATGCTTGA  TGGTCGGAAG  AGGCATAAAT  TCCGTCAGCC  AGTTTAGTCT  GACCATCTCA

    TCTGTAACAT  CATTGGCAAC  GCTACCTTTG  CCATGTTTCA  GAAACAACTC  TGGCGCATCG

    GGCTTCCCAT  ACAATCGATA  GATTGTCGCA  CCTGATTGCC  CGACATTATC  GCGAGCCCAT

 5  TTATACCCAT  ATAAATCAGC  ATCCATGTTG  GAATTTAATC  GCGGCCTCGA  GCAAGACGTT

    TCCCGTTGAA  TATGGCTCAT  AACACCCCTT  GTATTACTGT  TTATGTAAGC  AGACAGTTTT

    ATTGTTCATG  ATGATATATT  TTTATCTTGT  GCAATGTAAC  ATCAGAGATT  TTGAGACACA

    ACGTGGCTTT  CCCCCCCCCC  CCATTATTGA  AGCATTTATC  AGGGTTATTG  TCTCATGAGC

    GGATACATAT  TTGAATGTAT  TTAGAAAAAT  AAACAAATAG  GGGTTCCGCG  CACATTTCCC

10  CGAAAAGTGC  CACCTGACGT  CTAAGAAACC  ATTATTATCA  TGACATTAAC  CTATAAAAAT

    AGGCGTATCA  CGAGGCCCTT  TCGTC  (SEQ ID NO:9).
```

V1R – Vaccine vector V1R was constructed to obtain a minimum-sized vaccine vector without unneeded DNA sequences, which still retained the overall optimized heterologous gene expression characteristics and high plasmid yields that

15   V1J and V1Jns afford. It was determined that (1) regions within the pUC backbone comprising the *E. coli* origin of replication could be removed without affecting plasmid yield from bacteria; (2) the 3'-region of the *kan*ʳ gene following the kanamycin open reading frame could be removed if a bacterial terminator was inserted in its place; and, (3) ~300 bp from the 3'- half of the BGH terminator could

20   be removed without affecting its regulatory function (following the original KpnI restriction enzyme site within the BGH element). V1R was constructed by using PCR to synthesize three segments of DNA from V1Jns representing the CMVintA promoter/BGH terminator, origin of replication, and kanamycin resistance elements, respectively. Restriction enzymes unique for each segment were added to each

25   segment end using the PCR oligomers: SspI and XhoI for CMVintA/BGH; EcoRV and BamHI for the *kan* ʳ gene; and, BclI and SalI for the *ori* ʳ. These enzyme sites were chosen because they allow directional ligation of each of the PCR-derived DNA segments with subsequent loss of each site: EcoRV and SspI leave blunt-ended DNAs which are compatible for ligation while BamHI and BclI leave complementary

30   overhangs as do SalI and XhoI. After obtaining these segments by PCR each segment was digested with the appropriate restriction enzymes indicated above and then ligated together in a single reaction mixture containing all three DNA segments. The 5'-end of the *ori* ʳ was designed to include the T2 rho independent terminator sequence that is normally found in this region so that it could provide termination

information for the kanamycin resistance gene. The ligated product was confirmed by restriction enzyme digestion (>8 enzymes) as well as by DNA sequencing of the ligation junctions. DNA plasmid yields and heterologous expression using viral genes within V1R appear similar to V1Jns. The net reduction in vector size achieved was

5   1346 bp (V1Jns = 4.86 kb; V1R = 3.52 kb). PCR oligomer sequences used to synthesize V1R (restriction enzyme sites are underlined and identified in brackets following sequence) are as follows: (1) 5'-GGTACA<u>AATATT</u>GGCTATTGG CCATTGCATACG-3' (SEQ ID NO:19) [SspI]; (2) 5'-CCACAT<u>CTCGAG</u>GAAC CGGGTCAATTCTTCAGCACC-3' (SEQ ID NO:20) [XhoI] (for CMVintA/BGH

10 segment); (3) 5'-GGTACA<u>GATATC</u>GGAAAGCCACGTTGTG TCTCAAAATC-3' (SEQ ID NO:21) [EcoRV]; (4) 5'-CACAT<u>GGATCC</u>GTAAT GCTCTGCCAGTGTT ACAACC-3' (SEQ ID NO:2) [BamHI], (for kanamycin resistance gene segment) (5) 5'-GGTAC<u>ATG ATCA</u>CGTAGAAAAGATCA AAGGATCTTCTTG-3' (SEQ ID NO:23) [BclI]; (6) 5'-CCACAT<u>GTCGAC</u>CCGTAAA AAGGCCGCGTTGCTGG-3'

15 (SEQ ID NO:24): [SalI], (for *E. coli* origin of replication).
The nucleotide sequence of vector V1R is as follows:

```
        TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
        CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
        TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
20      ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
        CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
        TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
        GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
        CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
25      CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
        TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
        TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
        TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
        CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
30      CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
        CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
        AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
        TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
        TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCCTTGGC
```

```
     TTCTTATGCA TGCTATACTG TTTTTGGCTT GGGGTCTATA CACCCCCGCT TCCTCATGTT
     ATAGGTGATG GTATAGCTTA GCCTATAGGT GTGGGTTATT GACCATTATT GACCACTCCC
     CTATTGGTGA CGATACTTTC CATTACTAAT CCATAACATG GCTCTTTGCC ACAACTCTCT
     TTATTGGCTA TATGCCAATA CACTGTCCTT CAGAGACTGA CACGGACTCT GTATTTTTAC
   5 AGGATGGGGT CTCATTTATT ATTTACAAAT TCACATATAC AACACCACCG TCCCCAGTGC
     CCGCAGTTTT TATTAAACAT AACGTGGGAT CTCCACGCGA ATCTCGGGTA CGTGTTCCGG
     ACATGGGCTC TTCTCCGGTA GCGGCGGAGC TTCTACATCC GAGCCCTGCT CCCATGCCTC
     CAGCGACTCA TGGTCGCTCG GCAGCTCCTT GCTCCTAACA GTGGAGGCCA GACTTAGGCA
     CAGCACGATG CCCACCACCA CCAGTGTGCC GCACAAGGCC GTGGCGGTAG GGTATGTGTC
  10 TGAAAATGAG CTCGGGGAGC GGGCTTGCAC CGCTGACGCA TTTGGAAGAC TTAAGGCAGC
     GGCAGAAGAA GATGCAGGCA GCTGAGTTGT TGTGTTCTGA TAAGAGTCAG AGGTAACTCC
     CGTTGCGGTG CTGTTAACGG TGGAGGGCAG TGTAGTCTGA GCAGTACTCG TTGCTGCCGC
     GCGCGCCACC AGACATAATA GCTGACAGAC TAACAGACTG TTCCTTTCCA TGGGTCTTTT
     CTGCAGTCAC CGTCCTTAGA TCTGCTGTGC CTTCTAGTTG CCAGCCATCT GTTGTTTGCC
  15 CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCCTT TCCTAATAAA
     ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATTC TATTCTGGGG GGTGGGGTGG
     GGCAGCACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG
     GCTCTATGGG TACCCAGGTG CTGAAGAATT GACCCGGTTC CTCCTGGGCC AGAAAGAAGC
     AGGCACATCC CCTTCTCTGT GACACACCCT GTCCACGCCC CTGGTTCTTA GTTCCAGCCC
  20 CACTCATAGG ACACTCATAG CTCAGGAGGG CTCCGCCTTC AATCCCACCC GCTAAAGTAC
     TTGGAGCGGT CTCTCCCTCC CTCATCAGCC CACCAAACCA AACCTAGCCT CCAAGAGTGG
     GAAGAAATTA AAGCAAGATA GGCTATTAAG TGCAGAGGGA GAGAAAATGC CTCCAACATG
     TGAGGAAGTA ATGAGAGAAA TCATAGAATT TCTTCCGCTT CCTCGCTCAC TGACTCGCTG
     CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA
  25 TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAAGGCC
     AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCCATA GGCTCCGCCC CCCTGACGAG
     CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC
     CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT GCCGCTTACC
     GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG CTCACGCTGT
  30 AGGTATCTCA GTTCGGTGTA GGTCGTTCGC TCCAAGCTGG GCTGTGTGCA CGAACCCCCC
     GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA
     CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA
     GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA
     TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA
```

```
     TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG
     CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG
     TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC
     TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA TGAGTAAACT
   5 TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT
     CGTTCATCCA TAGTTGCCTG ACTCCGGGGG GGGGGGGCGC TGAGGTCTGC CTCGTGAAGA
     AGGTGTTGCT GACTCATACC AGGCCTGAAT CGCCCCATCA TCCAGCCAGA AAGTGAGGGA
     GCCACGGTTG ATGAGAGCTT TGTTGTAGGT GGACCAGTTG GTGATTTTGA ACTTTTGCTT
     TGCCACGGAA CGGTCTGCGT TGTCGGGAAG ATGCGTGATC TGATCCTTCA ACTCAGCAAA
  10 AGTTCGATTT ATTCAACAAA GCCGCCGTCC CGTCAAGTCA GCGTAATGCT CTGCCAGTGT
     TACAACCAAT TAACCAATTC TGATTAGAAA AACTCATCGA GCATCAAATG AAACTGCAAT
     TTATTCATAT CAGGATTATC AATACCATAT TTTTGAAAAA GCCGTTTCTG TAATGAAGGA
     GAAAACTCAC CGAGGCAGTT CCATAGGATG GCAAGATCCT GGTATCGGTC TGCGATTCCG
     ACTCGTCCAA CATCAATACA ACCTATTAAT TTCCCCTCGT CAAAAATAAG GTTATCAAGT
  15 GAGAAATCAC CATGAGTGAC GACTGAATCC GGTGAGAATG GCAAAAGCTT ATGCATTTCT
     TTCCAGACTT GTTCAACAGG CCAGCCATTA CGCTCGTCAT CAAAATCACT CGCATCAACC
     AAACCGTTAT TCATTCGTGA TTGCGCCTGA GCGAGACGAA ATACGCGATC GCTGTTAAAA
     GGACAATTAC AAACAGGAAT CGAATGCAAC CGGCGCAGGA ACACTGCCAG CGCATCAACA
     ATATTTTCAC CTGAATCAGG ATATTCTTCT AATACCTGGA ATGCTGTTTT CCCGGGGATC
  20 GCAGTGGTGA GTAACCATGC ATCATCAGGA GTACGGATAA AATGCTTGAT GGTCGGAAGA
     GGCATAAATT CCGTCAGCCA GTTTAGTCTG ACCATCTCAT CTGTAACATC ATTGGCAACG
     CTACCTTTGC CATGTTTCAG AAACAACTCT GGCGCATCGG GCTTCCCATA CAATCGATAG
     ATTGTCGCAC CTGATTGCCC GACATTATCG CGAGCCCATT TATACCCATA TAAATCAGCA
     TCCATGTTGG AATTTAATCG CGGCCTCGAG CAAGACGTTT CCCGTTGAAT ATGGCTCATA
  25 ACACCCCTTG TATTACTGTT TATGTAAGCA GACAGTTTTA TTGTTCATGA TGATATATTT
     TTATCTTGTG CAATGTAACA TCAGAGATTT TGAGACACAA CGTGGCTTTC CCCCCCCCCC
     CATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT
     TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC
     TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GGCGTATCAC GAGGCCCTTT
  30 CGTC (SEQ ID NO:25).
```

EXAMPLE 2

Codon Optimized HIV-1 Pol and HIV-1 IA Pol Derivatives as DNA Vector Vaccines

Synthesis of WT-optpol and IA-opt-pol Gene - Construction of both genes were conducted by Midland Certified Reagent Company (Midland, TX) following

5   established strategies. Ten double stranded oligonucleotides, ranging from 159 to 340 bases long and encompassing the entire pol gene, were synthesized by solid state methods and cloned separately into pUC18. For the wt-pol gene, the fragments are as follows:

*Bg*III#1-*Ecl*136II half site at 282	= pJS6A1-7
*Pml*I half site at #285 – *Ecl*136II half site at #597	= pJS6B2-5
*Ssp*I half site at #600 - *Ecl*136II half site at #866	= pJS6C1-4
*Sma*I half site at #869 – *Apa*I #1095	= pJS6D1-4
*Apa*I #1095 - *Kpn*I #1296	= pJS6E1-4
*Kpn*I #1296 – *Xcm*I #1636	= pJS6F1-5
*Xcm*I #1636 – *Nsi*I #1847	= pJS6G1-2
*Nsi*I #1847 – *Bcl*I half site at #2174	= pJS6H1-14
*Bcl*I half site at #2174 – *Sac*I #2333	= pJS6I1-2
*Sac*I #2333 - *Bg*III #2577	= pJS6J1-1

*Eco*RI and *Hind*III sequences were added upstream of each 5' end and downstream of

20   each 3' end, respectively, to allow cloning into the *Eco*RI-*Hind*III sites of pUC18.

The next stage of the synthesis was to consolidate these cassettes into three roughly equal fragments (alpha, beta, gamma) and was performed as follows:

Alpha: The *Ssp*I-*Hind*III small fragment of pJS6C1-4 was transferred into the *Ecl*136II-*Hind*III sites of pJS6B2-5 to give pJS6BC1-1. Into the *Eco*RI-*Pml*I sites of

25   this plasmid was inserted the *Eco*RI-*Ecl*136II small fragment of pJS6A1-7 to give pJS6α1-8.

Beta: The *Eco*RI-*Apa*I small fragment of pJS6D1-4 was inserted into the corresponding sites of pJS6E1-2 to give pJS6DE1-2. Also, the *Eco*RI-*Xcm*I small fragment of pJS6F1-5 was inserted into the corresponding sites of pJS6G1-2 to give

30   pJS6FG1-1. Then the *Eco*RI-*Kpn*I small fragment of pJS6DE1-2 was inserted into the corresponding sites of pJS6FG1-1 to give pJS6β1-1.

Gamma: The *Sac*I-*Hind*III small fragment of pJS6J1-1 was inserted into the corresponding sites of pJS6I1-2 to give pJS6IJ1-1. This plasmid was propagated through *E. coli* SCS110 (*dam-/dcm-*) to permit subsequent cleavage at the *Bcl*I site.

The *BclI-HindIII* small fragment of the unmethylated pJS6IJ1-1 was inserted into the *BglIII-HindIII* sites of pJS6H1-14 to give pJS6χ1-1.

The wt-pol alpha, beta, gamma were ligated into the entire sequence as follows:

5   The *EcoRI-Ecl*136II small fragment of pJS6α1-8 was inserted into the *EcoRI-SmaI* sites of pJS6β1-1 to give pJS6αβ2-1.

Into the *NsiI-HindIII* sites of this plasmid was inserted the *NsiI-HindIII* small fragment of pJS6χ1-1 to give pUC18-wt-pol. This final plasmid was completely resequenced in both strands.

10   To construct the entire IA-pol gene, only 3 new small fragments were synthesized:

*Pml*I half site at #285 – *Ecl*136II half site at #597	= pJS7B1-1
*Kpn*I #1296 – *Xcm*I #1636	= pJS7F1-2
*Nsi*I #1847 – *Bgl*II half site at #2174	= pJS7H1-5

15   These were then used in the same reconstruction strategy as described above to give pUC18-IA-pol.

Expression Vector Construction - pUC18-wt-pol and pUC18-IA-pol were digested with *Bgl*II in order to isolate fragments containing the entire pol genes. V1R, V1Jns, V1Jns-tpa (Shiver, et al., 1995, Immune responses to HIV gp120 elicited by

20   DNA vaccination. In *Vaccines 95* (eds. Chanock, R. M., Brown, F., Ginsberg, H.S., & Norrby, E.) @ pp. 95-98; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; see also Example Section 1) were digested with *Bgl*II. The cut vectors were then treated with calf intestinal alkaline phosphatase. Both wt-pol and IA-pol genes were ligated into cut V1R using T4 DNA ligase (16 °C, overnight).

25   Competent DH5α cells were transformed with aliquots of the ligation mixtures. Colonies were screened by restriction digestion of amplified plasmid isolates. Following a similar strategy, the *Bgl*II fragment containing the IA-pol was subcloned into the *Bgl*II site of V1Jns. To ligate the IA-pol gene into V1Jns-tpa, the IA-pol gene was PCR-amplified from V1R-IA-pol using pfu polymerase and the following

30   pair of primers: 5'-GGTACAAGATCTCCGCCCCCATCTCCCCCATTGAGA-3' (SEQ ID NO:26), and 5'-CCACATAGATCTGCCCGGGCTTTAGTCCTCATC-3' (SEQ ID NO:27). The upstream primer was designed to remove the initiation met codon and place the pol gene in frame with the tpa leader coding sequence from V1Jns-tpa. The PCR product was purified from the agarose gel slab using Sigma

DNA Purification spin columns. The purified products were digested with *Bgl*II and subcloned into the *Bgl*II site of V1Jns-tpa.

    Results - The codon humanized wt- and IA-pol genes were constructed via stepwise ligation of 10 synthetic dsDNA fragments (Ferretti, et al., 1986, *Proc. Natl.*

5   *Acad. Sci. USA* 83: 599-603). For expression in mammalian systems, the IA-pol gene was subcloned into V1R, V1Jns, and V1Jns-tpa. All these vectors place the gene under the control of the human cytomegalovirus/intron A hybrid promoter (hCMVIA). The DNA sequence of the IA-pol gene and the expressed protein product are shown in Figure 2A-B. Subcloning into V1Jns-tpa attaches the leader sequence

10   from human tissue-specific plasminogen activator (tpa) to the N-terminus of the IA-pol (Pennica, et al., 1983, *Nature* 301: 214-221) to allow secretion of the protein. The sequences of the tpa leader and the fusion junction are shown in Figure 3.

<div align="center">

EXAMPLE 3
</div>

15   <div align="center">HIV-1 POL Vaccine - Rodent Studies</div>

    Materials - *E. coli* DH5α strain, penicillin, streptomycin, ACK lysis buffer, hepes, L-glutamine, RPMI1640, and ultrapure CsCl were obtained from Gibco/BRL (Grand Island, NY). Fetal bovine serum (FBS) was purchased from Hyclone. Kanamycin, Tween 20, bovine serum albumin, hydrogen peroxide (30%),

20   concentrated sulfuric acid, β-mercaptoethanol (β-ME), and concanavalin A were obtained from Sigma (St. Louis, MO). Female balb/c mice at 4-6 wks of age were obtained from Taconic Farms (Germantown, NY). 0.3-mL insulin syringes were purchased from Myoderm. 96-well flat bottomed Maxisorp plates were obtained form NUNC (Rochester, NY). HIV-1$_{IIIB}$ RT p66 recombinant protein was obtained from

25   Advanced Biotechnologies, Inc. (Columbia, MD). 20-mer peptides were synthesized by Research Genetics (Huntsville, AL). Horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG1 was obtained from ZYMED (San Francisco, CA). 1,2-phenylenediamine dihydrochloride (OPD) tablets was obtained from DAKO (Norway). Purified rat anti-mouse IFN-gamma (IgG1, clone R4-6A2), biotin-

30   conjugated rat anti-mouse IFN-gamma (IgG1, clone XMG 1.2), and strepavidin-alkaline phosphatase conjugate were purchased from PharMingen (San Diego, CA). 1-STEP NBT/BCIP dye was obtained from Pierce Chemicals (Rockford, IL). 96-well Multiscreen membrane plate was purchased from Millipore (France). Cell strainer was obtained from Becton-Dickinson (Franklin Lakes, NJ).

<div align="center">-54-</div>

Plasmid Preparation - *E. coli* DH5α cells expressing the pol plasmids were
grown to saturation in LB broth supplemented with 100 ug/mL kanamycin. Plasmid
were purified by standard CsCl method and solubilized in saline at concentrations
greater than 5 mg/mL until further use.

5   *Vaccination* - The plasmids were prepared in phosphate-buffered saline and
administered into balb/c by needle injection (28-1/2G insulin syringe) of 50 uL
aliquot into each quad muscle. V1Jns-IApol was administered at 0.3, 3, 30 ug dose
and for comparison, V1Jns-tpa-IApol was given at 30 ug dose. Immunizations were
conducted at T=0 and T=8 wks (for select animals from the 30-ug dose cohorts).

10   *ELISA Assay* - At T=12 wks, blood samples were collected by making an
incision of a tail vein and the serum separated. Anti-RT titers were obtained
following standard secondary antibody-based ELISA. Briefly, Maxisorp plates were
coated by overnight incubation with 100 uL of 1 ug/mL HIV-1 RT protein (in PBS).
The plates were washed with PBS/0.05% Tween 20 and incubated for approx. 2h with

15   200 uL/well of blocking solution (PBS/0.05% tween/1% BSA). The blocking
solution was decanted; 100 uL aliquot of serially diluted serum samples were added
per well and incubated for 2 h at room temperature. The plates were washed and 100
uL of 1/1000-diluted HRP-rabbit anti-mouse IgG were added with 1 h incubation.
The plates were washed thoroughly and soaked with 100 uL OPD/H_2O_2 solution for

20   15 min. The reaction was quenched by adding 100 uL of 0.5M H_2SO4 per well.
OD_{492} readings were recorded.

           ELIspot - Spleens were collected from 5 mice/cohort at T=13-14 wks and
pooled into a tube of 8-mL R10 medium (RPMI1640, 10% FBS, 2mM L-glutamine,
100U/mL Penicillin, 100 u/mL streptomycin, 10 mM Hepes, 50 uM β-ME).

25   Multiscreen opaque plates were coated with 100μl/well of capture mAb (purified R4-
6A2 diluted in PBS to 5μg/ml) at 4°C overnight. The plates were washed with
PBS/Pen/Strep in hood and blocked with 200μl/well of complete R10 medium for
37°C for at least 2 hrs. The mouse spleens were ground on steel mesh, collected into
15ml tubes and centrifuged at 1200rpm for 10min. The pellet was treated in ACK

30   buffer (4ml of lysis buffer per spleen) for 5min at room temperature to lyse red blood
cells. The cell pellet was centrifuged as before, resuspended in K-medium (5ml per
mouse spleen), filtered through a cell strainer and counted using a hemacytometer.
Block medium was decanted from the plates and 100μl/well of cell samples (5.0x10e5
cells per well) plus antigens were added. Pol-specific $CD4^+$ cells were stimulated

using a mixture of previously identified two epitope-containing peptides (aa641-660, aa731-750). Antigen-specific CD8+ cells were stimulated using a pool of four peptide epitope-containing peptides (aa201-220, aa311-330, aa571-590, aa781-800) or with individual peptides. A final concentration of 4 ug/mL per peptide was used.

5   Each splenocyte sample is tested for IFN-gamma secretion by adding the mitogen, concanavalin A. Plates were incubated at 37°C, 5% CO_2 for 20-24 h. The plates were washed with PBS/0.05% Tween 20 and soaked with 100 uL/well of 5 ug/mL biotin-conjugated rat anti-mouse IFN- mAb (clone XMG1.2) at 4°C overnight. The plates were washed and soaked with 100 uL/well 1/2500 dilution of strepavidin-AP

10   (in PBS/0.005% Tween/5%FCS) for 30 min at 37 °C. Following a wash, spots were developed by incubating with 100µl/well 1-step NBT/BCIP for 6-10 min. The plates were washed with water and allowed to air dry. The number of spots in each wells were determined using a dissecting microscope and normalized to 10e6 cells.

        Results - Single vaccination of balb/c mice with V1Jns-IApol is able to induce

15   antigen-specific antibody (Figure 4) and T cell (Figure 5) responses in a dose response manner. IFN-gamma secretion from splenocytes can be detected from 3 and 30 ug cohort following stimulation with pools of peptides that contain CD4+ and CD8+ T cell epitopes. These epitopes were identified by (1) screening 20-mer peptides that encompass the entire pol sequence and overlap by 10 amino acid for

20   ability to stimulate IFN-gamma secretion from vaccinee splenocytes, and (2) determining the T cell type (CD4+ or CD8+) by depleting either population in an Elispot assay. Addition of tpa leader sequence to the pol gene is able to induce comparable, if not slightly higher, frequencies of pol-specific CD4+ and CD8+ cells. A second immunization with either V1Jns-IApol and V1Jns-tpa-IApol resulted in

25   effective boosting of the immune responses.

                                    EXAMPLE 4
                    HIV-1 Pol Vaccine - Non Human Primate Studies
               Materials - *E. coli* DH5α strain, penicillin, streptomycin, and ultrapure CsCl

30   were obtained from Gibco/BRL (Grand Island, NY). Kanamycin and phytohemagluttinin (PHA-M) were obtained from Sigma (St. Louis, MO). 20-mer peptides were synthesized by SynPep (Dublin, CA) and Research Genetics (Huntsville, AL). 96-well Multiscreen Immobilon-P membrane plates were obtained from Millipore (France). Strepavidin-alkaline phosphatase conjugate were purchased

form Pharmingen (San Diego, CA). 1-Step NBT/BCIP dye was obtained form Pierce
Chemicals (Rockford, IL). Rat anti-human IFN-gamma mAb and biotin-conjugated
anti-human IFN-gamma reagent were obtained from R&D Systems (Minneapolis,
MN). Dynabeads M-450 anti-human CD4 were obtained from Dynal (Norway).

5   HIVp24 antigen assay was purchased from Coulter Corporation (Miami, FL). HIV-
1_{IIIB} RT p66 recombinant protein was obtained from Advanced Biotechnologies, Inc.
(Columbia, MD). Plastic 8 well strips/plates, flat bottom, Maxisorp, are obtained
from NUNC (Rochester, NY). HIV+ human serum 9711234 was obtained from
Biological Specialty Corp.

10   *Plasmid Preparation* - *E. coli* DH5α cells expressing the pol plasmids were
grown to saturation in LB supplemented with 100 ug/mL kanamycin. Plasmid were
purified by standard CsCl method and solubilized in saline at concentrations greater
than 5 mg/mL until further use.

          Vaccination - Cohorts of 3 rhesus macaques (approx. 5-10 kg) were
15   vaccinated with 5 mg dose of either V1Jns-IApol or V1Jns-tpa-IApol. The vaccine
was administered by needle injection of two 0.5 mL aliquots of 5 mg/mL plasmid
solution (in phosphate-buffered saline, pH 7.2) into both deltoid muscles. Prior to
vaccination, the monkeys were chemically restraint with i.m. injection of 10 mg/kg
ketamine. The animals were immunized 3x at 4 week intervals (T=0, 4, 8 wks).

20   *Sample Collection* - Blood samples were collected at T = 0, 4, 8, 12, 16, 18
wks; sera and PBMCs were isolated using established protocols.

          ELIspot Assay - Immobilon-IP plates were coated with 100 uL/well of rat anti-
human IFN-gamma mAb at 15 ug/mL at 4 °C overnight. The plates are then washed
with PBS and block by adding 200 uL/well of R10 medium. 4x10e5 peripheral blood
25   cells were plated per well and to each well, either media or one of the pol peptide
pools (final concentration of 4 ug/mL per peptide) or PHA, a known mitogen, is
added to a final volume of 100 uL. Duplicate wells were set up per sample per
antigen and stimulation was performed for 20-24 h at 37 °C. The plates are then
washed; biotinylated anti-human IFN-gamma reagent is added (0.1 ug/mL, 100 uL
30   per well) and allowed to incubate for overnight at 4 °C. The plates are again washed
and 100 uL of 1:2500 dilution of the strepavidin-alkaline phosphatase reagent (in
PBS/0.005% Tween/5% FCS) is added and allowed to incubate for 2 h at ambient
room temperature. After another wash, spots are developed by incubating with 100
uL/well of 1-step NBT/BCIP for 6-10 min. CD4- T cell depletion was performed by

-57-

adding 1 bead particle/10 cell of Dynabeads M450 anti-human CD4, prewashed with PBS, and incubating on the shaker at 4 °C for 30 min. The beads are fractionated magnetically and the unbound cells collected and quantified before plating onto the ELISpot assay plates (at 4x10e5 cells per well).

5   *CTL Assay* - Procedures for establishing bulk CTL culture with fresh or cryopreserved peripheral blood mononuclear cells (PBMC) are as follows. Twenty percent total PBMC were infected in 0.5 ml volume with recombinant vaccinia virus, Vac-tpaPol, respectively, at multiplicity of infection (moi) of 5 for 1 hr at 37°C, and then combined with the remaining PBMC sample. The cells were washed once in 10

10   ml R-10 medium, and plated in a 12 well plate at approximately 5 to 10 x 10^6 cells/well in 4 ml R-10 medium. Recombinant human IL-7 was added to the culture at the concentration of 330 U/ml. Two or three days later, one milliliter of R-10 containing recombinant human IL-2 (100 U/ml) was added to each well. And twice weekly thereafter, two milliliters of cultured media were replaced with 2 ml fresh R-

15   10 medium with rhIL-2 (100 U/ml). The lymphocytes were cultured at 37°C in the presence of 5% CO_2 for approximately 2 weeks, and used in cytotoxicity assay as described below. The effector cells harvested from bulk CTL cultures were tested against autologous B lymphoid cell lines (BLCL) sensitized with peptide pools. To prepare for the peptide-sensitized targets, the BLCL cells were washed once with

20   R-10 medium, enumerated, and pulsed with peptide pool (about 4 to 8 $\mu g/ml$ concentration for each individual peptide) in 1 ml volume overnight. A mock target was prepared by pulsing cells with peptide-free DMSO diluent to match the DMSO concentration in the peptide-pulsed targets. The cells were enumerated the next morning, and 1 x 10^6 cells were resuspended in 0.5 ml R-10 medium. Five to ten

25   microliters of $Na^{51}CrO_4$ were added to the tubes at the same time, and the cells were incubated for 1 to 2 hr 37°C. The cells were then washed 3 times and resuspended at 5x10^4 cells/ml in R-10 medium to be used as target cells. The cultured lymphocytes were plated with target cells at designated effector to target (E:T) ratios in triplicates in 96-well plates, and incubated at 37°C for 4 hours in the presence of 5% CO_2. A

30   sample of 30 μl supernatant from each well of cell mixture was harvested onto a well of a Lumaplate-96 (Packard Instrument, Meriden, CT), and the plate was allowed to air dry overnight. The amount of ^{51}Cr in the well was determined through beta-particle emission, using a plate counter from Packard Instrument. The percentage of specific lysis was calculated using the formula as: % specific lysis = $(E-S)$ / $(M-S)$.

The symbol E represents the average cpm released from target cells in the presence of effector cells, S is the spontaneous cpm released in the presence of medium only, and M is the maximum cpm released in the presence of 2% Triton X-100.

     ELISA Assay - The pol-specific antibodies in the monkeys were measured in a

5   competitive RT EIA assay, wherein sample activity is determined by the ability to block RT antigen from binding to coating antibody on the plate well. Briefly, Maxisorp plates were coated with saturating amounts of pol positive human serum (97111234). 250 uL of each sample is incubated with 15 uL of 266 ng/mL RT recombinant protein (in RCM 563, 1% BSA, 0.1% tween, 0.1% NaN$_3$) and 20 uL of

10   lysis buffer (Coulter p24 antigen assay kit) for 15 min at room temperature. Similar mixtures are prepared using serially diluted samples of a standard and a negative control which defines maximum RT binding. 200 uL/well of each sample and standard were added to the washed plate and the plate incubated 16-24 h at room temperature. Bound RT is quantified following the procedures described in Coulter

15   p24 assay kit and reported in milliMerck units per mL arbitrarily defined by the chosen standard.

    Results - Repeated vaccinations with V1Jns-IApol induced in 1 of 3 monkeys (94R033) significant levels of antigen-specific T cell activation (Figure 6A-C and Table 2) and CTL killing of peptide-pulsed autologous cells (Figure 7A-B). A

20   significant CD8+ component to the T cell responses in this animal was confirmed by peptide-stimulation of CD4-depleted PBMCs in an ELIspot assay (Table 2).

    Immunization with V1Jns-tpa-IApol produced T cell responses from all 3 vaccinees (Figures 6A-C, Figure 7A-B; Table 2). Two (920078, 94R028) exhibited bulk CTL activity and detectable CD8+ components as measured by Elispot analyses

25   of CD4-depleted PBMCs. For the third monkey (920073), the activated T cells were largely CD4+ (Table 2). Table 3 shows the time course data on the frequency of IFN-gamma secreting cells (SFC/million cells) upon antigen-specific stimulation for monkeys vaccinated 3x with either V1Jns-IApol or V1Jns-tpa-IApol (5 mg dose). At T=18 wks, CD4-cell depletion were performed; the reported values are the number of

30   spots per million of fractionated cells and are not corrected for the resultant enrichment of CD8+ T cells. PBMCs were stimulated with peptide pools that represent either IA pol protein (mpol-1, mpol-2) or wt Pol (wtpol-1, wtpol-2).

TABLE 2

Vaccine	Animal No.	Antigen	T=0 wk	T=4 Wk	T=8 Wk	T=12 Wk	T=18 Wk	
			Dose 1	Dose 2	Dose 3			CD4-Depl
VIJns-lApd 5 mgs	94R008	medium	1	15	6	11	11	11
		mpd-1	3	69	28	61	20	15
		mpd-2	0	25	21	19	28	16
		wtpd-1		49	20	53	18	
		wtpd-2		34	24	24	19	
	94R013	medium	0	14	6	9	18	11
		mpd-1	0	9	63	25	34	9
		mpd-2	1	15	24	36	24	15
		wtpd-1		9	50	33	18	
		wtpd-2		6	21	29	25	
	94R033	medium	4	15	11	14	13	8
		mpd-1	3	29	86	51	41	24
		mpd-2	0	24	25	43	59	64
		wtpd-1		30	38	60	53	
		wtpd-2		48	46	86	61	
VIJns-tpclApd 5 mgs	920078	medium	0	24	13	11	14	11
		mpd-1	3	110	120	119	155	11
		mpd-2	1	221	130	561	289	145
		wtpd-1		115	53	70	116	
		wtpd-2		218	204	490	194	
	920073	medium	0	13	3	15	15	6
		mpd-1	0	36	51	113	90	14
		mpd-2	0	29	16	83	115	34
		wtpd-1		20	35	100	74	
		wtpd-2		25	16	79	61	
	94R028	medium	0	18	11	18	19	9
		mpd-1	1	30	24	29	30	28
		mpd-2	1	24	23	66	59	95
		wtpd-1		23	25	34	29	
		wtpd-2		26	28	71	40	
Naïve	920072	medium	1	19	3	38	9	4
		mpd-1	0	24	11	25	4	6
		mpd-2	1	24	5	28	6	5
		wtpd-1		18	13	20	6	
		wtpd-2		23	14	33	14	

5

For the Elispot assay, antigen specific stimulation were performed by using pools of 20-mer peptide pools based on the vaccine sequence. The vaccine pol sequence differs from the wild-type HIV-1 sequence by 9 point mutations, thereby affecting 16 of the 20-mer peptides in the pool. Comparable responses were observed

5   in the vaccinees when these peptides are replaced with those using the wild-type sequences.

Four of the vaccinees gave anti-RT titers above background after 3 dosages of the plasmids (Table 2).

10

TABLE 3

Anti-RT levels in Rhesus Macaques Vaccinated 3x (4 week intervals) with
5 mgs of V1Jns-IApol or V1Jns-tpa-IApol expressed in mMU/mL.

Vaccine/Monkey	T=0 Wk	T=4	T=8	T=12	T=16
	DOSE 1	DOSE 2	DOSE 3		
V1Jns-IApol, 5 mg					
94R008	ND	<10	<10	15	14
94R013	ND	<10	<10	<10	<10
94R033	ND	<10	<10	25	19
V1Jns-tpa-IApol, 5 mg					
920078	ND	<10	<10	35	17
920073	ND	<10	<10	<10	<10
94R028	ND	<10	<10	20	63

15

EXAMPLE 5

Effect of Codon Optimization on In Vivo Expression and

Cellular Immune Response of wt-pol

Materials and Methods - Extraction of virus-derived pol gene - The gene for RT-IN

20   (wt-pol; a non-codon optimized wild type pol gene derived directly from the HIV IIIB genome) was extracted and amplified from the HIV IIIB genome using two primers, 5'-CAG GCG AGA TCT ACC ATG GCC CCC ATT AGC CCT ATT GAG ACT GTA-3' (SEQ ID NO:29) and 5'-CAG GCG AGA TCT GCC CGG GCT TTA ATC CTC ATC CTG TCT ACT TGC CAC-3' (SEQ ID NO:30), containing *Bgl*II sites.

25   The reaction contained 200 nmol of each primer, 2.5 U of pfu Turbo DNA polymerase (Stratagene, La Jolla, CA), 0.2 mM of each dNTPs, and the template DNA in 10mM KCl, 10mM $(NH_4)_2SO_4$, 20mM Tris-HCl pH 8.75, 2mM $MgSO_4$, 0.1% TritonX-100, 0.1mg/ml bovine serum albumin (BSA). Thermocycling

-61-

conditions were as follows: 20 cycles of 1 min at 95 °C, 1 min at 56 °C, and 4 mins at 72 °C with 15-min capping at 72 °C. The digested PCR fragment was subcloned into the *BglII* site of the expression plasmid V1Jns (Shiver, et al., 1995, Immune responses to HIV gp120 elicited by DNA vaccination. In Chanock, R. M., Brown, F., Ginsberg,

5   H. S., and Norrby, E. (Eds.) *Vaccines 95.* Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 95-98; see also Example section 1 herein) expression plasmid following similar procedures as described above. The ligation mixtures were then used to transform competent *E. coli* DH5 cells and screened by PCR amplification of individual colonies. Sequence of the entire gene insert was

10   confirmed. All plasmid constructs for animal immunization were purified by CsCl method (Sambrook, et al., 1989, Fritsch and Maniatis, T. (Eds) *Molecular cloning: a laboratory manual.* Cold Spring Harbor Laboratory Press, Cold Spring Harbor).

       In vitro expression in mammalian cells - 1.5×10^6 293 cells were transfected with 1 or 10 μg of V1R-wt-pol (codon optimized) and V1Jns-wt-pol (virus derived)

15   using the Cell Phect kit and incubated for 48 h at 37 °C, 5% CO_2, 90% humidity. Supernatants and cell lysates were prepared and assayed for protein content using Pierce Protein Assay reagent (Rockford, IL). Aliquots containing equal amounts of total protein were loaded unto 10-20% Tris glycine gel (Novex, San Diego, CA) along with the appropriate molecular weight markers. The pol product was detected using

20   anti-serum from a seropositive patient (Scripps Clinic, San Diego, CA) diluted 1:1000 and the bands developed using goat anti-human IgG-HRP (Bethyl, Montgomery, TX) at 1:2000 dilution and standard ECL reagent kit (Pharmacia LKB Biotechnology, Uppsala, Sweden).

       Ultrasensitive RT activity assay of pol constructs - RT activities from codon

25   optimized wt-pol and IA pol plasmids were analyzed by the Product-Enhanced Reverse Transcriptase (PERT) assay using Perkin Elmer 7700, Taqman technology (Arnold, et al., 1999, One-step fluorescent probe product-enhanced reverse transcriptase assay. In McClelland, M., Pardee, A. (Eds.) *Expression genetics: accelerated and high-throughput methods.* Biotechniques Books, Natick, MA, pp.

30   201-210). Background levels for this assay were determined using 1:100,000 dilution of lysates from mock (chemical treatment only, no vector) transfected 293 cells. This background range is set as RT/reaction tube of 0.00 to 56.28 which is taken from the mean value of 13.80 +/- 3 standard deviations (sd=14.16). Any individual value >56.28 would be considered positive for PERT assay. Cells lysates were prepared

similarly for the following samples: mock transfection with empty V1Jns vector; no vector control; transfection with V1Jns-tpa-pol (codon optimized); and transfection with V1Jns-IApol (codon optimized). Samples were serially diluted to 1:100,000 in PERT buffer and 24 replicates for each sample at this dilution were assayed for RT activity.

Rodent immunization with optimized and virus-derived pol plasmids - To compare the immunogenic properties of wt-pol (codon optimized) and virus-derived pol gene, cohorts of BALB/c mice (N=10) were vaccinated with 1 μg, 10 μg, and 100 μg doses of V1R-wt-pol (codon optimized) and V1Jns-wt-pol plasmid (virus derived). At 5 weeks post dose 1, 5 of 10 mice per cohort were boosted with the same dose of plasmid they initially received. In all cases, the vaccines were suspended or diluted in 6 mM sodium phosphate, 150 mM sodium chloride, pH 7.2, and the total dose was injected to both quadricep muscles in 50 μL aliquots using a 0.3-mL insulin syringe with 28-1/2G needles (Becton-Dickinson, Franklin Lakes, NJ).

Anti-RT ELISA - Anti-RT titers were obtained following standard secondary antibody-based ELISA. Maxisorp plates (NUNC, Rochester, NY) were coated by overnight incubation with 100 μL of 1 μg /mL HIV-1 RT protein (Advanced Biotechnologies, Columbia, MD) in PBS. The plates were washed with PBS/0.05% Tween 20 using Titertek MAP instrument (Hunstville, AL) and incubated for approximately 2h with 200 μL/well of blocking solution (PBS/0.05% tween/1% BSA). The blocking solution was decanted; 100 μL aliquot of serially diluted serum samples were added per well and incubated for 2 h at room temperature. An initial dilution of 100-fold is performed followed by 4-fold serial dilution. The plates were washed and 100 μL of 1/1000-diluted HRP-rabbit anti-mouse IgG (ZYMED, San Francisco, CA) were added with 1 h incubation. The plates were washed thoroughly and soaked with 100 μL 1,2-phenylenediamine dihydrochloride/hydrogen peroxide (DAKO, Norway) solution for 15 min. The reaction was quenched by adding 100 μL of 0.5M H_2SO4 per well. OD_{492} readings were recorded using Titertek Multiskan MCC/340 with S20 stacker. Endpoint titers were defined as the highest serum dilution that resulted in an absorbance value of greater than or equal to 0.1 OD_{492} (2.5 times the background value).

ELIspot assay - Antigen-specific INFγ-secreting cells from mouse spleens were detected using the ELIspot assay (Miyahira, et al., 1995, Quantification of antigen specific CD8[+] T cells using an ELISPOT assay. *J. Immunol. Methods* 1995,

181, 45-54). Typically, spleens were collected from 3-5 mice/cohort and pooled into a tube of 8-mL complete RPMI media (RPMI1640, 10% FBS, 2mM L-glutamine, 100U/mL Penicillin, 100 u/mL streptomycin, 10 mM Hepes, 50 uM β-ME). Multiscreen opaque plates (Millipore, France) were coated with 100 μL/well of 5

5   μg/mL purified rat anti-mouse IFN-γ IgG1, clone R4-6A2 (Pharmingen, San Diego, CA), in PBS at 4°C overnight. The plates were washed with PBS/penicillin/streptomycin in hood and blocked with 200 μL/well of complete RPMI media for 37 °C for at least 2 h. The mouse spleens were ground on steel mesh, collected into 15ml tubes and centrifuged at 1200rpm for 10 min. The pellet

10   was treated with 4 mL ACK buffer (Gibco/BRL) for 5 min at room temperature to lyse red blood cells. The cell pellet was centrifuged as before, resuspended in complete RPMI media (5 ml per mouse spleen), filtered through a cell strainer and counted using a hemacytometer. Block media was decanted from the plates and to each well, 100 μL of cell samples (5×10^5 cells per well) and 100 μL of the antigen

15   solution were added. To the control well, 100 μL of the media were added; for specific responses, peptide pools containing either $CD4^+$ or $CD8^+$ epitopes were added. In all cases, a final concentration of 4 μg/mL per peptide was used. Each sample/antigen mixture were performed in triplicate wells. Plates were incubated at 37°C, 5% CO_2, 90% humidity for 20-24 h. The plates were washed with PBS/0.05%

20   Tween 20 and incubated with 100 μL/well of 1.25 μg/mL biotin-conjugated rat anti-mouse IFN-γ mAb, clone XMG1.2 (Pharmingen) at 4°C overnight. The plates were washed and incubated with 100 μL/well 1/2500 dilution of strepavidin-alkaline phosphatase conjugate (Pharmingen) in PBS/0.005% Tween/5% FBS for 30 min at 37 °C. Following a wash, spots were developed by incubating with 100 μl/well 1-step

25   NBT/BCIP (Pierce Chemicals) for 6-10 min. The plates were washed with water and allowed to air dry. The number of spots in each well was determined using a dissecting microscope and the data normalized to 10^6 cell input.

    Results - In vitro expression of Pol in mammalian cells - Heterologous expression of the optimized wt or IA pol genes (V1R-wt-pol (codon optimized),

30   V1Jns-IApol (codon optimized), V1Jns-tpa-IApol (codon optimized)) in 293 cells (Figure 8) yielded a single polypeptide of correct approximate molecular size (90-kDa) for the RT-IN fusion product. In contrast, no expression could be detected by transfecting cells with 1 and 10 μg of the V1Jns-wt-pol, which bears the virus-derived *pol*.

Ultrasensitive RT assay of cells transfected with Pol constructs - Table 4 summarizes the levels of polymerase activity from mock (vector only) control, IApol (codon optimized)and wt-pol plasmids (codon optimized). Results indicate that the wild-type POL transfected cells contained RT activity approximately 4-5 logs higher

5 than the 293 cell only baseline values. Mock transfected cells contained activity no higher than baseline values. The RT activity from opt-IApol-transfected cells was also found to be no different than baseline values; no individual reaction tube resulted in RT activity higher than the established cut-off value of 56.

10   Table 4

Sample	Avg. RT/tube	Standard deviation	Minimum	Maximum
Vector only	16.25	18.52	0.0	42.99
IApol (codon optimized)	2.99	8.01	0.0	35.20
Wt-pol (codon optimized)	126147	21338	68973	152007

Comparative immunogenicity of optimized and virus-derived pol plasmid - To compare the *in vivo* potencies of both constructs, BALB/c mice (N=10 per group)

15 were vaccinated with escalating doses (1, 10, 100 μg) of either V1Jns-wt-pol (virus derived) or V1R-wt-pol (codon optimized). At 5 wks post dose 1, 5 of 10 animals were randomly boosted with the same vaccine and dose they received initially. Figure 9 shows the geometric mean titers of the BALB/c cohorts determined at 2 wks past boost. No significant anti-RT titers can be observed from animals immunized

20 with one or two doses of the wt-pol plasmid (virus derived). In contrast, animals vaccinated with the humanized gene construct gave cohort anti-RT titers (>1000) significantly above background levels at doses above 10 ug. The responses seen at 10 and 100 ug dose of V1R-wt-pol (codon optimized) were boosted approximately 10-fold with a second immunization, reaching titers as high as 10^6.

25 Spleens from all mice in each of the cohorts were collected to be analyzed for IFN-γ secretion following stimulation with mixtures of either CD4+ peptide epitopes or CD8+ peptide epitopes. The results are shown in Figure 10. All wt-pol vaccinees did

not show any significant cellular response above the background controls. In contrast, strong antigen-stimulated IFN-γ secretion were observed in a dose-responsive manner from animals vaccinated with one or two doses of 10 or more μg of the wt-pol (codon optimized) construct.

5   The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

10

WHAT IS CLAIMED IS:

1.   A pharmaceutically acceptable DNA vaccine composition, which comprises:

(a)   a DNA expression vector; and,

5   (b)   a DNA molecule containing a codon optimized open reading frame encoding a Pol protein or inactivated Pol derivative thereof,

wherein upon administration of the DNA vaccine to a host the Pol protein or inactivated Pol derivative is expressed and generates a cellular immune response against HIV-1 infection. -

10

2.   The DNA vaccine of claim 1 wherein the DNA molecule encodes wild type Pol.

3.   The DNA vaccine of claim 2 wherein the DNA molecule comprises

15   the nucleotide sequence as set forth in SEQ ID NO:1.

4.   The DNA vaccine of claim 3 which is V1Jns-wt-pol.

5.   The DNA vaccine of claim 1 wherein the DNA molecule encodes an

20   inactivated Pol derivative which contains a nucleotide sequence encoding a human tissue plasminogen activator leader peptide.

6..   The DNA vaccine of claim 5 wherein the DNA molecule comprises the nucleotide sequence as set forth in SEQ ID NO:5

25

7.   The DNA vaccine of claim 6 which is V1Jns-tPA-wt-pol.

8.   The DNA vaccine of claim 1 wherein the inactivated Pol protein contains at least one amino acid modification within each region of the Pol protein

30   responsible for reverse transcriptase activity, RNase H activity and integrase activity, such that the inactivated Pol protein shows no substantial reverse transcriptase activity, RNase H activity and integrase activity.

9. The DNA vaccine of claim 8 wherein the DNA molecule comprises the nucleotide sequence as set forth in SEQ ID NO:3

10. The DNA vaccine of claim 9 which is V1Jns-IAPol.

5

11. The DNA vaccine of claim 8 wherein the DNA molecule encodes an inactivated Pol derivative which contains a nucleotide sequence encoding a human tissue plasminogen activator leader peptide.

10   12. The DNA vaccine of claim 11 wherein the DNA molecule comprises the nucleotide sequence as set forth in SEQ ID NO:7.

13. The DNA vaccine of claim 7 which is V1Jns-tPA-IAPol.

15   14. A method for inducing an immune response against infection or disease caused by virulent strains of HIV which comprises administering into the tissue of a mammalian host a pharmaceutically acceptable DNA vaccine composition which comprises a DNA expression vector and a DNA molecule containing a codon optimized open reading frame encoding a Pol protein or inactivated Pol derivative
20   thereof, wherein upon administration of the DNA vaccine to the vertebrate host the Pol protein or inactivated Pol derivative is expressed and generates the immune response.

15. The method of claim 16 wherein the mammalian host is a human.

25

16. The method of claim 17 wherein the DNA vaccine is selected from the group consisting of V1Jns-WTPol, V1Jns-tPA-WTPol, V1Jns-IAPol and V1Jns-tPA-IAPol.

30   17. A substantially purified protein which comprises an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

FIG.1A

FIG.1B

2/11

AGATCTACCATGGCCCCCATCTCCCCCATTGAGACTGTGCCTGTGAAGCTGAAGCCTGGCATGGATGGCCCCAAGGTGAA
Bg/II MetAlaProIleSerProIleGluThrValProValLysLeuLysProGlyMetAspGlyProLysValLy
1   10   20

GCAGTGGCCCCTGACTGAGGAGAAGATCAAGGCCCTGGTGGAAATCTGCACTGAGATGGAGAAGGAGGGCAAAATCTCCA
sGlnTrpProLeuThrGluGluLysIleLysAlaLeuValGluIleCysThrGluMetGluLysGluGlyLysIleSerL
30   40   50

AGATTGGCCCCGAGAACCCCTACAACACCCCTGTGTTTGCCATCAAGAAGAAGGACTCCACCAAGTGGAGGAAGCTGGTG
ysIleGlyProGluAsnProTyrAsnThrProValPheAlaIleLysLysLysAspSerThrLysTrpArgLysLeuVal
60   70

GACTTCAGGGAGCTGAACAAGAGGACCCAGGACTTCTGGGAGGTGCAGCTGGGCATCCCCCACCCCGCTGGCCTGAAGAA
AspPheArgGluLeuAsnLysArgThrGlnAspPheTrpGluValGlnLeuGlyIleProHisProAlaGlyLeuLysLy
80   90   100

GAAGAAGTCTGTGACTGTGCTGGCTGTGGGGGATGCCTACTTCTCTGTGCCCCTGGATGAGGACTTCAGGAAGTACACTG
sLysLysSerValThrValLeuAlaValGlyAspAlaTyrPheSerValProLeuAspGluAspPheArgLysTyrThrA
110   120   130

CCTTCACCATCCCCTCCATCAACAATGAGACCCCTGGCATCAGGTACCAGTACAATGTGCTGCCCCAGGGCTGGAAGGGC
laPheThrIleProSerIleAsnAsnGluThrProGlyIleArgTyrGlnTyrAsnValLeuProGlnGlyTrpLysGly
140   150

TCCCCTGCCATCTTCCAGTCCTCCATGACCAAGATCCTGGAGCCCTTCAGGAAGCAGAACCCTGACATTGTGATCTACCA
SerProAlaIlePheGlnSerSerMetThrLysIleLeuGluProPheArgLysGlnAsnProAspIleValIleTyrGl
160   170   180

GTACATGGCTGCCCTGTATGTGGGCTCTGACCTGGAGATTGGGCAGCACAGGACCAAGATTGAGGAGCTGAGGCAGCACC
nTyrMetAlaAlaLeuTyrValGlySerAspLeuGluIleGlyGlnHisArgThrLysIleGluGluLeuArgGlnHisL
190   200   210

TGCTGAGGTGGGGGCCTGACCACCCCTGACAAGAAGCACCAGAAGGAGCCCCCCTTCCTGTGGATGGGCTATGAGCTGCAC
euLeuArgTrpGlyLeuThrThrProAspLysLysHisGlnLysGluProProPheLeuTrpMetGlyTyrGluLeuHis
220   230

CCCGACAAGTGGACTGTGCAGCCCATTGTGCTGCCTGAGAAGGACTCCTGGACTGTGAATGACATCCAGAAGCTGGTGGG
ProAspLysTrpThrValGlnProIleValLeuProGluLysAspSerTrpThrValAsnAspIleGlnLysLeuValGl
240   250   260

CAAGCTGAACTGGGCCTCCCAAATCTACCCTGGCATCAAGGTGAGGCAGCTGTGCAAGCTGCTGAGGGGCACCAAGGCCC
yLysLeuAsnTrpAlaSerGlnIleTyrProGlyIleLysValArgGlnLeuCysLysLeuLeuArgGlyThrLysAlaL
270   280   290

FIG.2A

TGACTGAGGTGATCCCCCTGACTGAGGAGGCTGAGCTGGAGCTGGCTGAGAACAGGGAGATCCTGAAGGAGCCTGTGCAT
EuThrGluVal I leProLeuThrGluGluAlaGluLeuGluLeuAlaGluAsnArgGlul I leLeuLysGluProValHis
                    300   310

GGGGTGTACTATGACCCCTCCAAGGACCTGATTGCTGAGATCCAGAAGCAGGGCCAGGGCCAGTGGACCTACCAAATCTA
GlyValTyrTyrAspProSerLysAspLeul leAlaGlul leGlnLysGlnGlyGlnGlyGlnTrpThrTyrGlnl leTy
          320   330   340

CCAGGAGCCCTTCAAGAACCTGAAGACTGGCAAGTATGCCAGGATGAGGGGGGCCCACACCAATGATGTGAAGCAGCTGA
rGlnGluProPheLysAsnLeuLysThrGlyLysTyrAlaArgMetArgGlyAlaHisThrAsnAspValLysGlnLeuT
               350   360   370

CTGAGGCTGTGCAGAAGATCACCACTGAGTCCATTGTGATCTGGGGCAAGACCCCCAAGTTCAAGCTGCCCATCCAGAAG
hrGluAlaValGlnLysl leThrThrGluSerl leVal l leTrpGlyLysThrProLysPheLysLeuProl leGlnLys
                    380   390

GAGACCTGGGAGACCTGGTGGACTGAGTACTGGCAGGCCACCTGGATCCCTGAGTGGGAGTTTGTGAACACCCCCCCCCT
GluThrTrpGluThrTrpTrpThrGluTyrTrpGlnAlaThrTrpl leProGluTrpGluPheValAsnThrProProLe
          400   410   420

GGTGAAGCTGTGGTACCAGCTGGAGAAGGAGCCCATTGTGGGGGGCTGAGACCTTCTATGTGGCTGGGGCTGCCAACAGGG
uVal LysLeuTrpTyrGlnLeuGluLysGluProl leValGlyAlaGluThrPheTyrVal AlaGlyAlaAlaAsnArgG
               430   440   450

AGACCAAGCTGGGCAAGGCTGGCTATGTGACCAACAGGGGCAGGCAGAAGGTGGTGACCCTGACTGACACCACCAACCAG
luThrLysLeuGlyLysAlaGlyTyrValThrAsnArgGlyArgGlnLysValValThrLeuThrAspThrThrAsnGln
                    460   470

AAGACTGCCCTCCAGGCCATCTACCTGGCCCTCCAGGACTCTGGCCTGGAGGTGAACATTGTGACTGCCTCCCAGTATGC
LysThrAlaLeuGlnAlal leTyrLeuAlaLeuGlnAspSerGlyLeuGluValAsnl leValThrAlaSerGlnTyrAl
          480   490   500

CCTGGGCATCATCCAGGCCCAGCCTGATCAGTCTGAGTCTGAGCTGGTGAACCAGATCATTGAGCAGCTGATCAAGAAGG
aLeuGlyl lel leGlnAlaGlnProAspGlnSerGluSerGluLeuValAsnGlnl lel leGluGlnLeul leLysLysG
               510   520   530

AGAAGGTGTACCTGGCCTGGGTGCCTGCCCACAAGGGCATTGGGGGCAATGAGCAGGTGGACAAGCTGGTGTCTGCTGGC
luLysValTyrLeuAlaTrpValProAlaHisLysGlyl leGlyGlyAsnGluGlnValAspLysLeuValSerAlaGly
                    540   550

ATCAGGAAGGTGCTGTTCCTGGATGGCATTGACAAGGCCCAGGATGAGCATGAGAAGTACCACTCCAACTGGAGGGCTAT
l leArgLysVal LeuPheLeuAspGlyl leAspLysAlaGlnAspGluHisGluLysTyrHisSerAsnTrpArgAlaMe
          560   570   580

FIG.2B

SUBSTITUTE SHEET (RULE 26)

4/11

GGCCTCTGACTTCAACCTGCCCCCTGTGGTGGCTAAGGAGATTGTGGCCTCCTGTGACAAGTGCCAGCTGAAGGGGGAGG
tAloSerAspPheAsnLeuProProVolVolAloLysGluIleVolAloSerCysAspLysCysGlnLeuLysGlyGluA
                    590   600   610

CCATGCATGGGCAGGTGGACTGCTCCCCTGGCATCTGGCAGCTGGCCTGCACCCACCTGGAGGGCAAGGTGATCCTGGTG
loMetHisGlyGlnVolAspCysSerProGlyIleTrpGlnLeuAloCysThrHisLeuGluGlyLysVolIleLeuVol
                    620   630

GCTGTGCATGTGGCCTCCGGCTACATTGAGGCTGAGGTGATCCCTGCTGAGACAGGCCAGGAGACTGCCTACTTCCTGCT
AloVolHisVolAloSerGlyTyrIleGluAloGluVolIleProAloGluThrGlyGlnGluThrAloTyrPheLeuLe
                    640   650   660

GAAGCTGGCTGGCAGGTGGCCTGTGAAGACCATCCACACTGCCAATGGCTCCAACTTCACTGGGGGCCACAGTGAGGGCTG
uLysLeuAloGlyArgTrpProVolLysThrIleHisThrAloAsnGlySerAsnPheThrGlyAloThrVolArgAloA
                    670   680   690

CCTGCTGGTGGGCTGGCATCAAGCAGGAGTTTGGCATCCCCTACAACCCCCAGTCCCAGGGGGTGGTGGCCTCCATGAAC
loCysTrpTrpAloGlyIleLysGlnGluPheGlyIleProTyrAsnProGlnSerGlnGlyVolVolAloSerMetAsn
                         700   710

AAGGAGCTGAAGAAGATCATTGGGCAGGTGAGGGACCAGGCTGAGCACCTGAAGACAGCTGTGCAGATGGCTGTGTTCAT
LysGluLeuLysLysIleIleGlyGlnVolArgAspGlnAloGluHisLeuLysThrAloVolGlnMetAloVolPheIl
                    720   730   740

CCACAACTTCAAGAGGAAGGGGGGCATCGGGGGCTACTCCGCTGGGGAGAGGATTGTGGACATCATTGCCACAGACATCC
eHisAsnPheLysArgLysGlyGlyIleGlyGlyTyrSerAloGlyGluArgIleVolAspIleIleAloThrAspIleG
                    750   760   770

AGACCAAGGAGCTCCAGAAGCAGATCACCAAGATCCAGAACTTCAGGGTGTACTACAGGGACTCCAGGAACCCCCTGTGG
lnThrLysGluLeuGlnLysGlnIleThrLysIleGlnAsnPheArgVolTyrTyrArgAspSerArgAsnProLeuTrp
                    780   790

AAGGGCCCTGCCAAGCTGCTGTGGAAGGGGGAGGGGGCTGTGGTGATCCAGGACAACTCTGACATCAAGGTGGTGCCCAG
LysGlyProAloLysLeuLeuTrpLysGlyGluGlyAloVolVolIleGlnAspAsnSerAspIleLysVolVolProAr
                    800   810   820

GAGGAAGGCCAAGATCATCAGGGACTATGGCAAGCAGATGGCTGGGGATGACTGTGTGGCCTCCAGGCAGGATGAGGACT
gArgLysAloLysIleIleArgAspTyrGlyLysGlnMetAloGlyAspAspCysVolAloSerArgGlnAspGluAspx
                    830   840   850

AAAGCCCGGGCAGATCT (SEQ ID NO: 3)
Xx   BglII

FIG.2C

GATCACCATGGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGTGCGACCAGTCTTCGTTTCGC
MetAspAlaMetLysArgGlyLeuCysCysValLeuLeuLeuCysGlyAlaValPheValSerP
-25   -20   -10

CCAGCGAGATCTCCGCCCCATCTCCCCATTGAGACTGTGCCTGTGAAGCTGAAGCCTGGCATGGATGGC (within SEQ ID NO: 7)
RoSerGluIleSerProIleGluThrValProIleGluThrValProValLysLeuLysProGlyMetAspGly (within SEQ ID NO: 8)
-1 2   10   20

FIG.3

6/11

FIG.4

FIG.5

FIG.6A

FIG.6B

FIG.6C

FIG.7A

FIG.7B

FIG.8

FIG.9

FIG.10

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> POLYNUCLEOTIDE VACCINES EXPRESSING CODON
      OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL

<130> 20608Y PCT

<160> 30

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 2577
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (10)...(2562)

<400> 1
```
agatctacc atg gcc ccc atc tcc ccc att gag act gtg cct gtg aag ctg       51
          Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu
            1               5                  10

aag cct ggc atg gat ggc ccc aag gtg aag cag tgg ccc ctg act gag       99
Lys Pro Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu
 15              20                  25                      30

gag aag atc aag gcc ctg gtg gaa atc tgc act gag atg gag aag gag      147
Glu Lys Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu
                35                  40                  45

ggc aaa atc tcc aag att ggc ccc gag aac ccc tac aac acc cct gtg      195
Gly Lys Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val
            50                  55                  60

ttt gcc atc aag aag aag gac tcc acc aag tgg agg aag ctg gtg gac      243
Phe Ala Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp
            65                  70                  75

ttc agg gag ctg aac aag agg acc cag gac ttc tgg gag gtg cag ctg      291
Phe Arg Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu
         80                  85                  90

ggc atc ccc cac ccc gct ggc ctg aag aag aag aag tct gtg act gtg      339
Gly Ile Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val
 95                  100                 105                 110

ctg gat gtg ggg gat gcc tac ttc tct gtg ccc ctg gat gag gac ttc      387
Leu Asp Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe
                115                 120                 125

agg aag tac act gcc ttc acc atc ccc tcc atc aac aat gag acc cct      435
Arg Lys Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro
                130                 135                 140
```

```
ggc atc agg tac cag tac aat gtg ctg ccc cag ggc tgg aag ggc tcc        483
Gly Ile Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser
        145              150              155

cct gcc atc ttc cag tcc tcc atg acc aag atc ctg gag ccc ttc agg        531
Pro Ala Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg
    160              165              170

aag cag aac cct gac att gtg atc tac cag tac atg gat gac ctg tat        579
Lys Gln Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr
175              180              185              190

gtg ggc tct gac ctg gag att ggg cag cac agg acc aag att gag gag        627
Val Gly Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu
            195              200              205

ctg agg cag cac ctg ctg agg tgg ggc ctg acc acc cct gac aag aag        675
Leu Arg Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys
            210              215              220

cac cag aag gag ccc ccc ttc ctg tgg atg ggc tat gag ctg cac ccc        723
His Gln Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro
            225              230              235

gac aag tgg act gtg cag ccc att gtg ctg cct gag aag gac tcc tgg        771
Asp Lys Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp
    240              245              250

act gtg aat gac atc cag aag ctg gtg ggc aag ctg aac tgg gcc tcc        819
Thr Val Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser
255              260              265              270

caa atc tac cct ggc atc aag gtg agg cag ctg tgc aag ctg ctg agg        867
Gln Ile Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg
                275              280              285

ggc acc aag gcc ctg act gag gtg atc ccc ctg act gag gag gct gag        915
Gly Thr Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu
            290              295              300

ctg gag ctg gct gag aac agg gag atc ctg aag gag cct gtg cat ggg        963
Leu Glu Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly
            305              310              315

gtg tac tat gac ccc tcc aag gac ctg att gct gag atc cag aag cag       1011
Val Tyr Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln
    320              325              330

ggc cag ggc cag tgg acc tac caa atc tac cag gag ccc ttc aag aac       1059
Gly Gln Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn
335              340              345              350

ctg aag act ggc aag tat gcc agg atg agg ggg gcc cac acc aat gat       1107
Leu Lys Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp
            355              360              365

gtg aag cag ctg act gag gct gtg cag aag atc acc act gag tcc att       1155
Val Lys Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile
            370              375              380
```

```
gtg atc tgg ggc aag acc ccc aag ttc aag ctg ccc atc cag aag gag      1203
Val Ile Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu
        385              390              395

acc tgg gag acc tgg tgg act gag tac tgg cag gcc acc tgg atc cct      1251
Thr Trp Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro
    400              405              410

gag tgg gag ttt gtg aac acc ccc ccc ctg gtg aag ctg tgg tac cag      1299
Glu Trp Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln
415              420              425              430

ctg gag aag gag ccc att gtg ggg gct gag acc ttc tat gtg gat ggg      1347
Leu Glu Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly
                435              440              445

gct gcc aac agg gag acc aag ctg ggc aag gct ggc tat gtg acc aac      1395
Ala Ala Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn
            450              455              460

agg ggc agg cag aag gtg gtg acc ctg act gac acc acc aac cag aag      1443
Arg Gly Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys
            465              470              475

act gag ctc cag gcc atc tac ctg gcc ctc cag gac tct ggc ctg gag      1491
Thr Glu Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu
    480              485              490

gtg aac att gtg act gac tcc cag tat gcc ctg ggc atc atc cag gcc      1539
Val Asn Ile Val Thr Asp Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala
495              500              505              510

cag cct gat cag tct gag tct gag ctg gtg aac cag atc att gag cag      1587
Gln Pro Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln
                515              520              525

ctg atc aag aag gag aag gtg tac ctg gcc tgg gtg cct gcc cac aag      1635
Leu Ile Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys
            530              535              540

ggc att ggg ggc aat gag cag gtg gac aag ctg gtg tct gct ggc atc      1683
Gly Ile Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile
        545              550              555

agg aag gtg ctg ttc ctg gat ggc att gac aag gcc cag gat gag cat      1731
Arg Lys Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His
    560              565              570

gag aag tac cac tcc aac tgg agg gct atg gcc tct gac ttc aac ctg      1779
Glu Lys Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu
575              580              585              590

ccc cct gtg gtg gct aag gag att gtg gcc tcc tgt gac aag tgc cag      1827
Pro Pro Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln
                595              600              605

ctg aag ggg gag gcc atg cat ggg cag gtg gac tgc tcc cct ggc atc      1875
Leu Lys Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile
        610              615              620
```

-3-

```
tgg cag ctg gac tgc acc cac ctg gag ggc aag gtg atc ctg gtg gct    1923
Trp Gln Leu Asp Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala
        625             630             635

gtg cat gtg gcc tcc ggc tac att gag gct gag gtg atc cct gct gag    1971
Val His Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu
        640             645             650

aca ggc cag gag act gcc tac ttc ctg ctg aag ctg gct ggc agg tgg    2019
Thr Gly Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp
655             660     .       665                     670

cct gtg aag acc atc cac act gac aat ggc tcc aac ttc act ggg gcc    2067
Pro Val Lys Thr Ile His Thr Asp Asn Gly Ser Asn Phe Thr Gly Ala
                675             680             685

aca gtg agg gct gcc tgc tgg tgg gct ggc atc aag cag gag ttt ggc    2115
Thr Val Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly
                690             695             700

atc ccc tac aac ccc cag tcc cag ggg gtg gtg gag tcc atg aac aag    2163
Ile Pro Tyr Asn Pro Gln Ser Gln Gly Val Val Glu Ser Met Asn Lys
        705             710             715

gag ctg aag aag atc att ggg cag gtg agg gac cag gct gag cac ctg    2211
Glu Leu Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu
        720             725             730

aag aca gct gtg cag atg gct gtg ttc atc cac aac ttc aag agg aag    2259
Lys Thr Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys
735             740             745             750

ggg ggc atc ggg ggc tac tcc gct ggg gag agg att gtg gac atc att    2307
Gly Gly Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile
                755             760             765

gcc aca gac atc cag acc aag gag ctc cag aag cag atc acc aag atc    2355
Ala Thr Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile
                770             775             780     .

cag aac ttc agg gtg tac tac agg gac tcc agg aac ccc ctg tgg aag    2403
Gln Asn Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys
        785             790             795

ggc cct gcc aag ctg ctg tgg aag ggg gag ggg gct gtg gtg atc cag    2451
Gly Pro Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln
        800             805             810

gac aac tct gac atc aag gtg gtg ccc agg agg aag gcc aag atc atc    2499
Asp Asn Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile
815             820             825             830

agg gac tat ggc aag cag atg gct ggg gat gac tgt gtg gcc tcc agg    2547
Arg Asp Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg
                835     .       840             845

cag gat gag gac taa agcccgggca gatct                               2577
Gln Asp Glu Asp  *
                850
```

<210> 2

-4-

<211> 850
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 2

```
Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro
1               5                   10                  15
Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys
            20                  25                  30
Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys
        35                  40                  45
Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala
    50                  55                  60
Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg
65                  70                  75                  80
Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile
                85                  90                  95
Pro His Pro Ala Gly Leu Lys Lys Lys Ser Val Thr Val Leu Asp
            100                 105                 110
Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys
        115                 120                 125
Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile
    130                 135                 140
Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala
145                 150                 155                 160
Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln
                165                 170                 175
Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Gly
            180                 185                 190
Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg
        195                 200                 205
Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln
    210                 215                 220
Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys
225                 230                 235                 240
Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val
                245                 250                 255
Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile
            260                 265                 270
Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr
        275                 280                 285
Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu
    290                 295                 300
Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr
305                 310                 315                 320
Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln
                325                 330                 335
Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys
            340                 345                 350
Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys
        355                 360                 365
Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile
    370                 375                 380
Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp
385                 390                 395                 400
Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp
                405                 410                 415
Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu
            420                 425                 430
Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala
        435                 440                 445
```

```
Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly
    450                 455                 460
Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Glu
465                 470                 475                 480
Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn
                485                 490                 495
Ile Val Thr Asp Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro
                500                 505                 510
Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile
            515                 520                 525
Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile
    530                 535                 540
Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys
545                 550                 555                 560
Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys
                565                 570                 575
Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro
            580                 585                 590
Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys
            595                 600                 605
Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln
    610                 615                 620
Leu Asp Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His
625                 630                 635                 640
Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly
                645                 650                 655
Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val
            660                 665                 670
Lys Thr Ile His Thr Asp Asn Gly Ser Asn Phe Thr Gly Ala Thr Val
            675                 680                 685
Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro
    690                 695                 700
Tyr Asn Pro Gln Ser Gln Gly Val Val Glu Ser Met Asn Lys Glu Leu
705                 710                 715                 720
Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr
                725                 730                 735
Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly
            740                 745                 750
Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr
            755                 760                 765
Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn
    770                 775                 780
Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro
785                 790                 795                 800
Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn
                805                 810                 815
Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp
            820                 825                 830
Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp
            835                 840                 845
Glu Asp
850
```

```
<210> 3
<211> 2577
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (10)...(2562)
```

```
<400> 3
agatctacc atg gcc ccc atc tcc ccc att gag act gtg cct gtg aag ctg      51
          Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu
          1             5                     10

aag cct ggc atg gat ggc ccc aag gtg aag cag tgg ccc ctg act gag      99
Lys Pro Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu
15              20              25                  30

gag aag atc aag gcc ctg gtg gaa atc tgc act gag atg gag aag gag      147
Glu Lys Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu
                35                  40                  45

ggc aaa atc tcc aag att ggc ccc gag aac ccc tac aac acc cct gtg      195
Gly Lys Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val
            50                  55                  60

ttt gcc atc aag aag aag gac tcc acc aag tgg agg aag ctg gtg gac      243
Phe Ala Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp
            65                  70                  75

ttc agg gag ctg aac aag agg acc cag gac ttc tgg gag gtg cag ctg      291
Phe Arg Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu
        80                  85                  90

ggc atc ccc cac ccc gct ggc ctg aag aag aag aag tct gtg act gtg      339
Gly Ile Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val
95                  100                 105                 110

ctg gct gtg ggg gat gcc tac ttc tct gtg ccc ctg gat gag gac ttc      387
Leu Ala Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe
                115                 120                 125

agg aag tac act gcc ttc acc atc ccc tcc atc aac aat gag acc cct      435
Arg Lys Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro
            130                 135                 140

ggc atc agg tac cag tac aat gtg ctg ccc cag ggc tgg aag ggc tcc      483
Gly Ile Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser
            145                 150                 155

cct gcc atc ttc cag tcc tcc atg acc aag atc ctg gag ccc ttc agg      531
Pro Ala Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg
    160                 165                 170

aag cag aac cct gac att gtg atc tac cag tac atg gct gcc ctg tat      579
Lys Gln Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Ala Ala Leu Tyr
175                 180                 185                 190

gtg ggc tct gac ctg gag att ggg cag cac agg acc aag att gag gag      627
Val Gly Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu
                195                 200                 205

ctg agg cag cac ctg ctg agg tgg ggc ctg acc acc cct gac aag aag      675
Leu Arg Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys
            210                 215                 220

cac cag aag gag ccc ccc ttc ctg tgg atg ggc tat gag ctg cac ccc      723
His Gln Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro
            225                 230                 235
```

-7-

```
gac aag tgg act gtg cag ccc att gtg ctg cct gag aag gac tcc tgg          771
Asp Lys Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp
    240             245             250

act gtg aat gac atc cag aag ctg gtg ggc aag ctg aac tgg gcc tcc          819
Thr Val Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser
255             260             265             270

caa atc tac cct ggc atc aag gtg agg cag ctg tgc aag ctg ctg agg         867
Gln Ile Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg
            275             280             285

ggc acc aag gcc ctg act gag gtg atc ccc ctg act gag gag gct gag         915
Gly Thr Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu
            290             295             300

ctg gag ctg gct gag aac agg gag atc ctg aag gag cct gtg cat ggg         963
Leu Glu Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly
        305             310             315

gtg tac tat gac ccc tcc aag gac ctg att gct gag atc cag aag cag         1011
Val Tyr Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln
        320             325             330

ggc cag ggc cag tgg acc tac caa atc tac cag gag ccc ttc aag aac         1059
Gly Gln Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn
335             340             345             350

ctg aag act ggc aag tat gcc agg atg agg ggg gcc cac acc aat gat         1107
Leu Lys Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp
            355             360             365

gtg aag cag ctg act gag gct gtg cag aag atc acc act gag tcc att         1155
Val Lys Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile
            370             375             380

gtg atc tgg ggc aag acc ccc aag ttc aag ctg ccc atc cag aag gag         1203
Val Ile Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu
            385             390             395

acc tgg gag acc tgg tgg act gag tac tgg cag gcc acc tgg atc cct         1251
Thr Trp Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro
    400             405             410

gag tgg gag ttt gtg aac acc ccc ccc ctg gtg aag ctg tgg tac cag         1299
Glu Trp Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln
415             420             425             430

ctg gag aag gag ccc att gtg ggg gct gag acc ttc tat gtg gct ggg         1347
Leu Glu Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Ala Gly
            435             440             445

gct gcc aac agg gag acc aag ctg ggc aag gct ggc tat gtg acc aac         1395
Ala Ala Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn
            450             455             460

agg ggc agg cag aag gtg gtg acc ctg act gac acc acc aac cag aag         1443
Arg Gly Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys
        465             470             475
```

-8-

```
act gcc ctc cag gcc atc tac ctg gcc ctc cag gac tct ggc ctg gag        1491
Thr Ala Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu
    480                 485                 490

gtg aac att gtg act gcc tcc cag tat gcc ctg ggc atc atc cag gcc        1539
Val Asn Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala
495                 500                 505                 510

cag cct gat cag tct gag tct gag ctg gtg aac cag atc att gag cag        1587
Gln Pro Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln
                515                 520                 525

ctg atc aag aag gag aag gtg tac ctg gcc tgg gtg cct gcc cac aag        1635
Leu Ile Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys
                530                 535                 540

ggc att ggg ggc aat gag cag gtg gac aag ctg gtg tct gct ggc atc        1683
Gly Ile Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile
        545                 550                 555

agg aag gtg ctg ttc ctg gat ggc att gac aag gcc cag gat gag cat        1731
Arg Lys Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His
        560                 565                 570

gag aag tac cac tcc aac tgg agg gct atg gcc tct gac ttc aac ctg        1779
Glu Lys Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu
575                 580                 585                 590

ccc cct gtg gtg gct aag gag att gtg gcc tcc tgt gac aag tgc cag        1827
Pro Pro Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln
                595                 600                 605

ctg aag ggg gag gcc atg cat ggg cag gtg gac tgc tcc cct ggc atc        1875
Leu Lys Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile
                610                 615                 620

tgg cag ctg gcc tgc acc cac ctg gag ggc aag gtg atc ctg gtg gct        1923
Trp Gln Leu Ala Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala
        625                 630                 635

gtg cat gtg gcc tcc ggc tac att gag gct gag gtg atc cct gct gag        1971
Val His Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu
        640                 645                 650

aca ggc cag gag act gcc tac ttc ctg ctg aag ctg gct ggc agg tgg        2019
Thr Gly Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp
655                 660                 665                 670

cct gtg aag acc atc cac act gcc aat ggc tcc aac ttc act ggg gcc        2067
Pro Val Lys Thr Ile His Thr Ala Asn Gly Ser Asn Phe Thr Gly Ala
                675                 680                 685

aca gtg agg gct gcc tgc tgg tgg gct ggc atc aag cag gag ttt ggc        2115
Thr Val Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly
                690                 695                 700

atc ccc tac aac ccc cag tcc cag ggg gtg gtg gcc tcc atg aac aag        2163
Ile Pro Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Met Asn Lys
        705                 710                 715
```

```
gag ctg aag aag atc att ggg cag gtg agg gac cag gct gag cac ctg      2211
Glu Leu Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu
    720             725                 730

aag aca gct gtg cag atg gct gtg ttc atc cac aac ttc aag agg aag      2259
Lys Thr Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys
735                 740             745                 750

ggg ggc atc ggg ggc tac tcc gct ggg gag agg att gtg gac atc att      2307
Gly Gly Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile
                755             760                 765

gcc aca gac atc cag acc aag gag ctc cag aag cag atc acc aag atc      2355
Ala Thr Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile
            770             775                 780

cag aac ttc agg gtg tac tac agg gac tcc agg aac ccc ctg tgg aag      2403
Gln Asn Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys
            785             790                 795

ggc cct gcc aag ctg ctg tgg aag ggg gag ggg gct gtg gtg atc cag      2451
Gly Pro Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln
    800             805                 810

gac aac tct gac atc aag gtg gtg ccc agg agg aag gcc aag atc atc      2499
Asp Asn Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile
815             820             825                 830

agg gac tat ggc aag cag atg gct ggg gat gac tgt gtg gcc tcc agg      2547
Arg Asp Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg
                835             840                 845

cag gat gag gac taa agcccgggca gatct                                 2577
Gln Asp Glu Asp *
                850
```

```
<210> 4
<211> 850
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 4
Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro
1               5                   10                  15
Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys
            20                  25                  30
Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys
        35                  40                  45
Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala
    50                  55                  60
Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg
65                  70                  75                  80
Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile
                85                  90                  95
Pro His Pro Ala Gly Leu Lys Lys Lys Ser Val Thr Val Leu Ala
            100                 105                 110
Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys
        115                 120                 125
Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile
    130                 135                 140
```

```
Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala
145                 150                 155                 160
Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln
                165                 170                 175
Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly
            180                 185                 190
Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg
        195                 200                 205
Gln His Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln
    210                 215                 220
Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys
225                 230                 235                 240
Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val
            245                 250                 255
Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile
            260                 265                 270
Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr
        275                 280                 285
Lys Ala Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu
    290                 295                 300
Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr
305                 310                 315                 320
Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln
            325                 330                 335
Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys
            340                 345                 350
Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys
        355                 360                 365
Gln Leu Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile
    370                 375                 380
Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp
385                 390                 395                 400
Glu Thr Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp
            405                 410                 415
Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu
            420                 425                 430
Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Ala Gly Ala Ala
        435                 440                 445
Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly
    450                 455                 460
Arg Gln Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Ala
465                 470                 475                 480
Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn
                485                 490                 495
Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro
            500                 505                 510
Asp Gln Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile
    515                 520                 525
Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile
    530                 535                 540
Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys
545                 550                 555                 560
Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys
            565                 570                 575
Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro
        580                 585                 590
Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys
        595                 600                 605
Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln
    610                 615                 620
Leu Ala Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His
625                 630                 635                 640
```

```
Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly
              645                 650                 655
Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val
          660                 665                 670
Lys Thr Ile His Thr Ala Asn Gly Ser Asn Phe Thr Gly Ala Thr Val
      675                 680                 685
Arg Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro
  690                 695                 700
Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Met Asn Lys Glu Leu
705                 710                 715                 720
Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr
              725                 730                 735
Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly
          740                 745                 750
Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr
          755                 760                 765
Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn
      770                 775                 780
Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro
785                 790                 795                 800
Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn
              805                 810                 815
Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp
          820                 825                 830
Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp
      835                 840                 845
Glu Asp
    850


<210> 5
<211> 2650
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (8)...(2635)

<400> 5
gatcacc atg gat gca atg aag aga ggg ctc tgc tgt gtg ctg ctg ctg       49
        Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu
        1               5                   10

tgt gga gca gtc ttc gtt tcg ccc agc gag atc tcc gcc ccc atc tcc       97
Cys Gly Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser
15                  20                  25                  30

ccc att gag act gtg cct gtg aag ctg aag cct ggc atg gat ggc ccc      145
Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro
                35                  40                  45

aag gtg aag cag tgg ccc ctg act gag gag aag atc aag gcc ctg gtg      193
Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val
            50                  55                  60

gaa atc tgc act gag atg gag aag gag ggc aaa atc tcc aag att ggc      241
Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly
        65                  70                  75

ccc gag aac ccc tac aac acc cct gtg ttt gcc atc aag aag aag gac      289
Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp
    80                  85                  90
```

- 12 -

```
tcc acc aag tgg agg aag ctg gtg gac ttc agg gag ctg aac aag agg     337
Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg
 95              100             105             110

acc cag gac ttc tgg gag gtg cag ctg ggc atc ccc cac ccc gct ggc     385
Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly
                115             120             125

ctg aag aag aag aag tct gtg act gtg ctg gat gtg ggg gat gcc tac     433
Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr
            130             135             140

ttc tct gtg ccc ctg gat gag gac ttc agg aag tac act gcc ttc acc     481
Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr
            145             150             155

atc ccc tcc atc aac aat gag acc cct ggc atc agg tac cag tac aat     529
Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn
        160             165             170

gtg ctg ccc cag ggc tgg aag ggc tcc cct gcc atc ttc cag tcc tcc     577
Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser
175             180             185             190

atg acc aag atc ctg gag ccc ttc agg aag cag aac cct gac att gtg     625
Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val
                195             200             205

atc tac cag tac atg gat gac ctg tat gtg ggc tct gac ctg gag att     673
Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Gly Ser Asp Leu Glu Ile
                210             215             220

ggg cag cac agg acc aag att gag gag ctg agg cag cac ctg ctg agg     721
Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg
        225             230             235

tgg ggc ctg acc acc cct gac aag aag cac cag aag gag ccc ccc ttc     769
Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe
        240             245             250

ctg tgg atg ggc tat gag ctg cac ccc gac aag tgg act gtg cag ccc     817
Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro
255             260             265             270

att gtg ctg cct gag aag gac tcc tgg act gtg aat gac atc cag aag     865
Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys
                275             280             285

ctg gtg ggc aag ctg aac tgg gcc tcc caa atc tac cct ggc atc aag     913
Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys
            290             295             300

gtg agg cag ctg tgc aag ctg ctg agg ggc acc aag gcc ctg act gag     961
Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu
        305             310             315

gtg atc ccc ctg act gag gag gct gag ctg gag ctg gct gag aac agg    1009
Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg
        320             325             330
```

```
gag atc ctg aag gag cct gtg cat ggg gtg tac tat gac ccc tcc aag      1057
Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys
335             340             345             350

gac ctg att gct gag atc cag aag cag ggc cag ggc cag tgg acc tac      1105
Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr
                355             360             365

caa atc tac cag gag ccc ttc aag aac ctg aag act ggc aag tat gcc      1153
Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala
                370             375             380

agg atg agg ggg gcc cac acc aat gat gtg aag cag ctg act gag gct      1201
Arg Met Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala
                385             390             395

gtg cag aag atc acc act gag tcc att gtg atc tgg ggc aag acc ccc      1249
Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro
    400             405             410

aag ttc aag ctg ccc atc cag aag gag acc tgg gag acc tgg tgg act      1297
Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr
415             420             425             430

gag tac tgg cag gcc acc tgg atc cct gag tgg gag ttt gtg aac acc      1345
Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr
                435             440             445

ccc ccc ctg gtg aag ctg tgg tac cag ctg gag aag gag ccc att gtg      1393
Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val
            450             455             460

ggg gct gag acc ttc tat gtg gat ggg gct gcc aac agg gag acc aag      1441
Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Glu Thr Lys
        465             470             475

ctg ggc aag gct ggc tat gtg acc aac agg ggc agg cag aag gtg gtg      1489
Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val
    480             485             490

acc ctg act gac acc acc aac cag aag act gag ctc cag gcc atc tac      1537
Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Glu Leu Gln Ala Ile Tyr
495             500             505             510

ctg gcc ctc cag gac tct ggc ctg gag gtg aac att gtg act gac tcc      1585
Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Asp Ser
                515             520             525

cag tat gcc ctg ggc atc atc cag gcc cag cct gat cag tct gag tct      1633
Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser
                530             535             540

gag ctg gtg aac cag atc att gag cag ctg atc aag aag gag aag gtg      1681
Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val
                545             550             555

tac ctg gcc tgg gtg cct gcc cac aag ggc att ggg ggc aat gag cag      1729
Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln
560             565             570
```

- 14 -

```
gtg gac aag ctg gtg tct gct ggc atc agg aag gtg ctg ttc ctg gat          1777
Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp
575             580             585             590

ggc att gac aag gcc cag gat gag cat gag aag tac cac tcc aac tgg          1825
Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp
                595             600             605

agg gct atg gcc tct gac ttc aac ctg ccc cct gtg gtg gct aag gag          1873
Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu
                610             615             620

att gtg gcc tcc tgt gac aag tgc cag ctg aag ggg gag gcc atg cat          1921
Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His
                625             630             635

ggg cag gtg gac tgc tcc cct ggc atc tgg cag ctg gac tgc acc cac          1969
Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Asp Cys Thr His
        640             645             650

ctg gag ggc aag gtg atc ctg gtg gct gtg cat gtg gcc tcc ggc tac          2017
Leu Glu Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr
655             660             665             670

att gag gct gag gtg atc cct gct gag aca ggc cag gag act gcc tac          2065
Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr
                675             680             685

ttc ctg ctg aag ctg gct ggc agg tgg cct gtg aag acc atc cac act          2113
Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr
                690             695             700

gac aat ggc tcc aac ttc act ggg gcc aca gtg agg gct gcc tgc tgg          2161
Asp Asn Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp
                705             710             715

tgg gct ggc atc aag cag gag ttt ggc atc ccc tac aac ccc cag tcc          2209
Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser
        720             725             730

cag ggg gtg gtg gag tcc atg aac aag gag ctg aag aag atc att ggg          2257
Gln Gly Val Val Glu Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly
735             740             745             750

cag gtg agg gac cag gct gag cac ctg aag aca gct gtg cag atg gct          2305
Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala
                755             760             765

gtg ttc atc cac aac ttc aag agg aag ggg ggc atc ggg ggc tac tcc          2353
Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser
                770             775             780

gct ggg gag agg att gtg gac atc att gcc aca gac atc cag acc aag          2401
Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys
        785             790             795

gag ctc cag aag cag atc acc aag atc cag aac ttc agg gtg tac tac          2449
Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr
        800             805             810
```

- 15 -

```
agg gac tcc agg aac ccc ctg tgg aag ggc cct gcc aag ctg ctg tgg     2497
Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp
815             820             825             830

aag ggg gag ggg gct gtg gtg atc cag gac aac tct gac atc aag gtg     2545
Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val
                835             840             845

gtg ccc agg agg aag gcc aag atc atc agg gac tat ggc aag cag atg     2593
Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met
            850             855             860

gct ggg gat gac tgt gtg gcc tcc agg cag gat gag gac taa            2635
Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp  *
        865             870             875

agcccgggca gatct                                                    2650
```

```
<210> 6
<211> 875
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 6
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1               5                   10                  15
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile
            20              25                  30
Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val
            35              40                  45
Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile
    50              55                  60
Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu
65              70                  75                  80
Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr
                85                  90                  95
Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln
            100                 105                 110
Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys
        115                 120                 125
Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr Phe Ser
    130                 135                 140
Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro
145                 150                 155                 160
Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu
                165                 170                 175
Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr
                180                 185                 190
Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr
            195                 200                 205
Gln Tyr Met Asp Asp Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln
    210                 215                 220
His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly
225                 230                 235                 240
Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp
                245                 250                 255
Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val
            260                 265                 270
Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val
            275                 280                 285
Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg
    290                 295                 300
```

- 16 -

```
Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile
305                 310                 315                 320
Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile
                325                 330                 335
Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu
                340                 345                 350
Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile
                355                 360                 365
Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met
    370                 375                 380
Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln
385                 390                 395                 400
Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe
                405                 410                 415
Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr
                420                 425                 430
Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro
                435                 440                 445
Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala
    450                 455                 460
Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly
465                 470                 475                 480
Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu
                485                 490                 495
Thr Asp Thr Thr Asn Gln Lys Thr Glu Leu Gln Ala Ile Tyr Leu Ala
                500                 505                 510
Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Asp Ser Gln Tyr
                515                 520                 525
Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu
    530                 535                 540
Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu
545                 550                 555                 560
Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp
                565                 570                 575
Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile
                580                 585                 590
Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala
                595                 600                 605
Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val
    610                 615                 620
Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln
625                 630                 635                 640
Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Asp Cys Thr His Leu Glu
                645                 650                 655
Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu
                660                 665                 670
Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu
    675                 680                 685
Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Asp Asn
    690                 695                 700
Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala
705                 710                 715                 720
Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly
                725                 730                 735
Val Val Glu Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val
                740                 745                 750
Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe
    755                 760                 765
Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly
    770                 775                 780
Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu
785                 790                 795                 800
```

```
Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp
                805                 810                 815
Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly
            820                 825                 830
Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro
        835                 840                 845
Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly
    850                 855                 860
Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp
865                 870                 875
```

<210> 7
<211> 2650
<212> DNA
<213> Human Immunodeficiency Virus-1

<220>
<221> CDS
<222> (8)...(2635)

<400> 7
```
gatcacc atg gat gca atg aag aga ggg ctc tgc tgt gtg ctg ctg ctg     49
        Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu
         1               5                  10

tgt gga gca gtc ttc gtt tcg ccc agc gag atc tcc gcc ccc atc tcc     97
Cys Gly Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser
 15                  20                  25                  30

ccc att gag act gtg cct gtg aag ctg aag cct ggc atg gat ggc ccc    145
Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro
                35                  40                  45

aag gtg aag cag tgg ccc ctg act gag gag aag atc aag gcc ctg gtg    193
Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val
            50                  55                  60

gaa atc tgc act gag atg gag aag gag ggc aaa atc tcc aag att ggc    241
Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly
            65                  70                  75

ccc gag aac ccc tac aac acc cct gtg ttt gcc atc aag aag aag gac    289
Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp
        80                  85                  90

tcc acc aag tgg agg aag ctg gtg gac ttc agg gag ctg aac aag agg    337
Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg
 95                  100                 105                 110

acc cag gac ttc tgg gag gtg cag ctg ggc atc ccc cac ccc gct ggc    385
Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly
                115                 120                 125

ctg aag aag aag aag tct gtg act gtg ctg gct gtg ggg gat gcc tac    433
Leu Lys Lys Lys Lys Ser Val Thr Val Leu Ala Val Gly Asp Ala Tyr
            130                 135                 140

ttc tct gtg ccc ctg gat gag gac ttc agg aag tac act gcc ttc acc    481
Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr
        145                 150                 155
```

```
atc ccc tcc atc aac aat gag acc cct ggc atc agg tac cag tac aat        529
Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn
    160                 165                 170

gtg ctg ccc cag ggc tgg aag ggc tcc cct gcc atc ttc cag tcc tcc        577
Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser
175                 180                 185                 190

atg acc aag atc ctg gag ccc ttc agg aag cag aac cct gac att gtg        625
Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val
                195                 200                 205

atc tac cag tac atg gct gcc ctg tat gtg ggc tct gac ctg gag att        673
Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly Ser Asp Leu Glu Ile
            210                 215                 220

ggg cag cac agg acc aag att gag gag ctg agg cag cac ctg ctg agg        721
Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg
        225                 230                 235

tgg ggc ctg acc acc cct gac aag aag cac cag aag gag ccc ccc ttc        769
Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe
    240                 245                 250

ctg tgg atg ggc tat gag ctg cac ccc gac aag tgg act gtg cag ccc        817
Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro
255                 260                 265                 270

att gtg ctg cct gag aag gac tcc tgg act gtg aat gac atc cag aag        865
Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys
                275                 280                 285

ctg gtg ggc aag ctg aac tgg gcc tcc caa atc tac cct ggc atc aag        913
Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys
            290                 295                 300

gtg agg cag ctg tgc aag ctg ctg agg ggc acc aag gcc ctg act gag        961
Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu
        305                 310                 315

gtg atc ccc ctg act gag gag gct gag ctg gag ctg gct gag aac agg        1009
Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg
    320                 325                 330

gag atc ctg aag gag cct gtg cat ggg gtg tac tat gac ccc tcc aag        1057
Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys
335                 340                 345                 350

gac ctg att gct gag atc cag aag cag ggc cag ggc cag tgg acc tac        1105
Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr
                355                 360                 365

caa atc tac cag gag ccc ttc aag aac ctg aag act ggc aag tat gcc        1153
Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala
            370                 375                 380

agg atg agg ggg gcc cac acc aat gat gtg aag cag ctg act gag gct        1201
Arg Met Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala
        385                 390                 395
```

```
gtg cag aag atc acc act gag tcc att gtg atc tgg ggc aag acc ccc     1249
Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro
    400             405             410

aag ttc aag ctg ccc atc cag aag gag acc tgg gag acc tgg tgg act     1297
Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr
415             420             425             430

gag tac tgg cag gcc acc tgg atc cct gag tgg gag ttt gtg aac acc     1345
Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr
                435             440             445

ccc ccc ctg gtg aag ctg tgg tac cag ctg gag aag gag ccc att gtg     1393
Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val
            450             455             460

ggg gct gag acc ttc tat gtg gct ggg gct gcc aac agg gag acc aag     1441
Gly Ala Glu Thr Phe Tyr Val Ala Gly Ala Ala Asn Arg Glu Thr Lys
            465             470             475

ctg ggc aag gct ggc tat gtg acc aac agg ggc agg cag aag gtg gtg     1489
Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val
    480             485             490

acc ctg act gac acc acc aac cag aag act gcc ctc cag gcc atc tac     1537
Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Ala Leu Gln Ala Ile Tyr
495             500             505             510

ctg gcc ctc cag gac tct ggc ctg gag gtg aac att gtg act gcc tcc     1585
Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Ala Ser
            515             520             525

cag tat gcc ctg ggc atc atc cag gcc cag cct gat cag tct gag tct     1633
Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser
            530             535             540

gag ctg gtg aac cag atc att gag cag ctg atc aag aag gag aag gtg     1681
Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val
            545             550             555

tac ctg gcc tgg gtg cct gcc cac aag ggc att ggg ggc aat gag cag     1729
Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln
    560             565             570

gtg gac aag ctg gtg tct gct ggc atc agg aag gtg ctg ttc ctg gat     1777
Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp
575             580             585             590

ggc att gac aag gcc cag gat gag cat gag aag tac cac tcc aac tgg     1825
Gly Ile Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp
            595             600             605

agg gct atg gcc tct gac ttc aac ctg ccc cct gtg gtg gct aag gag     1873
Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu
            610             615             620

att gtg gcc tcc tgt gac aag tgc cag ctg aag ggg gag gcc atg cat     1921
Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His
            625             630             635
```

```
ggg cag gtg gac tgc tcc cct ggc atc tgg cag ctg gcc tgc acc cac        1969
Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Ala Cys Thr His
    640             645             650

ctg gag ggc aag gtg atc ctg gtg gct gtg cat gtg gcc tcc ggc tac        2017
Leu Glu Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr
655             660             665             670

att gag gct gag gtg atc cct gct gag aca ggc cag gag act gcc tac        2065
Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr
                675             680             685

ttc ctg ctg aag ctg gct ggc agg tgg cct gtg aag acc atc cac act        2113
Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr
            690             695             700

gcc aat ggc tcc aac ttc act ggg gcc aca gtg agg gct gcc tgc tgg        2161
Ala Asn Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp
        705             710             715

tgg gct ggc atc aag cag gag ttt ggc atc ccc tac aac ccc cag tcc        2209
Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser
    720             725             730

cag ggg gtg gtg gcc tcc atg aac aag gag ctg aag aag atc att ggg        2257
Gln Gly Val Val Ala Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly
735             740             745             750

cag gtg agg gac cag gct gag cac ctg aag aca gct gtg cag atg gct        2305
Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala
                755             760             765

gtg ttc atc cac aac ttc aag agg aag ggg ggc atc ggg ggc tac tcc        2353
Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser
            770             775             780

gct ggg gag agg att gtg gac atc att gcc aca gac atc cag acc aag        2401
Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys
        785             790             795

gag ctc cag aag cag atc acc aag atc cag aac ttc agg gtg tac tac        2449
Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr
    800             805             810

agg gac tcc agg aac ccc ctg tgg aag ggc cct gcc aag ctg ctg tgg        2497
Arg Asp Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp
815             820             825             830

aag ggg gag ggg gct gtg gtg atc cag gac aac tct gac atc aag gtg        2545
Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val
                835             840             845

gtg ccc agg agg aag gcc aag atc atc agg gac tat ggc aag cag atg        2593
Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met
            850             855             860

gct ggg gat gac tgt gtg gcc tcc agg cag gat gag gac taa              2635
Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp *
        865             870             875

agcccgggca gatct                                                      2650
```

<210> 8
<211> 875
<212> PRT
<213> Human Immunodeficiency Virus-1

<400> 8
```
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1               5                   10                  15
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ala Pro Ile Ser Pro Ile
            20                  25                  30
Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro Lys Val
        35                  40                  45
Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val Glu Ile
    50                  55                  60
Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Glu
65                  70                  75                  80
Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr
                85                  90                  95
Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln
            100                 105                 110
Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys
        115                 120                 125
Lys Lys Lys Ser Val Thr Val Leu Ala Val Gly Asp Ala Tyr Phe Ser
    130                 135                 140
Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro
145                 150                 155                 160
Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu
                165                 170                 175
Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr
            180                 185                 190
Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val Ile Tyr
        195                 200                 205
Gln Tyr Met Ala Ala Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln
210                 215                 220
His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg Trp Gly
225                 230                 235                 240
Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp
                245                 250                 255
Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro Ile Val
            260                 265                 270
Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val
        275                 280                 285
Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg
    290                 295                 300
Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu Val Ile
305                 310                 315                 320
Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile
                325                 330                 335
Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu
            340                 345                 350
Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr Gln Ile
        355                 360                 365
Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala Arg Met
    370                 375                 380
Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln
385                 390                 395                 400
Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe
                405                 410                 415
Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr Trp Trp Thr Glu Tyr
            420                 425                 430
Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro
        435                 440                 445
```

- 22 -

```
Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val Gly Ala
    450                 455                 460
Glu Thr Phe Tyr Val Ala Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly
465                 470                 475                 480
Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln Lys Val Val Thr Leu
                485                 490                 495
Thr Asp Thr Thr Asn Gln Lys Thr Ala Leu Gln Ala Ile Tyr Leu Ala
            500                 505                 510
Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Ala Ser Gln Tyr
        515                 520                 525
Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln Ser Glu Ser Glu Leu
    530                 535                 540
Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys Val Tyr Leu
545                 550                 555                 560
Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp
                565                 570                 575
Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile
            580                 585                 590
Asp Lys Ala Gln Asp Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala
        595                 600                 605
Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile Val
    610                 615                 620
Ala Ser Cys Asp Lys Cys Gln Leu Lys Gly Glu Ala Met His Gly Gln
625                 630                 635                 640
Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Ala Cys Thr His Leu Glu
                645                 650                 655
Gly Lys Val Ile Leu Val Ala Val His Val Ala Ser Gly Tyr Ile Glu
            660                 665                 670
Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu
        675                 680                 685
Leu Lys Leu Ala Gly Arg Trp Pro Val Lys Thr Ile His Thr Ala Asn
    690                 695                 700
Gly Ser Asn Phe Thr Gly Ala Thr Val Arg Ala Ala Cys Trp Trp Ala
705                 710                 715                 720
Gly Ile Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly
                725                 730                 735
Val Val Ala Ser Met Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val
            740                 745                 750
Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val Phe
        755                 760                 765
Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly
    770                 775                 780
Glu Arg Ile Val Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu
785                 790                 795                 800
Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp
                805                 810                 815
Ser Arg Asn Pro Leu Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly
            820                 825                 830
Glu Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro
        835                 840                 845
Arg Arg Lys Ala Lys Ile Ile Arg Asp Tyr Gly Lys Gln Met Ala Gly
    850                 855                 860
Asp Asp Cys Val Ala Ser Arg Gln Asp Glu Asp
865                 870                 875
```

```
<210> 9
<211> 4945
<212> DNA
<213> E. coli (V1Jns-tpa)

<400> 9
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca        60
```

- 23 -

```
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg    120
ttggcgggtg tcgggcgtgg cttaactatg cggcatcaga gcagattgta ctgagagtgc    180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg    240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg    300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac    360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg    420
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc    480
catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac    540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgcccccta ttgacgtcaa    600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac    660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta    720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga    780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa    840
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag    900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca    960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat   1020
tccccgtgcc aagagtgacg taagtaccgc ctatagactc tataggcaca cccctttggc   1080
tcttatgcat gctatactgt ttttggcttg gggcctatac accccgctt cctatgcta    1140
taggtgatgg tatagcttag cctataggtg tgggttattg accattattg accactcccc   1200
tattggtgac gatactttcc attactaatc cataacatgg ctctttgcca caactatctc   1260
tattggctat atgccaatac tctgtccttc agagactgac acggactctg tattttaca    1320
ggatggggtc ccatttatta tttacaaatt cacatataca acaacgccgt ccccgtgcc    1380
cgcagttttt attaaacata gcgtgggatc tccacgcgaa tctcgggtac gtgttccgga   1440
catgggctct tctccggtag cggcggagct tccacatccg agccctggtc ccatgcctcc   1500
agcggctcat ggtcgctcgg cagctccttg ctcctaacag tggaggccag acttaggcac   1560
agcacaatgc ccaccaccac cagtgtgccg cacaaggccg tggcggtagg gtatgtgtct   1620
gaaaatgagc gtggagattg ggctcgcacg gctgacgcag atggaagact taaggcagcg   1680
gcagaagaag atgcagagcag ctgagttgtt gtattctgat aagagtcaga ggtaactccc   1740
gttgcggtgc tgttaacggt ggagggcagt gtagtctgag cagtactcgt tgctgccgcg   1800
cgcgccacca gacataatag ctgacagact aacagactgt tcctttccat gggtcttttc   1860
tgcagtcacc gtccttagat caccatggat gcaatgaaga gagggctctg ctgtgtgctg   1920
ctgctgtgtg gagcagtctt cgttcgccc agcgagatct gctgtgcctt ctagttgcca   1980
gccatctgtt gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg ccactcccac   2040
tgtcctttcc taataaaatg aggaaattgc atcgcattgt ctgagtaggt gtcattctat   2100
tctggggggt ggggtggggc aggacagcaa ggggaggat tgggaagaca atagcaggca   2160
tgctggggat gcggtgggct ctatggccgc tgcggccagg tgctgaagaa ttgacccggt   2220
tcctcctggg ccagaaagaa gcaggcacat ccccttctct gtgacacacc ctgtccacgc   2280
ccctggttct tagttccagc cccactcata ggacactcat agctcaggag ggctccgcct   2340
tcaatcccac ccgctaaagt acttggagcg gtctctccct ccctcatcag cccaccaaac   2400
caaacctagc ctccaagagt gggaagaaat taaagcaaga taggctatta agtcagagg    2460
gagagaaaat gcctccaaca tgtgaggaag taatgagaga aatcatagaa tttcttccgc   2520
ttcctcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg tatcagctca   2580
ctcaaaggcg gtaatacggt tatccacaga atcaggggat aacgcaggaa agaacatgtg   2640
agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca   2700
taggctccgc cccccctgacg agcatcacaa aaatcgacga tcaagtcaga ggtggcgaaa   2760
cccgacagga ctataaagat accaggcgtt tccccctgga agctccctcg tgcgctctcc   2820
tgttccgacc ctgccgctta ccggatacct gtccgccttt ctcccttcgg gaagcgtggc   2880
gctttctcat agctcacgct gtaggtatct cagttcggtg taggtcgttc gctccaagct   2940
gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg   3000
tcttgagtcc aacccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag   3060
gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggt ggcctaacta   3120
cggctacact agaagaacag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg   3180
aaaaagagtt ggtagctctt gatccggcaa acaaaccacc gctggtagcg gtggtttttt   3240
tgtttgcaag cagcagatta cgcgcagaaa aaaaggatct caagaagatc ctttgatctt   3300
ttctacgggg tctgacgctc agtggaacga aaactcacgt taagggattt ggtcatgag    3360
attatcaaaa aggatcttca cctagatcct tttaaattaa aaatgaagtt ttaaatcaat   3420
ctaaagtata tatgagtaaa cttggtctga cagttaccaa tgcttaatca gtgaggcacc   3480
tatctcagcg atctgtctat ttcgttcatc catagttgcc tgactggggg ggggggggcg   3540
ctgaggtctg cctcgtgaag aaggtgttgc tgactcatac caggcctgaa tcgccccatc   3600
atccagccag aaagtgaggg agccacggtt gatgagagct ttgttgtagg tggaccagtt   3660
ggtgattttg aacttttgct ttgccacgga acggtctgcg ttgtcgggaa gatgcgtgat   3720
ctgatccttc aactcagcaa aagttcgatt tattcaacaa agccgccgtc ccgtcaagtc   3780
```

                                     - 24 -

```
agcgtaatgc tctgccagtg ttacaaccaa ttaaccaatt ctgattagaa aaactcatcg    3840
agcatcaaat gaaactgcaa tttattcata tcaggattat caataccata tttttgaaaa    3900
agccgtttct gtaatgaagg agaaaactca ccgaggcagt tccataggat ggcaagatcc    3960
tggtatcggt ctgcgattcc gactcgtcca acatcaatac aacctattaa tttcccctcg    4020
tcaaaaataa ggttatcaag tgagaaatca ccatgagtga cgactgaatc cggtgagaat    4080
ggcaaaagct tatgcatttc tttccagact tgttcaacag gccagccatt acgctcgtca    4140
tcaaaatcac tcgcatcaac caaaccgtta ttcattcgtg attgcgcctg agcgagacga    4200
aatacgcgat cgctgttaaa aggacaatta caaacaggaa tcgaatgcaa ccggcgcagg    4260
aacactgcca gcgcatcaac aatattttca cctgaatcag gatattcttc taatacctgg    4320
aatgctgttt tcccggggat cgcagtggtg agtaaccatg catcatcagg agtacggata    4380
aaatgcttga tggtcggaag aggcataaat tccgtcagcc agtttagtct gaccatctca    4440
tctgtaacat cattggcaac gctacctttg ccatgtttca gaaacaactc tggcgcatcg    4500
ggcttcccat acaatcgata gattgtcgca cctgattgcc cgacattatc gcgagcccat    4560
ttatacccat ataaatcagc atccatgttg gaatttaatc gcggcctcga gcaagacgtt    4620
tcccgttgaa tatggctcat aacacccctt gtattactgt ttatgtaagc agacagtttt    4680
attgttcatg atgatatatt tttatcttgt gcaatgtaac atcagagatt ttgagacaca    4740
acgtggcttt cccccccccc ccattattga agcatttatc agggttattg tctcatgagc    4800
ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc    4860
cgaaaagtgc cacctgacgt ctaagaaacc attattatca tgacattaac ctataaaaat    4920
aggcgtatca cgaggccctt tcgtc                                          4945
```

```
<210> 10
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 10
ctatataagc agagctcgtt tag                                               23

<210> 11
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 11
gtagcaaaga tctaaggacg gtgactgcag                                        30

<210> 12
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 12
gtatgtgtct gaaaatgagc gtggagattg ggctcgcac                             39

<210> 13
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide
```

<400> 13
gtgcgagccc aatctccacg ctcattttca gacacatac   39

<210> 14
<211> 4432
<212> DNA
<213> E. coli (V1J plasmid)

<400> 14
```
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca    60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcggtg    120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc    180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg    240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg    300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac    360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg    420
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc    480
catagtaacg ccaatagggа ctttccattg acgtcaatgg gtggagtatt tacggtaaac    540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa    600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac    660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta    720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga    780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa    840
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag    900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca    960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat   1020
tccccgtgcc aagagtgacg taagtaccgc ctatagagtc tataggccca ccccttggc   1080
ttcttatgca tgctatactg tttttggctt ggggtctata caccccgct tcctcatgtt   1140
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc   1200
ctattggtga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct   1260
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtattttac   1320
aggatggggt ctcatttatt atttacaaat tcacatatac aacaccaccg tccccagtgc   1380
ccgcagtttt tattaaacat aacgtgggat ctccacgcga atctcgggta cgtgttccgg   1440
acatggactc ttctccggta gcggcggagc ttctacatcc gagccctgct cccatgcctc   1500
cagcgactca tggtcgctcg gcagctcctt gctcctaaca gtggaggcca gacttaggca   1560
cagcacgatg cccaccacca ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc   1620
tgaaaatgag ctcggggagc gggcttgcac cgctgacgca tttggaagac ttaaggcagc   1680
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggtaactcc   1740
cgttgcggtg ctgttaacgg tggagggtga tgtagtctga gcagtactcg ttgctgccgc   1800
gcgcgccacc agacataata gctgacagac taacgactg ttcctttcca tgggtctttt   1860
ctgcagtcac cgtccttaga tctgctgtgc cttctagttg ccagccatct gttgtttgcc   1920
cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa   1980
atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg   2040
ggcagcacag caagggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg   2100
gctctatggg tacccaggtg ctgaagaatt gacccggttc ctcctgggcc agaaagaagc   2160
aggcacatcc ccttctctgt gacacaccct gtccacgccc ctggttctta gttccagccc   2220
cactcatagg acactcatag ctcaggaggg ctccgccttc aatcccaccc gctaaagtac   2280
ttggagcggt ctctccctcc ctcatcagcc caccaaacca aacctagcct ccaagagtgg   2340
gaagaaatta aagcaagata ggctattaag tgcagaggga gagaaaatgc ctccaacatg   2400
tgaggaagta atgagagaaa tcatagaatt tcttccgctt cctcgctcac tgactcgctg   2460
cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta   2520
tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc   2580
aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc cctgacgag   2640
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac   2700
caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc   2760
ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt   2820
aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc   2880
gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga   2940
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta   3000
ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta   3060
tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga   3120
tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg   3180
```

```
cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag    3240
tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc    3300
tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact    3360
tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt    3420
cgttcatcca tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggctta    3480
ccatctggcc ccagtgctgc aatgataccg cgagacccac gctcaccggc tccagattta    3540
tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc aactttatcc    3600
gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat    3660
agtttgcgca acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc gtcgtttggt    3720
atggcttcat tcagctccgg ttcccaacga tcaaggcgag ttacatgatc ccccatgttg    3780
tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa gttggccgca    3840
gtgttatcac tcatggttat ggcagcactg cataattctc ttactgtcat gccatccgta    3900
agatgctttt ctgtgactgg tgagtactca accaagtcat tctgagaata gtgtatgcgg    3960
cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca tagcagaact    4020
ttaaaagtgc tcatcattgg aaaacgttct cggggcgaa aactctcaag gatcttaccg    4080
ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc agcatctttt    4140
actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga    4200
ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc    4260
atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa    4320
caaataggGG ttccgcgcac atttccccga aaagtgccac ctgacgtcta agaaaccatt    4380
attatcatga cattaaccta taaaaatagg cgtatcacga ggccctttcg tc            4432
```

```
<210> 15
<211> 4864
<212> DNA
<213> E. coli (V1Jneo plasmid)

<400> 15
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca      60
cagcttgtct gtaagcggat gccggggagca gacaagcccg tcaggggcgcg tcagcgggtg    120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc    180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg    240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg    300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatgat aatcaattac    360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg    420
cccgcctggc tgaccgccca acgaccccg cccattgacg tcaataatga cgtatgttcc    480
catagtaacg ccaatagga ctttccattg acgtcaatgg gtggagtatt tacggtaaac    540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgcccccta ttgacgtcaa    600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac    660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta    720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga    780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa    840
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct ataagcag    900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca    960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat    1020
tccccgtgcc aagagtgacg taagtaccgc ctatagagtc tataggccca ccccttggc    1080
ttcttatgca tgctatactg ttttttggctt ggggtctata caccccccgct tcctcatgtt    1140
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc    1200
ctattggtga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct    1260
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtattttac    1320
aggatgggt ctcatttatt atttacaaat tcacatatac aacaccaccg tcccagtga    1380
ccgcagtttt tattaaacat aacgtgggat ctccacgcga atctcgggtca cgtgttccgg    1440
acatgggctc ttctccggta gcggcggagc ttctacatcc gagccctgct cccatgcctc    1500
cagcgactca tggtcgctcg gcagctcctt gctcctaaca gtggaggcca gacttaggca    1560
cagcacgatg cccaccacca ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc    1620
tgaaaatgag ctcggggagc gggcttgcac cgctgacgca tttggaagac ttaaggcagc    1680
ggcagaagaa gatgcaggacga gctgagttgt tgtgttctga taagagtcag aggtaactcc    1740
cgttgcggtg ctgttaacgg tggagggcag tgtagtctga gcagtactcg ttgctgccgc    1800
gcgcgccacc agacataata gctgacagac taacagactg ttcctttcca tgggtctttt    1860
ctgcagtcac cgtccttaga tctgctgtgc cttctagttg ccagccatct gttgtttgcc    1920
cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa    1980
atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg    2040
```

```
ggcagcacag caaggggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg    2100
gctctatggg tacccaggtg ctgaagaatt gacccggttc ctcctgggcc agaaagaagc    2160
aggcacatcc ccttctctgt gacacaccct gtccacgccc ctggttctta gttccagccc    2220
cactcatagg acactcatag ctcaggaggg ctccgccttc aatcccaccc gctaaagtac    2280
ttggagcggt ctctccctcc ctcatcagcc caccaaacca aacctagcct ccaagagtgg    2340
gaagaaatta aagcaagata ggctattaag tgcagaggga gagaaaatgc ctccaacatg    2400
tgaggaagta atgagagaaa tcatagaatt tcttccgctt cctcgctcac tgactcgctg    2460
cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta    2520
tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc    2580
aggaaccgta aaaaggccgc gttgctggcg ttttttccata ggctccgccc ccctgacgag    2640
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac    2700
caggcgtttc ccccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc    2760
ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt    2820
aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaaccccccc    2880
gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga    2940
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta    3000
ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta    3060
tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga    3120
tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg    3180
cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag    3240
tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc    3300
tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact    3360
tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt    3420
cgttcatcca tagttgcctg actccggggg gggggggcgc tgaggtctgc ctcgtgaaga    3480
aggtgttgct gactcatacc aggcctgaat cgccccatca tccagccaga aagtgaggga    3540
gccacggttg atgagagctt tgttgtaggt ggaccagttg gtgattttga acttttgctt    3600
tgccacggaa cggtctgcgt tgtcgggaag atgcgtgatc tgatccttca actcagcaaa    3660
agttcgattt attcaacaaa gccgccgtcc cgtcaagtca gcgtaatgct ctgccagtgt    3720
tacaaccaat taaccaattc tgattagaaa aactcatcga gcatcaaatg aaactgcaat    3780
ttattcatat caggattatc aataccatat ttttgaaaaa gccgtttctg taatgaagga    3840
gaaaactcac cgaggcagtt ccataggatg gcaagatcct ggtatcggtc tgcgattccg    3900
actcgtccaa catcaataca acctattaat ttcccctcgt caaaaataag gttatcaagt    3960
gagaaatcac catgagtgac gactgaatcc ggtgagaatg gcaaaagctt atgcatttct    4020
ttccagactt gttcaacagg ccagccatta cgctcgtcat caaaatcact cgcatcaacc    4080
aaaccgttat tcattcgtga ttgcgcctga gcgagacgaa atacgcgatc gctgttaaaa    4140
ggacaattac aaacaggaat cgaatgcaac cggcgcagga acactgccag cgcatcaaca    4200
atattttcac ctgaatcagg atattcttct aatacctgga atgctgtttt cccggggatc    4260
gcagtggtga gtaaccatgc atcatcagga gtacggataa aatgcttgat ggtcggaaga    4320
ggcataaatt ccgtcagcca gtttagtctg accatctcat ctgtaacatc attggcaacg    4380
ctacctttgc catgtttcag aaacaactct ggcgcatcgg gcttcccata caatcgatag    4440
attgtcgcac ctgattgccc gacattatcg cgagccatt tatacccata taaatcagca    4500
tccatgttgg aatttaatcg cggcctcgag caagacgttt cccgttgaat atggctcata    4560
acaccccttg tattactgtt tatgtaagca gacagtttta ttgttcatga tgatatattt    4620
ttatcttgtg caatgtaaca tcagagattt tgagacacaa cgtggctttc cccccccccc    4680
cattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt    4740
tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc    4800
taagaaacca ttattatcat gacattaacc tataaaaata ggcgtatcac gaggcccttt    4860
cgtc                                                                 4864
```

<210> 16
<211> 4867
<212> DNA
<213> E. coli (V1Jns plasmid)

<400> 16
```
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca     60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcggggtg    120
ttggcggggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc    180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg    240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg    300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac    360
gggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg    420
```

```
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc    480
catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac    540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa    600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac    660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta    720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga    780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa    840
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag    900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca    960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat   1020
tccccgtgcc aagagtgacg taagtaccgc ctatagactc tataggcaca cccctttggc   1080
tcttatgcat gctatactgt ttttggcttg gggcctatac acccccgctt cctatgcta   1140
taggtgatgg tatagcttag cctataggtg tgggttattg accattattg accactcccc   1200
tattggtgac gatactttcc attactaatc cataacatgg ctctttgcca caactatctc   1260
tattggctat atgccaatac tctgtccttc agagactgac acggactctg tattttaca   1320
ggatggggtc ccatttatta tttacaaatt cacatataca acaacgccgt ccccccgtgcc   1380
cgcagttttt attaaacata gcgtgggatc tccacgcgaa tctcgggtac gtgttccgga   1440
catgggctct tctccggtag cggcggagct tccacatccg agccctggtc ccatgcctcc   1500
agcggctcat ggtcgctcgg cagctccttg ctcctaacag tggaggccag acttaggcac   1560
agcacaatgc ccaccaccac cagtgtgccg cacaaggccg tggcggtagg gtatgtgtct   1620
gaaaatgagc gtggagattg ggctcgcacg gctgacgcag atggaagact taaggcagcg   1680
gcagaagaag atgcaggcag ctgagttgtt gtattctgat aagagtcaga ggtaactcgc   1740
gttgcggtgc tgttaacggt ggagggcagt gtagtctgag cagtactcgt tgctgccgcg   1800
cgcgccacca gacataatag ctgacagact aacagactgt tccttccat gggtctttc   1860
tgcagtcacc gtccttagat ctgctgtgcc ttctagttgc cagccatctg ttgtttgccc   1920
ctcccccgtg ccttccttga ccctggaagg tgccactccc actgtccttt cctaataaaa   1980
tgaggaaatt gcatcgcatt gtctgagtag gtgtcattct attctggggg gtggggtggg   2040
gcaggacagc aaggggagg attgggaaga caatagcagt catgctgggg atgcggtggg   2100
ctctatggcc gctgcggcca ggtgctgaag aattgacccg gttcctcctg ggccagaaag   2160
aagcaggcac atccccttct ctgtgacaca ccctgtccac gccctggtt cttagttcca   2220
gccccactca taggacactc atagctcagg agggctccgc cttcaatccc acccgctaaa   2280
gtacttggag cggtctctcc ctccctcatc agcccaccaa accaaaccta gcctccaaga   2340
gtgggaagaa attaaagcaa gataggctat taagtgcaga gggagagaaa atgcctccaa   2400
catgtgagga agtaatgaga gaaatcatag aatttcttcc gcttcctcgc tcactgactc   2460
gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg cggtaatacg   2520
gttatccaca gaatcagggg ataacgcagg aaagaacatg tgagcaaaag gccagcaaaa   2580
ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc cataggctcc gcccccctga   2640
cgagcatcac aaaaatcgac gctcaagtca gaggtggcga acccgacag gactataaag   2700
ataccaggcg tttccccctg gaagctccct cgtgcgctct cctgttccga ccctgccgct   2760
taccggatac ctgtccgcct ttctcccttc gggaagcgtg gcgctttctc atagctcacg   2820
ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag ctgggctgtg tgcacgaacc   2880
ccccgttcag cccgaccgct gcgccttatc cggtaactat cgtcttgagt ccaacccggt   2940
aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca gagcgaggta   3000
tgtaggcggt gctacagagt tcttgaagtg gtggcctaac tacggctaca ctagaagaac   3060
agtatttggt atctgcgctc tgctgaagcc agttaccttc ggaaaaagag ttggtagctc   3120
ttgatccggc aaacaaacca ccgctggtag cggtggtttt tttgtttgca agcagcagat   3180
tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc ttttctacgg ggtctgacgc   3240
tcagtggaac gaaaactcac gttaagggat tttggtcatg agattatcaa aaaggatctt   3300
cacctagatc cttttaaatt aaaaatgaag ttttaaatca atctaaagta tatatgagta   3360
aacttggtct gacagttacc aatgcttaat cagtgaggca cctatctcag cgatctgtct   3420
atttcgttca tccatagttg cctgactcgg gggggggggg cgctgaggtc tgcctcgtga   3480
agaaggtgtt gctgactcat accaggcctg aatcgcccca tcatccagcc agaaagtgag   3540
ggagccacgg ttgatgagag ctttgttgta ggtggaccag ttggtgattt tgaactttg   3600
ctttgccacg gaacggtctg cgttgtcggg aagatgcgtg atctgatcct tcaactcagc   3660
aaaagttcga tttattcaac aaagccgccg tcccgtcaag tcagcgtaat gctctgccag   3720
tgttacaacc aattaaccaa ttctgattag aaaaactcat cgagcatcaa atgaaactgc   3780
aatttattca tatcaggatt atcaatacca tatttttgaa aaagccgttt ctgtaatgaa   3840
ggagaaaact caccgaggca gttccatagg atggcaagat cctggtatcg gtctgcgatt   3900
ccgactcgtc caacatcaat acaacctatt aatttcccct cgtcaaaaat aaggttatca   3960
agtgagaaat caccatgagt gacgactgaa tccggtgaga atggcaaaag cttatgcatt   4020
tctttccaga cttgttcaac aggccagcca ttacgctcgt catcaaaatc actcgcatca   4080
accaaaccgt tattcattcg tgattgcgcc tgagcgagac gaaatacgcg atcgctgtta   4140
```

- 29 -

```
aaaggacaat tacaaacagg aatcgaatgc aaccggcgca ggaacactgc cagcgcatca      4200
acaatatttt cacctgaatc aggatattct tctaatacct ggaatgctgt tttcccgggg      4260
atcgcagtgg tgagtaacca tgcatcatca ggagtacgga taaaatgctt gatggtcgga      4320
agaggcataa attccgtcag ccagtttagt ctgaccatct catctgtaac atcattggca      4380
acgctacctt tgccatgttt cagaaacaac tctggcgcat cgggcttccc atacaatcga      4440
tagattgtcg cacctgattg cccgacatta tcgcgagccc atttataccc atataaaatca     4500
gcatccatgt tggaatttaa tcgcggcctc gagcaagacg tttcccgttg aatatggctc      4560
ataacacccc ttgtattact gtttatgtaa gcagacagtt ttattgttca tgatgatata      4620
tttttatctt gtgcaatgta acatcagaga ttttgagaca caacgtggct ttccccccccc     4680
ccccattatt gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt      4740
atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccacctgac      4800
gtctaagaaa ccattattat catgacatta acctataaaa ataggcgtat cacgaggccc      4860
tttcgtc                                                                4867
```

<210> 17
<211> 75
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 17
```
gatcaccatg gatgcaatga agagagggct ctgtgtgctg ctgctgtgtg gagcagtctt      60
cgtttcgccc agcga                                                        75
```

<210> 18
<211> 78
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 18
```
gatctcgctg ggcgaaacga agactgctcc acacagcagc agcacacagc agagccctct      60
cttcattgca tccatggt                                                     78
```

<210> 19
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 19
```
ggtacaaata ttggctattg gccattgcat acg                                    33
```

<210> 20
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 20
```
ccacatctcg aggaaccggg tcaattcttc agcacc                                 36
```

<210> 21
<211> 38

- 30 -

```
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 21
ggtacagata tcggaaagcc acgttgtgtc tcaaaatc                          38

<210> 22
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 22
cacatggatc cgtaatgctc tgccagtgtt acaacc                            36

<210> 23
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 23
ggtacatgat cacgtagaaa agatcaaagg atcttcttg                         39

<210> 24
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 24
ccacatgtcg acccgtaaaa aggccgcgtt gctgg                             35

<210> 25
<211> 4864
<212> DNA
<213> E. coli (V1R plasmid)

<400> 25
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca   60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg  120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc  180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg  240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg  300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac  360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg  420
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc  480
catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac  540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa   600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac  660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta  720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga  780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa  840
```

-31-

```
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag      900
agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca      960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat     1020
tccccgtgcc aagagtgacg taagtaccgc ctatagagtc tataggccca cccccttggc     1080
ttcttatgca tgctatactg tttttggctt ggggtctata cacccccgct tcctcatgtt     1140
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc     1200
ctattggtga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct     1260
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtatttttac     1320
aggatggggt ctcatttatt atttacaaat tcacatatac aacaccaccg tccccagtgc     1380
ccgcagtttt tattaaacat aacgtgggat ctccacgcga atctcgggta cgtgttccgg     1440
acatgggctc ttctccggta gcggcggagc ttctacatcc gagccctgct cccatgcctc     1500
cagcgactca tggtcgctcg gcagctcctt gctcctaaca gtggaggcca gacttaggca     1560
cagcacgatg cccaccacca ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc     1620
tgaaaatgag ctcgggggagc gggcttgcac cgctgacgca tttggaagac ttaaggcagc     1680
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggtaactcc     1740
cgttgcggtg ctgttaacgg tggagggcag tgtagtctga gcagtactcg ttgctgccgc     1800
gcgcgccacc agacataata gctgacagac taacagactg ttcctttcca tgggtctttt     1860
ctgcagtcac cgtccttaga tctgctgtgc cttctagttg ccagccatct gttgtttgcc     1920
cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa     1980
atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg     2040
ggcagcacag caagggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg     2100
gctctatggg tacccaggtg ctgaagaatt gacccggttc ctcctgggcc agaaagaagc     2160
aggcacatcc ccttctctgt gacacaccct gtcccgcccc ctggttctta gttccagccc     2220
cactcatagg acactcatag ctcaggaggg ctccgccttc aatcccaccc gctaaagtac     2280
ttggagcggt ctctccctcc ctcatcagcc caccaaacca aacctagcct ccaagagtgg     2340
gaagaaatta aagcaagata ggctattaag tgcagaggga gagaaaatgc ctccaacatg     2400
tgaggaagta atgagagaaa tcatagaatt tcttccgctt cctcgctcac tgactcgctg     2460
cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta     2520
tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc     2580
aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc cctgacgag      2640
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac     2700
caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc     2760
ggatacctgt ccgcctttct ccccttcggga agcgtggcgc tttctcaatg ctcacgctgt     2820
aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc     2880
gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga     2940
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta     3000
ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta     3060
tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga     3120
tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg     3180
cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag     3240
tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc     3300
tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact     3360
tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt     3420
cgttcatcca tagttgcctg actccggggg ggggggcgc tgaggtctgc ctcgtgaaga     3480
aggtgttgct gactcatacc aggcctgaat cgccccatca tccagccaga aagtgaggga     3540
gccacggttg atgagagctt tgttgtaggt ggaccagttg gtgattttga acttttgctt     3600
tgccacggaa cggtctgcgt tgtcgggaag atgcgtgatc tgatccttca actcagcaaa     3660
agttcgattt attcaacaaa gccgccgtcc cgtcaagtca gcgtaatgct ctgccagtgt     3720
tacaaccaat taaccaattc tgattagaaa aactcatcga gcatcaaatg aaactgcaat     3780
ttattcatat caggattatc aataccatat ttttgaaaaa gccgtttctg taatgaagga     3840
gaaaactcac cgaggcagtt ccataggatg gcaagatcct ggtatcggtc tgcgattccg     3900
actcgtccaa catcaataca acctattaat ttcccctcgt caaaaataag gttatcaagt     3960
gagaaatcac catgagtgac gactgaatcc ggtgagaatg gcaaaagctt atgcatttct     4020
ttccagactt gttcaacagg ccagccatta cgctcgtcat caaaatcact cgcatcaacc     4080
aaaccgttat tcattcgtga ttgcgcctga gcgagacgaa atacgcgatc gctgttaaaa     4140
ggacaattac aaacaggaat cgaatgcaac cggcgcagga acactgccag cgcatcaaca     4200
atattttcac ctgaatcagg atattcttct aatacctgga atgctgtttt cccggggatc     4260
gcagtggtga gtaaccatgc atcatcagga gtacggataa aatgcttgat ggtcggaaga     4320
ggcataaatt ccgtcagcca gtttagtctg accatctcat ctgtaacatc attggcaacg     4380
ctacctttgc catgtttcag aaacaactct ggcgcatcgg gcttcccata caatcgatag     4440
attgtcgcac ctgattgccc gacattatcg cgagcccatt tatacccata taaatcagca     4500
tccatgttgg aatttaatcg cggcctcgag caagacgttt cccgttgaat atggctcata     4560
```

```
acaccccttg tattactgtt tatgtaagca gacagtttta ttgttcatga tgatatattt          4620
ttatcttgtg caatgtaaca tcagagattt tgagacacaa cgtggctttc cccccccccc          4680
cattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt          4740
tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc          4800
taagaaacca ttattatcat gacattaacc tataaaaata ggcgtatcac gaggcccttt          4860
cgtc                                                                        4864
```

<210> 26
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 26
ggtacaagat ctccgccccc atctccccca ttgaga   36

<210> 27
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 27
ccacatagat ctgcccgggc tttagtcctc atc   33

<210> 28
<211> 27
<212> PRT
<213> Homo sapien

<400> 28
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1   5   10   15
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ser
            20   25

<210> 29
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 29
caggcgagat ctaccatggc ccccattagc cctattgaga ctgta   45

<210> 30
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 30
caggcgagat ctgcccgggc tttaatcctc atcctgtcta cttgccac   48

                                    -33-
```

# INTERNATIONAL SEARCH REPORT

| International application No. |
| --- |
| PCT/US00/34724 |

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7)  :  A61K 48/00; C12Q 1/70.
US CL  :  514/44; 435/5; 424/93.1.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
    U.S. : 514/44; 435/5; 424/93.1.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Medline, embase, scisearch, biosis, caplus and WEST

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| --- | --- | --- |
| Y,P | US 6,099,848 A (FRANKEL et al) 08 August 2000 (08.08.2000), page 12 paragraph 6. | 1-14, 17 |
| Y | WO 97/31115 A2 (MERCK & CO. INC.), 28 August 1997, page 36. | 4 |
| X | WO 90/10230 A1 (UNIVERSITY OF OTTAWA) 07 September 1990, page 11. | 17 |
| Y | US 5,858,646 A (KANG) 12 January 1999 (12.01.1999), col. 2, lines 10-17 | 1-14, 17 |

☐ Further documents are listed in the continuation of Box C.     ☐ See patent family annex.

| * | Special categories of cited documents: | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| --- | --- | --- | --- |
| "A" | document defining the general state of the art which is not considered to be of particular relevance | | |
| "E" | earlier application or patent published on or after the international filing date | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "L" | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" | document referring to an oral disclosure, use, exhibition or other means | | |
| "P" | document published prior to the international filing date but later than the priority date claimed | "&" | document member of the same patent family |

| Date of the actual completion of the international search | Date of mailing of the international search report |
| --- | --- |
| 22 February 2001 | **09 MAR 2001** |
| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231<br>Facsimile No. (703)305-3230 | Authorized officer<br><br>Eleanor Sorbello<br><br>Telephone No. 703-308-0196 |

Form PCT/ISA/210 (second sheet) (July 1998)

# INTERNATIONAL SEARCH REPORT

## Box I  Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claim Nos.: 15 & 16
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II  Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**  ☐ The additional search fees were accompanied by the applicant's protest.
                        ☐ No protest accompanied the payment of additional search fees.